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THESIS	  OUTLINE	  
	   Diabetes	   Mellitus	   (DM)	   and	   insulin	   resistant	   (IR)	   are	   highly	   prevalent	  among	  heart	  failure	  (HF)	  patients.	  There	  is	  now	  increasing	  evidence	  to	  suggest	  a	  bi-­‐directional	  relationship	  between	  IR	  and	  HF.	  DM	  and	  IR	  not	  only	  lead	  to	  heart	  failure,	  but	  heart	  failure	  can	  also	  lead	  toward	  the	  development	  of	  DM	  or	  IR.	  
The	  degree	  of	  IR	  also	  correlates	  with	  the	  severity	  and	  mortality	  of	  CHF.	  The	   pathophysiology	   of	   IR	   in	   CHF	   has	   yet	   to	   be	   fully	   defined.	   Activation	   of	  sympathetic	  nervous	  system,	  abnormal	  regulation	  of	  adipocytokines	  systems,	  activation	  of	   inflammatory	  and	  coagulation	  cascade,	  accumulation	  of	  glycated	  products,	   endothelial	   dysfunction	   and	   hyperinsulinaemia	   are	   potential	  explanations	   of	   the	   development	   of	   IR	   in	   CHF.	   Additionally,	   it	   remains	   to	   be	  determined	  if	  IR	  is	  merely	  a	  marker	  reflecting	  the	  severity	  of	  CHF	  or	  whether	  it	  contributes	   to	   the	   disease	   in	   CHF.	   If	   IR	   is	   truly	   a	   culprit	   that	   worsens	   CHF,	  reversing	  IR	  may	  potentially	  be	  a	  new	  target	  for	  treatment	  in	  CHF,	  which	  may	  result	   in	   an	   improvement	   in	   symptoms	   and	   even	  mortality	   in	   patients	   with	  CHF.	  However,	   there	  are	   concerns	  over	   the	  use	  of	   certain	   insulin	   sensitizers,	  most	   notably,	   the	   thiazolidinediones	   (TZDs),	   which	   has	   been	  linked	  with	  increased	   risk	   of	   hospitalizations	   for	   CHF	   and	   concerns	   regarding	   its	  association	  with	  increased	  myocardial	  infarction.	  Despite	  previous	  concerns	  of	  lactic	  acidosis,	  there	  is	  now	  evidence	  that	  metformin	  may	  not	  only	  be	  safe	  but	  could	   potentially	   be	   useful	   in	   the	   setting	   of	   CHF.	   We	   have	   conducted	   a	  randomised	   double-­‐blind,	   placebo-­‐controlled	   trial	   testing	   the	   hypothesis	   of	  reversing	   IR	   with	   metformin	   in	   insulin-­‐resistant	   CHF	   will	   have	   beneficial	  effects.	  If	  IR	  is	  a	  possible	  target	  for	  the	  treatment	  of	  CHF,	  what	  are	  the	  new	  and	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potential	  treatment	  modalities?	  We	  have	  now	  had	  better	  understandings	  of	  the	  adipocytokines	   systems,	   which	   may	   prove	   to	   be	   a	   therapeutic	   option	   to	  improve	  IR	  in	  CHF.	  AMP-­‐activated	  protein	  kinase	  (AMPK)	  pathway	  has	  become	  the	  focus	  of	  research	  as	  a	  novel	  therapeutic	  target	  in	  cardio-­‐metabolic	  disease.	  It	   has	   been	   shown	   to	   mediate,	   at	   least	   in	   part,	   the	   effects	   of	   a	   number	   of	  physiological	   and	   pharmacological	   factors	   that	   improve	   IR.	   It	   also	   exerts	  beneficial	  effects	  on	  the	  vasculature	  and	  the	  heart.	  There	  have	  been	  some	  new	  AMPK	  activators	   that	   are	   currently	   being	   tested	   in	   vivo	   setting	   or	  phase	  1-­‐2	  trials,	  and	  the	  early	  results	  are	  somewhat	  promising.	  










	   CHAPTER	  1:	  DIABETES	  AND	  CHF	  
INTRODUCTION	  
	   Diabetes	  and	  CHF	  often	  co-­‐exist	  with	  an	  inter-­‐relationship	  such	  that	  each	  condition	  may	  impact	  on	  each	  other	  in	  terms	  of	  causation	  and	  outcome	  (Figure	  1).	  The	  Framingham	  Study	  highlighted	  the	  co-­‐existence	  of	  diabetes	  and	  CHF	  (1).	  Kannel	  et	  al	  reported	  that	  19%	  of	  patients	  with	  CHF	  in	  the	  Framingham	  Study	  have	  diabetes	  and	  that	  the	  risk	  of	  CHF	  increases	  by	  2-­‐8	  folds	  in	  the	  presence	  of	  diabetes	   (1).	   The	   prevalence	   of	  DM	   is	   around	  4-­‐7%	   in	   the	   general	   population	  and	   0.5%	   of	   the	   general	   population	   has	   both	   DM	   and	   HF	   (2,	   3).	   From	  population-­‐based	  studies	  and	  in	  CHF	  trials,	  the	  prevalence	  of	  T2DM	  is	  estimated	  to	   be	   between	   11%	   and	   28%	   and	   increased	   to	   25-­‐30%	   among	   all	   patients	  hospitalized	  for	  CHF	  (4-­‐6)	  (Table	  1).	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TABLE	  1:	  The	  prevalence	  of	  DM	  in	  populations	  with	  and	  without	  LVSD.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
MacDonald	  MR	  et	  al.	  Eur	  Heart	  J	  2008;29:1224-­‐40	  	  
As	   stated	   earlier,	   there	   has	   been	   a	   pathophysiological	   linkage	   between	  T2DM	   and	   HF.	   There	   are	   numbers	   of	   independent	   risk	   factors	   that	   were	  identified	   as	   predictors	   of	   the	   development	   of	   HF	   in	   DM.	   These	   include	  increased	  body	  mass	  index	  (BMI),	  age,	  the	  presence	  of	  coronary	  artery	  disease,	  New	  York	  Heart	  Association	  functional	  class	  and	  glycaemic	  control	  measured	  by	  HbA1c	  (6-­‐8).	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NYHA	  FUNCTIONAL	  CLASS	  –	  PREDICTOR	  OF	  RISK	  OF	  DEVELOPING	  DM	  IN	  CHF	  
In	   an	   Italian	   population-­‐based	   study	   of	   1,339	   elderly	   subjects	   with	   a	  mean	   (+/-­‐	   SD)	   age	   of	   74.2	   +/-­‐	   6.4	   years.	   CHF	   has	   been	   shown	   to	   be	   a	   strong	  predictor	  of	  the	  development	  of	  DM	  independently	  of	  age,	  sex,	  family	  history	  of	  diabetes,	   BMI,	   waist/hip	   ratio,	   systolic	   and	   diastolic	   blood	   pressure,	   and	  treatment	   for	   CHF	   (OR	  =	  1.4,	   95%	  CI	   =	   1.1-­‐1.8)(9).	   This	   strongest	   association	  was	  observed	  in	  patients	  with	  more	  severe	  HF	  (NYHA	  III	  and	  IV)	  than	  patients	  with	   milder	   HF	   (NYHA	   I	   and	   II).	   Similar	   observation	   was	   found	   in	   the	  Bezafibrate	   Infarction	  Prevention	  study.	   Incidence	  of	  diabetes	  was	  determined	  by	  baseline	  NYHA	  functional	  classification.	  2616	  non-­‐diabetic	  patients	  aged	  45	  to	   74	   years	   were	   divided	   into	   three	   groups	   according	   to	   New	   York	   Heart	  Association	  (NYHA)	  criteria:	  class	  I	  (n	  =	  1986	  patients),	  class	  II	  (n	  =	  518),	  and	  class	   III	   (n	   =	   112).	   The	   detection	   of	   a	   fasting	   blood	   glucose	   level	   ≥7	  mmol/L	  during	  follow-­‐up	  was	  defined	  as	  the	  criterion	  for	  the	  development	  of	  diabetes.	  259	  patients	  (13%)	  in	  NYHA	  class	  I	  developed	  DM,	  76	  (15%)	  in	  class	  II,	  and	  22	  (20%)	   in	   class	   III	   (P	   for	   trend	  =	   0.05)	   during	   8	   years	   follow	  up	   of	   this	   study.	  NYHA	  class	  III	  were	  twice	  as	  likely	  (17%	  [n	  =	  19])	  to	  have	  fasting	  blood	  glucose	  levels	   of	   ≥7	  mmol/L	   than	   those	   in	   NYHA	   class	   I	   (7.8%	   [n	   =	   154])	   or	   class	   II	  (8.7%	  [n	  =	  45])	  (P	  =	  0.005)	  (Figure	  2).	  In	  a	  multivariate	  analysis,	  NYHA	  class	  III	  was	   found	   to	  be	   the	   strongest	  predictor	  of	   the	  development	  of	  DM	  associated	  with	  a	  1.7-­‐fold	  (95%	  confidence	  interval	  [CI]:	  1.1	  to	  2.6)	  increase	  of	  the	  rate	  of	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FIGURE	  2	  Bezafibrate	  infarction	  prevention	  study.	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GLYCAEMIC	  CONTROL-­‐	  PREDICTOR	  OF	  RISK	  OF	  DEVELOPING	  HF	  IN	  DM	  
The	   risk	   of	   CHF	   appears	   to	   be	   related	   to	   the	   blood	   sugar	   control	   in	  patients	   with	   diabetes.	   Iribarren	   and	   colleagues	   demonstrated	   that	   a	   1%	  increase	   in	   HbA1C	   was	   associated	   with	   an	   8%	   increased	   in	   risk	   of	   CHF	  independent	  of	  blood	  pressure,	  body	  mass	  index,	  age	  and	  presence	  of	  coronary	  artery	  disease	  (1).	  Conversely,	  the	  UKPDS	  study	  showed	  that	  a	  1%	  reduction	  of	  HbA1c	   was	   associated	   with	   a	   16%	   reduced	   risk	   of	   developing	   CHF	   (2).	   The	  presence	   of	   diabetes	   mellitus	   is	   also	   associated	   with	   worse	   outcome	   in	   CHF	  trials.	   	  In	  the	  Left	  Ventricular	  Dysfunction	  (SOLVD)	  trial,	  diabetes	  mellitus	  was	  an	   independent	   predictor	   of	   mortality	   and	   morbidity	   in	   patients	   in	   CHF	   (3).	  Similarly,	  in	  the	  Beta-­‐Blocker	  Evaluation	  of	  Survival	  Trial	  (BEST),	  patients	  with	  DM	  were	   associated	  with	  more	   severe	  HF	   and	   adverse	   outcome	   compared	   to	  CHF	   patients	   without	   DM	   (4).	   Held	   et	   al	   (5)	   showed	   each	  millimols	   per	   litre	  increased	   in	   fasting	   plasma	   glucose	   in	   patients	   with	   diabetes	   was	   associated	  with	  a	  1.10-­‐fold-­‐increased	  risk	  of	  CHF	  hospitalization	  after	  adjustment	  for	  age	  and	  sex.	  All	  these	  findings	  showed	  a	  clear	  and	  important	  link	  between	  diabetes	  and	  CHF.	  	  
However,	  we	   are	   not	   certain	   of	   the	   association	   between	   the	   degree	   of	  dysglycaemia	  and	  risk	  of	  HF.	  If	  the	  degree	  of	  dysglycaemia	  does	  associate	  with	  increased	   risk	   of	   HF,	   then	   the	   next	   question	   naturally	   asked	   is	   what	   is	   the	  degree	   of	   dysglycaemia	   carries	   the	   highest	   risk	   of	   developing	   HF	   in	   patients	  with	   T2DM?	  We	  would	   have	   as	   a	  matter	   of	   course	   thought	   that	  more	   severe	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dysglycaemia	   is	   associated	   with	   a	   higher	   incidence	   of	   HF	   than	   patients	   with	  normoglycaemia.	  However,	   there	  have	  been	  some	  controversies	  regarding	   the	  degree	   of	   dysglycaemia	   and	   incident	   HF.	   Recent	   retrospective	   studies	   have	  achieved	  different	  conclusions.	  	  
The	   benefit	   of	   improved	   glycaemic	   control	   on	   microvascular	  complications	   in	   T2DM	   is	   well	   established	   (7,14),	   and	   recent	   trials	   have	  attempted	  to	  clarify	  the	  role	  of	  glycaemic	  control	  on	  	  	  macrovascular	  outcomes	  (15,16).	   These	   data	   suggested	   that	   improved	   glycaemic	   control	   has	   the	  potential	   to	   reduce	   the	   risk	   of	   both	   micro-­‐	   and	   macrovascular	   disease	  significantly	  when	  instigated	  early	  in	  the	  disease	  course,	  but	  in	  more	  advanced	  T2DM,	   the	   benefits	   of	   improved	   control	  were	   less	   evident	   (17).	   Furthermore,	  recent	   studies	   suggested	   that	   tight	   glycaemic	   control	   can	   sometimes	   be	  associated	  with	  a	  poorer	  macrovascular	  outcome	  (18,19)	  than	  standard	  care.	  In	  patients	   with	   co-­‐existing	   CHF	   and	   T2DM,	   the	   relevance	   of	   good	   glycaemic	  control	  is	  a	  critical	  issue	  not	  only	  as	  the	  combination	  may	  be	  associated	  with	  a	  significantly	  poorer	  outcome	  but	  also	  as	  the	  choice	  of	  drugs	  available	  to	  manage	  hyperglycaemia	  in	  CHF	  are	  perhaps	  more	  limited	  (20,21).	  There	  are	  conflicting	  reports	  of	  the	  importance	  of	  glycaemic	  control	  in	  patients	  with	  T2DM	  and	  CHF	  (22-­‐26).	   The	   relationship	   between	   glycaemic	   control	   and	   outcomes	   has	   been	  reported	   to	  be	   “U”	  shaped	   (26),	   “J”	   shaped	   (25),	   linear	   (24),	  and	  even	   inverse	  (23).	  The	  main	  findings	  from	  relevant	  trials	  regarding	  incident	  HF	  and	  degree	  of	  dysglycaemia	  are	  summarised	  as	  followed:	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UKPDS—HBA1C,	  A	  PROGRESSIVE	  RISK	  FOR	  ADVERSE	  OUTCOME	  (2)	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VETERANS	  AFFAIRS	  STUDY—U	  SHAPE	  CURVE	  RELATIONSHIP	  (6)	  
At	   the	   Veterans	   Affairs	   medical	   centres,	   Aguilar	   et	   al	   conducted	   a	  retrospective	  study	  to	  determine	  the	  relationship	  between	  HbA1c	  and	  CHF	  by	  assessing	   the	   association	   of	   different	   quintiles	   of	   HbA1c	   and	   CHF-­‐related	  outcome	  (mortality	  and	  risk	  of	  HF	  hospitalization).	  5815	  veterans	  with	  CHF	  and	  T2DM	  treated	  in	  ambulatory	  clinics	  were	  included	  in	  the	  study.	  After	  periods	  of	  two	  years	   follow	  up,	   a	  U	   shape	   curve	   relationship	  was	   found	  between	  HbA1c	  and	  mortality.	  Death	  occurred	  in	  25%	  of	  patients	  in	  Quintile1	  (HbA1C	  ≤6.4%),	  23%	   in	   Quintile	   2	   (6.4%	   9.0%).	   The	   middle	   quintile	   was	   found	   to	   have	   the	  lowest	   mortality	   after	   adjustment	   for	   potential	   confounders	   when	   compared	  with	   the	   lowest	   quintile	   (risk-­‐adjusted	   hazard	   ratio:	   0.73,	   95%	   confidence	  interval:	  0.61	  to	  0.88,	  p	  =	  0.001).	  Conversely,	  it	  was	  a	  linear	  relationship	  for	  HF	  hospitalization	  with	   increasing	  quintiles	  of	  HbA1C	  (Q1:	  13.3%,	  Q2:	  13.1%,	  Q3:	  15.5%,	   Q4:	   16.4%,	   and	   Q5:	   18.2%).	   However,	   this	   association	   was	   not	  statistically	  significant	  when	  adjusted	  for	  potential	  confounders	  (26)(Figure	  3),	  suggesting	   that	   the	  differences	   in	   baseline	  demographics	   and	   treatments	  may	  be	   accounting	   for	   the	   increased	   rate	   of	   heart	   failure	   hospitalization	   This	  highlighted	  the	  complex	  relationship	  between	  HbA1c	  and	  mortality	  in	  patients	  with	   diabetes	   and	   heart	   failure.	   Patients	   in	   the	   lower	   and	   higher	   quintiles	   of	  HbA1c	   have	   a	   higher	  mortality	   than	   patients	   with	  modest	   glycaemic	   control.	  They	  postulated	  that	  the	  increased	  mortality	  in	  patients	  with	  the	  higher	  quintile	  of	  HbA1c	   levels	  was	   likely	  multifactorial	   secondary	   to	   the	   direct	   and	   indirect	  effects	   of	   hyperglycaemia.	   The	   adverse	   effects	   of	   hyperglycaemia	   include	  increased	  oxidative	  stress,	  endothelial	  dysfunction,	   increased	  protein	  kinase	  C	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activation,	  and	  ultimately	  accelerate	  atherosclerosis.	  Chronic	  hyperglycaemia	  is	  associated	  with	  accumulation	  of	  advanced	  glycation	  end	  products,	  which	  lead	  to	  increased	  myocardial	  stiffness,	  and	  dys-­‐regulation	  of	  various	  cellular	  signaling	  pathways,	   and	   eventually	   cellular	   dysfunction.	   Elevated	   HbA1c	   is	   also	   linked	  with	   increased	   insulin	   resistance	  and	  may	  also	  be	   related	   to	  poor	   compliance	  with	  medications,	  which	   in	   turn	  may	  be	   associated	  with	   a	  poor	  outcome.	  The	  potential	   explanations	   of	   increased	   mortality	   in	   patients	   with	   the	   lowest	  quintile	   of	   HbA1c	   are	   likely	   to	   be	   secondary	   to	   the	   hazardous	   effects	   of	  intensive	  glucose	   control,	   and	  possibly	   related	   to	  protein	  malnutrition	  and	  an	  increased	  in	  inflammatory	  syndrome	  associated	  with	  advanced	  heart	  failure.	  
	  
FIGURE	   3:	   The	   association	   between	  mortality	   and	   HbA1C	   in	   diabetic	   patients	   with	   HF	  
appears	  U-­‐shaped,	  with	   the	   lowest	   risk	   of	   death	   in	   those	  patients	  with	  modest	   glucose	  
control	  (7.1%	  <	  HbA1C	  ≤7.8%).	  	  	  
The	   graph	   represents	   the	   proportion	   of	   patients	   who	   died	   at	   2-­‐year	   follow-­‐up	   with	  
quintiles	   (Q)	   of	   glycosylated	   haemoglobin	   (HbA1c).	   Global	   chi-­‐square	   p=0.001.	   Error	  
bars	  indicate	  the	  95%	  confidence	  intervals.	  	  Aguilar	  et	  al.	  J	  Am	  Coll	  Cardiol	  2009;54:422-­‐
8	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ESHAGHIAN	  AND	  COLLEAGUES—A	  PARADOXICAL	  RELATIONSHIP	  OF	  HBA1C	  AND	  OUTCOME	  
(7)	  








FIGURE	  4:	  A	  Paradoxical	  Relationship	  of	  HbA1c	  and	  outcome.	  	  
Paradoxically,	   elevated	   HbA1c	   levels	   were	   associated	   with	   improved	   survival	   in	   this	  
cohort	   of	   patients	   with	   diabetes	   and	   advanced	   HF.	   Mortality	   rates	   by	   Kaplan-­‐Meier	  
analysis	   for	   advanced	   systolic	  heart	   failure	  patients	  with	  diabetes	  at	  2	   years	  by	  HbA1c	  
quartiles.	  The	  number	  of	  events	  and	  the	  number	  of	  subjects	  in	  each	  quartile	  are	  shown	  
above	  each	  bar.	  Eshaghian	  et	  al.	  Am	  Heart	  J	  2006;151:91	  
	  	  	  	  	  	  	  	  	  	  	  




WHAT	  DO	  WE	  LEARN	  FROM	  CHARM?	  —LINEAR	  RELATIONSHIP	  BETWEEN	  HBA1C	  AND	  
ADVERSE	  OUTCOME	  (8)	  









FIGURE	   5:	   Candesartan	   in	   Heart	   failure:	   Assessment	   of	   Reduction	   in	   Mortality	   and	  
Morbidity	  (CHARM)	  program.	  	  
In	   diabetic	   and	   non-­‐diabetic	   patients	   with	   symptomatic	   chronic	   HF,	   HbA1c	   level	   is	   an	  
independent	   progressive	   risk	   factor	   for	   CV	   death,	   hospitalization	   for	   HF,	   and	   total	  
mortality.	   (P	   for	   trend	  <0.001).	   Error	  bars	   indicate	  95%	  confidence	   intervals.	   Gerstein	  













ATHEROSCLEROSIS	  RISK	  IN	  COMMUNITIES	  (ARIC)	  STUDY-­‐INCREASED	  HBA1C	  ASSOCIATE	  
WITH	  INCREASED	  RISK	  OF	  DEVELOPING	  HF	  (9)	  
In	   a	   prospective	   population-­‐based	   study,	   Pazin-­‐Filho	   et	   al	   studied	   the	  incidence	   of	   death	   and	   HF	   hospitalization	   in	   patients	   with	   diabetes	   but	   no	  evidence	  of	  HF	  at	  baseline.	  Each	  per	  cent	  increase	  of	  HbA1c	  was	  associated	  with	  17%	  increased	  risk	  of	  developing	  HF	  in	  the	  non-­‐coronary	  heart	  disease	  group.	  The	   risk	   was	   20%	   in	   patients	   with	   coronary	   heart	   disease.	   HbA1c	   has	   been	  shown	   to	   be	   an	   independent	   predictor	   of	   risk	   of	   developing	   HF	   in	   diabetic	  patients	  with	  and	  without	  coronary	  heart	  disease(9).	  
	  
SWEDISH	  NATIONAL	  DIABETES	  REGISTRY	  STUDY-­‐	  POOR	  GLYCAEMIC	  CONTROL	  WITH	  
HBA1C>7%	  ASSOCIATED	  WITH	  INCREASED	  RISK	  OF	  HOSPITALISATION	  OF	  HF	  
In	  a	  Swedish	  National	  Diabetes	  Registry	  study,	  Lind	  et	  al	  has	   identified	  10,969	  (13.2%)	  among	  83,021	  patients	  with	  T2DM	  who	  were	  hospitalized	  with	  a	  primary	  or	   secondary	  diagnosis	   of	   heart	   failure	  during	   a	  mean	   follow-­‐up	  of	  7.2	  years.	   Male	   sex	   (p < 0.001),	   older	   age	   (p < 0.001)	   and	   longer	   diabetes	  duration	   (p < 0.001)	   correlates	   with	   increased	   incident	   HF	   hospitalization.	  After	  adjusting	  for	  risk	  factors	  of	  heart	  failure,	  the	  HR	  per	  each	  percentage	  unit	  higher	  HbA1c	  for	  heart-­‐failure	  hospitalization	  was	  1.12	  (95%	  CI	  1.10,	  1.14).	  By	  category	  of	  mean	  HbA1c,	  the	  HR	  for	  heart	  failure	  hospitalization	  was:	  HbA1c	  6.0	  to	   <7.0%,	   0.91	   (95%	   CI	   0.84,	   0.98);	   HbA1c	   7.0	   to	   <8.0%,	   0.99	   (95%	   CI	   0.91,	  1.07);	  HbA1c	  8.0	  to	  <9.0%,	  1.10	  (95%	  CI	  1.01,	  1.20);	  HbA1c	  9.0	  to	  <10.0%,	  1.27	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(95%	  CI	   1.15,	   1.41);	  HbA1c	   ≥10.0	  %,	   1.71	   (1.51,	   1.93)	   (reference	  HbA1c	   <6%).	  The	  HR	  for	  patients	  with	  HbA1c	  7.0	  to	  <8.0%	  compared	  with	  patients	  with	  HbA1c	  6.0	  to	  <7.0%	  was	  1.09	  (95%	  CI	  1.03,	  1.14).	  They	  concluded	  that	  HbA1c	  >7%	  is	  associated	   with	   an	   increased	   risk	   of	   heart	   failure	   hospitalization	   in	   patients	  with	  T2DM	  (10).	  
	  
CHAPTER	  SUMMARY	  
The	   bi-­‐directional	   relationship	   between	   DM/IR	   and	   CHF	   is	   well	  established.	   NYHA	   functional	   class	   is	   the	   strongest	   predictor	   of	   the	  development	   of	   DM	   in	   CHF,	   whereas	   glycaemic	   control	   is	   the	   strongest	  predictor	   of	   the	   development	   of	   CHF	   in	   DM.	   The	   level	   of	   glycosylated	  haemoglobin	  (HbA1c)	  provides	  a	  measure	  of	   the	  glycaemic	  control	  of	  patients	  with	  T2DM	  during	  the	  previous	  2–3	  months	  (11).	  It	  is	  a	  useful	  prognosticator	  in	  patients	  with	  DM	  and	  CHF	  as	  demonstrated	   from	  the	  above	  studies.	  However,	  we	  are	  not	  certain	  about	  what	  is	  the	  optimal	  glycaemic	  control	  in	  patients	  with	  DM	   and	   CHF.	   Studies	   that	   assessed	   the	   importance	   of	   glycaemic	   control	   in	  diabetic	   patients	   with	   CHF	   (6-­‐9,12)	   usually	   used	   a	   single	   measure	   of	   HbA1c	  which	   underestimated	   the	   importance	   of	   overall	   glycaemic	   control	   (13).	  	  Calculation	  of	  a	  mean	  HbA1c	  has	  been	  found	  to	  be	  a	  better	  predictor	  of	  diabetic	  complications	  (2,14,15)	  as	   it	   incorporates	  multiple	  measures	  over	  time	  (2,13).	  Therefore,	  we	  conducted	  a	  study	  to	  determine	  the	  relationship	  between	  mean	  
HbA1c	  and	  outcome	  in	  a	  large	  cohort	  of	  patients	  with	  T2DM	  and	  incident	  CHF.	  
	   CHAPTER	  2:	  GLYCAEMIC	  CONTROL	  AND	  OUTCOME	  IN	  PATIENTS	  WITH	  CHF	  
STUDY	  AIM	  AND	  OBJECTIVE	  
In	   a	   retrospective	   analysis,	   we	   sought	   to	   determine	   the	   relationship	  between	  mean	  HbA1c	  and	  outcome	  in	  a	  large	  cohort	  of	  patients	  with	  T2DM	  and	  incident	  CHF.	  
STUDY	  POPULATION	  AND	  DESIGN	  
We	   performed	   a	   retrospective	   cohort	   study	   within	   the	   population	   of	  Tayside,	   Scotland	   (population	   400,000)	   between	   1st	   January	   1992	   and	   31st	  March	  2010	  exploiting	  the	  unique	  advanced	  medical	  informatics	  infrastructure	  available	   in	   the	   region.	   	  This	  makes	  use	  of	   a	  unique	  health	   record	   identifier	  –	  The	  Community	  Health	  Index	  number	  (CHI)	  which	  has	  been	  used	  for	  all	  patient	  healthcare	  activity	  in	  the	  region	  for	  the	  past	  20	  years.	  It	  means	  multiple	  clinical	  data	  sets	  can	  be	  deterministically	  linked	  at	  the	  level	  of	  the	  individual	  with	  high	  accuracy.	   	   Study	   subjects	   had	   both	   T2DM	   and	   CHF	   and	   were	   anonymously	  identified	   from	   three	   data	   resources;	   the	   Diabetes	   Audit	   and	   Research	   in	  Tayside	   Study	   (DARTS)	   (16),	   the	   Tayside	   echocardiographic	   database	  (>100,000)	   maintained	   by	   the	   Department	   of	   Cardiology,	   Ninewells	   Hospital	  and	   the	   Health	   Informatics	   dispensed	   prescribing	   database	   developed	   by	   the	  Medicines	  Monitoring	  Unit	   (MEMO)(17),	  which	   holds	   details	   on	   all	   dispensed	  prescriptions	  for	  all	  individuals	  in	  the	  region	  since	  1993.	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CHF	  was	  defined	  as	  a	  record	  of	  an	  echocardiogram	  with	  evidence	  of	  left	  ventricular	   systolic	   dysfunction	   (LVSD)	   and	   either	   a	   prescription	   for	   a	   loop-­‐diuretic	   (provided	   not	   greater	   than	   1	   year	   prior	   to	   echocardiogram)	   or	   an	  admission	   to	   hospital	  with	   an	   associated	   heart	   failure	   diagnostic	   code	   (ICD-­‐9	  428,	   ICD-­‐10	   I50).	   The	   index	   date	   for	   development	   of	   CHF	  was	   defined	   as	   the	  minimum	   of	   first	   echocardiogram,	   valid	   prescription	   for	   a	   loop	   diuretic	   or	  admission	  to	  hospital	  with	  CHF.	  We	  previously	  used	  similar	  criteria	  to	  identify	  CHF	  from	  large	  datasets	  in	  Tayside,	  and	  have	  refined	  the	  criteria	  for	  CHF	  with	  the	  inclusion	  of	  echocardiographic	  information	  (18).	  
HBA1C	  MEASURES	  
To	  be	  included	  in	  the	  study,	  patients	  were	  required	  to	  have	  at	  least	  two	  HbA1c	  measures	   recorded	   between	   index	   date	   and	   end	   of	   study.	   HbA1c	  was	  analysed	   as	   an	   updated	   mean.	   The	   updated	   mean	   was	   calculated	   for	   each	  individual	   from	  each	  year	  of	   follow-­‐up	  e.g.	   in	  year	  1	   the	  mean	  of	   the	  baseline	  HbA1c	   and	   all	   other	  HbA1cs	  measured	   in	   the	   first	   12	  months	  was	   calculated,	  year	  2	  is	  the	  mean	  of	  all	  measures	  at	  baseline	  years	  1	  and	  2	  and	  so	  forth	  until	  the	  end	  of	   the	   study	  period.	  A	  weighted	  mean	  HbA1c	  was	  calculated	  using	  all	  available	   HbA1c	   measures	   during	   the	   'at	   risk'	   study	   time.	   The	   mean	   was	  weighted	  by	  time	  between	  measures	  and	  was	  then	  used	  to	  group	  patients	  into	  five	  categories	  of	  HbA1c	  (≤6%,	  >6-­‐≤7%,	  >7-­‐≤8%,	  >8-­‐≤9%	  and	  >9%).	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  STATISTICAL	  ANALYSIS	  
Cox’s	  proportional	  hazards	  models	  (19)	  were	  used	  to	  model	   time	  to	  all	  cause	   death.	   The	   entry	   date	  was	   index	   date	   for	   diagnosis	  with	   CHF.	   Updated	  mean	   HbA1c	   was	   analysed	   as	   a	   time-­‐dependent	   covariate.	   Other	   covariates,	  averaged	  over	  the	  study	  period,	  which	  were	  utilized	  as	  continuous	  variables	  in	  the	  model	  included:	  age	  at	  diabetes	  diagnosis,	  age	  at	  index	  date,	  and	  estimated	  glomerular	  filtration	  rate	  (eGFR).	  History	  of	  smoking,	  history	  of	  ischaemic	  heart	  disease	   and	   cardiovascular	  medication	  use	   (aspirin,	   statins,	   thiazide	  diuretics,	  beta	  blockers,	  ACE	  inhibitors	  or	  ARBs,	  calcium	  channel	  blockers)	  were	  included	  as	   dichotomous	   variables.	   Diabetic	   medications	   (insulin	   therapy,	   oral	  hypoglycaemics	   only	   or	   no	   drug	   therapy)	   were	   considered	   as	   dichotomous	  time-­‐dependent	   covariates.	   Differences	   in	   patient	   characteristics	   were	  determined	   by	   chi-­‐squared	   test	   for	   linear	   trend	   for	   categorical	   variables	   and	  ANOVA	  test	  for	  linear	  trend	  for	  continuous	  variables	  with	  a	  two	  sided	  p-­‐value	  of	  <	  0.05	  considered	  significant.	  	  All	  statistical	  analysis	  was	  performed	  using	  SPSS	  for	  windows	  (v9.2)	  
RESULTS	  
PATIENT	  CHARACTERISTICS	  	   From	  an	   initial	  2567	  T2DM	  subjects	   in	   the	  echocardiographic	  database	  with	   evidence	   of	   left	   ventricular	   systolic	   dysfunction,	   1597	   (62%)	   had	   a	  hospitalisation	  for	  CHF	  and/or	  valid	  loop	  diuretic	  prescription.	  After	  exclusion	  for	  CHF	  incident	  date	  preceding	  DM	  diagnosis,	  1100	  subjects	  were	  left,	  of	  those	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795	  had	  an	  HbA1c	  measurement	  during	  their	  observable	  study	  period	  (Figure	  6).	  	  	  
	  
	  
FIGURE	  6	  CONSORT	  (Consolidated	  Standards	  of	  reporting	  trial)	  Diagram	  for	  Glycaemic	  Control	  and	  outcome	  in	  
patients	  with	  CHF	  	  	   Characteristics	  of	  the	  795	  patients	  in	  the	  study	  population	  are	  provided	  in	  Table	  2	  split	  by	  HbA1c	  category.	  Patients	  in	  the	  lowest	  two	  HbA1c	  categories	  had	   shorter	   study	   duration	   and	   therefore	   fewer	  HbA1c	  measures.	   They	  were	  diagnosed	  with	  CHF	  and	  T2DM	  at	  an	  older	  age,	  and	  had	  a	  lower	  BMI	  and	  eGFR	  at	  baseline.	  In	  addition,	  although	  not	  statistically	  significant,	  they	  tended	  to	  be	  more	  likely	  to	  smoke	  but	  had	  fewer	  myocardial	  infarction	  (MI)	  events	  prior	  to	  baseline.	  With	   respect	   to	   prescribing,	   there	  were	   relatively	  more	   diet	   treated	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and	  fewer	  insulin	  treated	  patients.	  They	  were	  also	  more	  likely	  to	  be	  prescribed	  thiazide	  diuretics	  at	  baseline.	  In	  addition,	  patients	  in	  the	  lowest	  category	  were	  prescribed	   less	   aspirin	   at	   baseline.	   In	   contrast,	   patients	   in	   the	   highest	  HbA1c	  category	  were	  diagnosed	  with	  CHF	  and	  T2DM	  at	   a	   younger	   age,	   had	   a	  higher	  BMI	   and	   eGFR,	   relatively	   more	   MI	   events	   at	   baseline,	   and	   comprised	   the	  smallest	  proportion	  of	  diet	  and	  largest	  proportion	  of	  insulin	  treated	  patients.	  In	  addition,	  they	  were	  more	  likely	  to	  be	  prescribed	  aspirin	  at	  baseline.	  	  
HBA1C	  AND	  MORTALITY	  	   Over	  a	  median	   follow	  up	  of	  3.8	  years,	   there	  were	  491(61.8%)	  all-­‐cause	  deaths.	  In	  a	  Cox	  regression	  model,	  adjusted	  for	  all	  other	  significant	  predictors,	  with	   the	   middle	   HbA1c	   category	   (>7-­‐≤8%)	   as	   the	   reference,	   we	   found	   a	   U	  shaped	  relationship	  of	  HbA1c	  and	  outcome	  with	  the	  two	  lowest	  and	  the	  highest	  HbA1c	  categories	  significantly	  associated	  with	  a	  higher	  risk	  of	  death	  (HR	  95%	  CI	   1.78(1.26-­‐2.52);	   1.29(1.01-­‐1.66)	   and	   1.38(1.03-­‐1.84)	   respectively)	   (Figure	  7).	  	  
	  
HBA1C	  AND	  MORTALITY:	  DIET	  AND	  DRUG	  TREATED	  T2DM	  	   To	  more	  carefully	  explore	  this	  U	  shaped	  association,	  we	  considered	  the	  HbA1c	   ≤7%	   group	   and	  made	   a	   comparison	   of	   patients	   split	   by	   diet	   and	   drug	  treatment	  (Table	  3).	  The	  diet	  treated	  T2DM	  patient	  group	  were	  diagnosed	  with	  diabetes	   at	   an	   older	   age,	   had	   a	   lower	   study	   and	   baseline	   HbA1c	   and	   were	  prescribed	   less	   ACE	   inhibitors	   at	   baseline.	   Significantly,	   when	   comparing	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baseline	  HbA1c	   and	   study	  HbA1c,	   there	  was	   no	   difference	   in	   the	   diet	   treated	  group	  ((mean	  ±SD)	  (6.01±	  0.64	  vs.	  6.07±	  0.52),	  p=0.29),	  but	  in	  the	  drug	  treated	  group	   HbA1c	   was	   significantly	   lower	   after	   CHF	   diagnosis	   ((7.42±	   1.18)	   vs.	  (6.36±	   0.47),	   p<0.0001)	   indicating	   that	   drug	   treatment	   resulted	   in	   more	  aggressive	  HbA1c	  lowering.	  	  
We	  therefore	  went	  on	  to	  split	   the	  entire	  study	  population	   into	  diet	  and	  drug	  treated	  to	  investigate	  the	  relationship	  between	  HbA1c	  and	  death	  in	  these	  groups	   separately.	   As	   the	   number	   of	   patients	   in	   each	   group	   is	   smaller	   and	  Figure	   6	   indicated	   a	   U-­‐shaped	   relationship	   between	   HbA1c	   and	   death,	   we	  reduced	  the	  number	  of	  HbA1c	  categories	  to	  three	  (≤7,	  >7-­‐≤9,	  >9).	  The	  adjusted	  and	   unadjusted	   Cox	   regression	   models	   are	   presented	   in	   Table	   4.	   In	   the	   diet	  treated	  group,	   lower	  HbA1c	  was	  associated	  with	   lower	  risk	  of	  death.	  Whereas	  the	  U	  shaped	  association	  observed	  in	  the	  overall	  study	  population	  remained	  in	  the	  drug	  treated	  group.	  	  
DISCUSSION	  
This	  study	  had	  2	  main	   findings.	  Firstly,	   in	  our	  cohort	  of	  T2DM	  patients	  with	  incident	  CHF,	  we	  observed	  a	  U	  shaped	  relationship	  between	  mortality	  and	  glycaemic	  control,	  as	  assessed	  by	  a	  mean	  HbA1c.	  Secondly,	  additional	  analysis	  show	   that	   this	  U	   shape	   relationship	   is	   present	   in	  drug	   treated	  but	  not	   in	  diet	  treated	   T2DM	   patients.	   In	   diet	   treated	   patients,	   lower	   HbA1c	   was	   associated	  with	   lower	   mortality	   risk.	   These	   latter	   observations	   may	   suggest	   that	   the	  outcomes	  observed	  in	  the	  low	  HbA1c	  categories	  may	  be	  related	  to	  the	  response	  of	  patients	  to	  the	  DM	  drug	  medications.	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The	   relationship	   between	   glycaemic	   control	   and	   outcome	   in	   patients	  with	   CHF	   and	   T2DM	   has	   previously	   been	   studied	   in	   at	   least	   4	   retrospective	  studies	   with	   different	   conclusions	   reported.	   The	   relationship	   between	  glycaemic	   control	   and	   outcome	   has	   been	   reported	   to	   be	   	   “U”	   shaped	   (6),	   	   “J”	  shaped	   (12),	   linear	   (8)	   and	   even	   inverse	   (7).	   	   In	   the	   most	   recent	   analysis,	  Aguilar	   et	  al	   (6)	   performed	   a	   retrospective	   analysis	   of	   5815	   	   veterans	   (94	  %	  male)	   with	   T2DM	   and	   CHF	   defined	   by	   clinic	   coding,	   45.5%	   of	   which	   had	  significantly	   impaired	  LV	   function.	  Over	  a	  2	  year	   follow-­‐up	   they	  observed	  a	  U	  shaped	   relationship	   between	   HbA1c	   and	   mortality,	   with	   a	   “sweet	   spot”	   seen	  with	   individuals	   in	   quintile	   3	   (HbA1c	   7.1-­‐7.8	   %).	   Compared	   to	   Q3,	   all	   other	  quintiles	   had	   significantly	   elevated	   risk	   of	   death	   at	   2	   years	  with	   those	   in	   the	  lowest	   and	   highest	   quintiles	   faring	   worst.	   	   Our	   data	   would	   support	   these	  findings.	   It	   should	   be	   noted	   that	   Aguilar’s	   study	   like	   all	   the	   previous	   studies,	  only	   a	   single	   HbA1c	  was	   used	   to	   assess	   glycaemic	   control.	   However,	   a	   single	  HbA1c	  may	  not	  be	  reliable,	  especially	  if	  sampled	  at	  the	  time	  of	  the	  diagnosis	  of	  CHF	   when	   it	   is	   potentially	   influenced	   by	   recent	   alterations	   in	   therapy.	  Individuals	  may	  consult	  physicians	  with	  symptoms	  prior	  to	  diagnosis	  leading	  to	  alterations	   in	   oral	   hypoglycaemics	   or	   initiation	   of	   diuretic	   therapy	   that	   may	  affect	   the	   single	   HbA1c	   measurement	   recorded	   in	   the	   specialist	   clinic	   at	   the	  time	  of	  CHF	  diagnosis.	   Indeed,	   the	  practice	  of	  using	  baseline	  HbA1c	   in	  studies	  on	   diabetes	   complications	   can	   lead	   to	   underestimation	   of	   the	   importance	   of	  HbA1c	  as	  a	   risk	   factor,	   as	  only	  one	  value	   is	  used	   (13,15).	   Studies	  have	  shown	  that	  HbA1c	  levels	  have	  a	  persistent	  effect	  on	  complications	  several	  years	  after	  their	  measurement	  (20,21).	  Our	  data	  are	  unique	  as	  we	  were	  able	   to	  utilise	  all	  HbA1c	   measures	   recorded	   for	   each	   individual,	   enabling	   us	   to	   consider	   the	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importance	   of	   longer	   term	   glycaemic	   control	   over	   a	   long	   period	   of	   time	   in	   a	  large	   patient	   cohort.	   In	   our	   study,	   we	   used	   a	  weighted	  mean	   to	   examine	   the	  impact	  of	  glycaemic	  control	  on	  outcome.	  The	  mean	  HbA1c	  has	  been	  shown	  to	  offer	  superior	  predictive	  power	  over	  time	  when	  compared	  to	  a	  single	  baseline	  measure,	   which	   can	   result	   in	   underestimations	   of	   the	   impact	   of	   glycaemic	  control	   (2,13,22).	   It	   should	   be	   noted	   that	   other	   HbA1c	   variables	   have	   been	  studied	   including	   the	   last	   HbA1c	   value	   and	   HbA1c	   variation	   as	   described	   by	  standard	  deviation,	  neither	  of	  which	  has	  been	  shown	  to	  be	  superior	  to	  the	  mean	  (14,23).	   Importantly,	   the	  weighted	  mean	  HbA1c	   and	   our	  median	   follow-­‐up	   of	  3.8	   years	   enhances	   the	   ability	   of	   this	   study	   to	   accurately	   determine	   the	  relationship	   between	   HbA1c	   and	   mortality,	   as	   the	   predictive	   power	   of	   mean	  HbA1c,	  out	  with	  CHF,	  is	  known	  to	  increase	  with	  longer	  study	  length	  (20-­‐22).	  	  
The	   finding	   of	   a	   higher	   mortality	   risk	   in	   patients	   in	   the	   lower	   HbA1c	  categories	   (HbA1c	  ≤6%	  and	  HBA1c	  >6-­‐≤7%)	  deserves	   some	   consideration.	   In	  our	  study,	  patients	  in	  these	  low	  HbA1c	  categories	  had	  both	  favourable	  and	  less	  favourable	   clinical	   characteristics.	   On	   one	   hand,	   these	   patients	   had	   fewer	  previous	  MIs	  and	  had	   less	   intensive	  DM	  treatment	  with	   less	  use	  of	   insulin.	  On	  the	  other	  hand,	  these	  patients	  were	  older	  when	  they	  developed	  their	  CHF	  and	  they	  had	   a	   lower	   eGFR.	   Interpretation	   of	   these	   findings	   is	   always	   going	   to	   be	  limited	  by	  a	  lack	  of	  information	  on	  the	  underlying	  cause	  of	  death.	  However,	  our	  finding	   that	   this	  U	  shaped	  relationship	  was	  present	   in	  drug	   treated	  but	  not	   in	  diet	  treated	  T2DM	  patients	  may	  suggest	  that	  the	  outcomes	  observed	  in	  the	  low	  HbA1c	   categories	   may	   be	   related	   to	   the	   response	   of	   patients	   to	   the	   DM	  medications.	   This	   group	   of	   patients	   had	   developed	   their	   CHF	   later	   in	   life	   and	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may	   be	   more	   vulnerable	   to	   hypoglycaemia	   as	   a	   result	   of	   sulphonylurea	   and	  insulin	   use,	   which	   can	   contribute	   to	   morbidity	   and	   mortality	   in	   high-­‐risk	  patients	  with	  low	  HbA1c	  (24).	  	  It	  should	  be	  noted	  that	  the	  current	  findings	  are	  concordant	  with	  recent	  ACCORD(25)	  study,	  which	  demonstrated	  that	  very	  tight	  control	   of	   glucose	   in	   patients	  with	   diabetes	  may	   not	   be	   beneficial	   in	   patients	  with	  existing	  cardiovascular	  disease	  and	  a	  longer	  duration	  of	  diabetes.	  	  
In	  our	  study,	  we	  also	  observed	  a	  poor	  outcome	  in	  CHF	  patients	  with	  the	  highest	  HbA1c.	   In	   a	   sense,	   this	  was	  not	   unexpected.	   These	  patients	   had	  more	  previous	   MIs	   at	   baseline,	   had	   more	   aggressive	   DM	   therapy	   with	   the	   largest	  proportion	   of	   insulin	   treated	   patients.	  With	   respect	   to	   CHF	   patients,	   there	   is	  conflicting	  data	  on	  the	  relationship	  between	  insulin	  use	  and	  outcome	  in	  T2DM	  patients	  with	  CHF.	  Although	  T2DM	  on	  insulin	  had	  a	  higher	  risk	  of	  death	  in	  CHF	  trials	  (8)	  (26),	  the	  UKPDS	  33	  study	  (27)	  as	  well	  as	  a	  retrospective	  cohort	  study,	  of	  16	  000	  Medicare	  diabetic	  beneficiaries	  with	  CHF,	  showed	  that	  insulin	  use	  did	  not	  predict	  mortality	  (28).	  	  Those	  with	  poorer	  control	  also	  tended	  to	  come	  from	  more	   deprived	   socio-­‐economic	   groups	  which	   is	   known	   to	   be	   an	   independent	  risk	   factor	   for	   poor	   outcome	   in	   diabetes	   (29).	   	   Furthermore,	   our	   finding	   of	   a	  poor	  outcome	  among	  patients	  with	  poor	  glycaemic	  control	   is	  concordant	  with	  studies	   showing	   the	   wide	   spread	   and	   detrimental	   effects	   of	   hyperglycaemia	  including	  progressive	  atherosclerosis,	  elevated	  levels	  of	  advanced	  glycation	  end	  products	   which	   may	   lead	   to	   increased	   myocardial	   stiffness	   (30),	   diabetic	  nephropathy,	   endothelial	   dysfunction	   (31),	   	   microangiopathy	   (32),	   increased	  oxidative	  stress	  (33)	  and	  protein	  kinase	  C	  activation	  (34).	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Obviously,	   the	   mechanisms	   for	   reduced	   survival	   associated	   with	   both	  very	   tight	   glycaemic	   as	   well	   those	   with	   poor	   glycaemic	   control	   in	   CHF	   must	  remain	  speculative	  and	  cannot	  be	  inferred	  directly	  from	  this	  study.	  
LIMITATIONS	  	  
We	  recognize	  the	   limitations	  of	  our	  study,	  which	  are	   inherent	  with	  any	  retrospective,	  non-­‐randomized,	  observational	  data.	  However,	  the	  current	  study	  reflects	   the	   true	  population	   and	   a	   “real	  world	   scenario”	   and	   adds	   to	  previous	  studies	  by	  selecting	  a	  large	  number	  of	  patients	  with	  T2DM	  and	  CHF	  with	  a	  long	  follow-­‐up	  period.	  In	  common	  with	  all	  observational	  studies,	  it	  was	  impossible	  in	  our	   study	   to	   account	   for	   all	   confounding	   influences	   that	  may	   have	   biased	   the	  observed	   differences	   between	   the	   groups	   considered.	   We	   have	   sought	   to	  minimise	   these	   as	   far	   as	   practicable	   by	   utilising	   multivariate	   models	   and	  incorporating	   data	   on	   drug	   prescribing,	   laboratory	   blood	   tests	   and	   smoking	  status.	   Additionally	  we	   utilised	  multiple	   HbA1c	  measures	   for	   each	   individual,	  and	  as	  these	  were	  not	  sampled	  at	  specified	  intervals	  this	  may	  potentially	  result	  in	  survival	  bias	  for	  those	  who	  have	  a	  greater	  number	  of	  measures,	  in	  turn	  this	  was	  minimised	  by	  utilising	  a	  mean	  weighted	   for	   time.	  Due	   to	   the	   incidence	  of	  recording	  of	   renal	   function	  and	  BMI,	  we	  utilised	  a	  mean	  value	   throughout	   the	  study	   period	   in	   our	  model.	   The	   study	   does	   have	  much	   strength	   including	   the	  large	   number	   of	   subjects,	   the	   large	   number	   of	  HbA1c	  measures	   available,	   the	  high	   event	   rate	   (62%	   died)	   and	   the	   reliable	   and	   comprehensive	   data,	   which	  were	  available	  with	  which	  to	  build	  the	  statistical	  model.	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  CONCLUSION	  	  
In	   patients	   with	   T2DM	   and	   CHF,	   our	   observational	   study	   shows	   that	  there	  is	  a	  U	  shaped	  relationship	  between	  HbA1c	  and	  mortality	  with	  the	  lowest	  mortality	  risk	  in	  patients	  with	  modest	  glycaemic	  control	  (HbA1c,	  >7-­‐≤9%).	  This	  observational	   data	   adds	   support	   to	   the	   growing	   concern	   that	   we	   need	   to	  redefine	   the	   optimal	   HbA1c	   level	   in	   this	   high-­‐risk	   group	   of	   patients	   with	   co-­‐existing	  T2DM	  and	  CHF.	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Figure	  7:	  Hazard	  ratio	  by	  different	  HbA1c	  categories	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Table	  3:	  	  Clinical	  characteristics	  of	  HbA1c	  split	  by	  diabetes	  treatment	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TABLE	  4:	  Cox	  models	  analysing	  HbA1c	  by	  3	  categories	  	  	  
HbA1c	   >7	   -­‐	   ≤9%	   is	   the	   reference	   category.	   Bold	   values	   indicate	   a	   statistically	   significant	   test	  with	  
P<0.05.	  *There	  were	  no	  individuals	  in	  this	  group	  
	  
	  
	   All	  (n=795)	   Diet	  only	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   Drug	  treated	  only	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   CHAPTER	  3:	  INSULIN	  RESISTANCE	  AND	  CHF	  
INTRODUCTION	  
Diabetes	   and	   chronic	   heart	   failure	   (CHF)	   often	   co-­‐exist	   with	   an	   inter-­‐relationship	   such	   that	   each	   condition	   may	   impact	   on	   each	   other	   in	   terms	   of	  causation	  and	  outcome.	  This	  bi-­‐directional	  inter-­‐relationship	  between	  CHF	  and	  diabetes	   also	   extends	   to	   insulin	   resistance	   (IR).	   Longitudinal	   epidemiological	  data	  such	  as	   the	  Uppsala	  study	  of	  1187	  middle-­‐aged	  and	  elderly	  men	  showed	  that	   IR	   precedes	   and	   predicts	   the	   development	   of	   CHF,	   independent	   of	  established	  risk	  factors	  for	  CHF,	  including	  diabetes	  itself.	  They	  found	  a	  striking	  inverse	   relationship	   between	   the	   risk	   of	   incident	   CHF	   and	   insulin	   sensitivity.	  Insulin	   sensitivity	  was	   defined	   by	   euglycaemic	   insulin	   clamp	   glucose	   disposal	  rate	  (49).	  Other	  groups	  have	  also	  investigated	  the	  relationship	  between	  IR	  and	  CHF.	  Swan	  et	  al	  has	  previously	  assessed	  insulin	  sensitivity	  in	  patients	  with	  CHF	  using	   minimal	   modeling	   analysis	   (HOMA-­‐IR)	   during	   a	   weight	   adjusted	  intravenous	   glucose	   tolerance	   test	   in	   which	   they	   have	   established	   the	  relationship	   between	   the	   degree	   of	   IR	   and	   severity	   of	   CHF	   (Figure	   8)	   (50).	  Patients	   with	   CHF	   were	   associated	   with	   marked	   IR.	   Insulin	   sensitivity	   was	  reduced	  by	  58%	  in	  patients	  with	  CHF	  compared	  with	  healthy	  control	  subjects.	  Moreover,	   the	   degree	   of	   IR	   also	   correlates	   positively	   with	   severity	   of	   heart	  failure	  characterized	  by	  low	  peak	  oxygen	  consumption	  (VO2).	  Peak	  VO2	  derived	  from	   cardiac	   pulmonary	   exercise	   testing	   is	   a	   useful	   prognosticator	   to	   assess	  outcomes	   in	  CHF	   (51,52).	  Doehner	  et	   al	  has	   shown	   that	   the	  presence	  and	   the	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severity	  of	  IR	  in	  patients	  with	  CHF	  were	  independently	  associated	  with	  a	  poorer	  outcome,	  characterized	  by	  reduced	  peak	  VO2	  and	  NYHA	  classes	  (53).	  
	  
Figure	  8:	  Heart	  Failure:	  An	  Insulin	  Resistant	  state	  
Heart	   Failure	   is	   associated	   with	   dysglycaemia	   and	   inversely	   correlates	   with	   insulin	  
sensitivity.	  Swan	  et	  al.	  J	  Am	  Coll	  Cardiol	  1997;30:527-­‐32	  	  
It	  should	  be	  noted	  that	  all	  these	  studies	  have	  utilized	  the	  HOMA-­‐IR	  during	  an	  intravenous	  glucose	  tolerance	  test	  to	  determine	  insulin	  resistance/	  sensitivity,	  which	  is	  a	  demanding	  technique.	  We	  recently	  evaluated	  the	  prevalence	  of	  IR	  in	  patients	  with	  CHF	  using	  fasting	  insulin	  resistance	  index	  (FIRI),	  which	  consists	  of	  the	  product	  of	  plasma	  insulin	  and	  glucose	  divided	  by	  25.	  The	  presence	  of	  IR	  is	  defined	  by	  FIRI	  of	  ≥2.7	  according	  to	  local	  laboratory	  normal	  ranges	  (54).	  Among	  92	  non-­‐diabetic	  patients	  with	  CHF,	  67%	  of	  these	  patients	  were	  insulin	  resistant.	  IR	  is	  highly	  prevalent	  in	  CHF	  population,	  and	  the	  degree	  of	  IR	  also	  correlates	  with	  severity	  of	  CHF,	  characterized	  by	  higher	  NYHA	  classes	  and	  lower	  peak	  VO2	  and	  cardiac	  output	  (55)	  (Figure	  9).	  The	  presence	  of	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IR	  also	  correlates	  with	  poorer	  endothelial	  function	  compared	  to	  CHF	  patients	  without	  IR.	  
	  
Figure	  9:	  Relationship	  between	  Insulin	  Resistance	  and	  Severity	  of	  CHF	  
Degree	   of	   insulin	   resistance	   correlates	   with	   severity	   of	   heart	   failure	   and	   insulin	  
resistance	   is	   associated	  with	   significant	   reduction	   in	  exercise	   capacity.	  Alzadjali	   et	   al.	   J	  
Am	  Coll	  Cardiol	  2009;53:747-­‐53	  	  
More	   importantly,	   IR	   in	  CHF	  not	  only	  predicts	  disease	  severity	  but	  also	  mortality	   (35).	   In	   a	   community-­‐based	   HF	   clinic,	   Goode	   et	   al	   assessed	   the	  prognostication	  of	  HbA1c	  for	  mortality	  in	  patients	  with	  HF	  in	  970	  non-­‐diabetic	  patients	  who	  were	   referred	   to	   HF	   clinic.	   Patients	  with	   reduced	   EF	   of	   ≤	   45%,	  HbA1c	  of	  >6.7%	  were	  associated	  with	   an	  abrupt	   increase	   in	  mortality	   (n=68)	  compared	  with	   those	  with	  HbA1c	  of	  ≤6.7%	  (n	  =	  368)	   (hazard	   ratio	   (HR):	  2.4,	  p<0.001).	  This	  observation	  persisted	  after	  adjustment	  for	  age	  and	  comorbidity	  (HR	   1.9,	   p	   =	   0.008)	   with	   respective	   1-­‐year	   mortalities	   of	   26.5%	   and	   9.4%.	  Conversely,	   this	   increase	   in	  mortality	  was	  not	  observed	   in	   those	  with	  LVEF	  of	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greater	  than	  45%	  (HR	  1.44,	  p	  =	  0.36	  after	  adjustment)(12).	  	  The	  exact	  role	  of	  IR	  in	  patients	  with	  CHF	  is	  still	  yet	  to	  be	  defined,	  as	  these	  observational	  studies	  do	  not	  distinguish	  between	  the	  cause	  and	  effect.	  
PATHOPHYSIOLOGY	  OF	  IR	  AND	  CHF	  
	   Does	  IR	  lead	  to	  CHF	  or	  CHF	  lead	  to	  IR?	  There	  are	  still	  no	  definite	  answers	  to	  these	  questions.	  IR	  and	  CHF	  are	  a	  pair	  of	   intricate	  disease	  with	  overlapping	  pathophysiological	  processes.	  What	  we	  do	  know	  from	  observational	  studies	  on	  certain	   rare	   genetic	   diseases	   associated	   with	   severe	   IR	   such	   as	   Alstrom	  syndrome,	  60%	  of	  these	  patients	  progressed	  to	  severe	  dilated	  cardiomyopathy	  (DCM)	  (56).	  The	  presence	  of	  cardiomyopathy	  in	  the	  absence	  of	  coronary	  artery	  disease	  and	  hypertension	  is	  increasingly	  recognized	  in	  diabetic	  patients,	  but	  the	  exact	  pathophysiology	  is	  still	  remained	  to	  be	  defined.	  Rodent	  models	  were	  used	  to	  study	  the	  relationship	  between	  diabetes	  and	  cardiomyopathy	  as	  rodents	  are	  resistant	   to	   atherosclerosis;	   therefore,	   these	   have	   provided	   evidence	   on	   the	  occurrence	  of	  IR	  or	  diabetic	  cardiomyopathy	  in	  the	  absence	  of	  coronary	  artery	  disease	   and	   hypertension.	   	   Various	   in	   vivo	   or	   in	   vitro	   measurements	   were	  performed	   during	   the	   study	   of	   these	   animal	   models.	   Type	   1	   diabetes	   (either	  streptozotocin-­‐induced	  rats	  or	  genetic	  non-­‐obese	  diabetic	  mice)	  (57-­‐60)	  rodent	  models	   have	   been	   shown	   to	   have	   echocardiographic	   evidence	   of	   systolic	   and	  diastolic	   dysfunction	   (57,61),	   endothelial	   dysfunction	   (58),	   elevated	   LV	   end-­‐diastolic	   pressure,	   reduced	   LV	   systolic	   pressure,	   cardiac	   output	   and	   cardiac	  power	   (62).	   However,	   studies	   on	   Type	   2	   diabetic,	   insulin	   resistant,	   obese	  Zucker	   rats	   have	   yielded	   conflicting	   results	   (63,64).	   It	   is	   likely	   that	   these	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conflicting	   findings	   arose	   from	   different	   models	   used;	   as	   Type	   1	   and	   Type	   2	  diabetic	   rodent	   models	   have	   different	   cardiac	   energy	   metabolism	   and	  neurohormonal	  changes,	  resulting	   in	  different	   impact	  on	  cardiac	   function.	  The	  severity	  of	  cardiomyopathy	  may	  vary	  among	  different	  models	  depending	  upon	  the	   severity	   and	  duration	   of	   alterations	   of	   plasma	  parameters	   such	   as	   insulin	  level,	  leptin,	  glucose,	  fatty	  acids,	  cytokines,	  tumour	  necrosis	  factor-­‐alpha	  (TNF-­‐α).	   Therefore,	   experimental	   data	   obtained	   using	   animals	   models	   of	   diabetes	  should	   be	   used	   in	   caution	   when	   extrapolating	   to	   the	   human	   diabetes.	  Additionally,	   aetiology	   of	   cardiomyopathy,	   neurohormonal	   changes	   and	  severity	   of	   these	   alterations	   may	   vary	   between	   animal	   and	   patients	   with	  diabetes	  mellitus	  (65).	  
	  	   In	   a	   chronically	   pacing	   dog	   model,	   Nikolaidis	   et	   al	   have	   successfully	  shown	   us	   how	   CHF	   can	   lead	   to	   IR	   (66).	   Thirty-­‐four	   conscious,	   chronically	  instrumented	  dogs	  were	  studied	  at	   four	  stages	  during	   the	  evolution	  of	  dilated	  cardiomyopathy	  (DCM)	  induced	  by	  rapid	  right	  ventricular	  pacing.	  They	  showed	  that	  severe	  DCM	  is	  associated	  with	  the	  development	  of	  myocardial	  and	  systemic	  IR.	   There	   was	   impaired	   myocardial	   glucose	   uptake	   and	   altered	   myocardial	  insulin	   signaling,	   involving	   decreased	   Ser	   473	   phosphorylation	   of	   Akt-­‐1.	  Myocardial	  insulin	  resistance	  in	  advanced,	  severe	  DCM	  was	  also	  associated	  with	  reduced	   myocardial	   adenosine	   triphosphate	   (ATP)	   levels.	   There	   are	   no	   clear	  explanations	   of	   how	   IR	   leads	   to	   worsening	   of	   CHF.	   Various	   research	   groups	  have	   proposed	   a	   few	   possible	   hypotheses	   on	   the	   overlapping	  pathophysiological	  processes	  in	  both	  conditions	  over	  the	  last	  decade.	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(1)	   SYMPATHETIC	  NERVOUS	  SYSTEM	  AND	  RENIN-­‐ANGIOTENSIN	  ALDOSTERONE	  SYSTEM	  
	   ACTIVATION	  
	   CHF	   invokes	   compensatory	   sympathetic	   nervous	   system	   (SNS)	   and	  renin-­‐angiotensin	   aldosterone	   system	   activation,	  which	   leads	   to	   increase	   free	  fatty	   acids	   (FFA),	   thereby	   inhibits	   glucose	   uptake	   by	   muscle,	   and	   causes	  pancreatic	  damage.	  The	  increased	  plasma	  glucose	  elicits	  a	  compensatory	  insulin	  response	  but	  it	  is	  inadequate	  to	  compensate	  the	  hyperglycaemia	  because	  of	  the	  pancreatic	   damage	   mediated	   by	   cytokines	   such	   as	   TNF-­‐α,	   angiotensin	   II	   and	  FFA.	  This	  leads	  to	  aberrant	  metabolism	  and	  IR.	  The	  increased	  FFA	  and	  glucose	  predispose	   to	   increased	   hepatic	   synthesis	   of	   triglycerides	   (TG)	   and	   increased	  angiotensin	   II,	   which	   in	   turn	   increases	   tissue	   TG	   levels	   and	   promote	   insulin	  receptor	  substrate-­‐1	  damage	  in	  the	  pancreas,	  thereby	  magnifies	  IR.	  Angiotensin	  II	  also	  promotes	  vasoconstriction,	  which	  in	  turn	  increase	  cardiac	  afterload	  (36).	  Angiotensin	   II	   activation	   and	   SNS	   activation	   are	   also	   common	   features	   of	   IR	  secondary	  to	  the	  compensatory	  hyperinsulinaemia	  (37,38).	  	  
(2)	   INFLAMMATION	  
	   Systemic	   abnormalities	   in	   CHF	   have	   become	   a	   focus	   of	   cardiology	  research	  lately.	  IR	  and	  CHF	  are	  increasing	  recognized	  as	  an	  inflammatory	  state.	  There	   is	  mounting	  evidence	  to	  suggest	   that	   these	   inflammatory	  mediators	  can	  predict	  the	  development	  of	  IR	  or	  diabetes	  in	  population	  at	  risk	  (39-­‐42).	  Opie	  et	  al	  and	  Wisniaki	  et	  al	  	  (43)	  have	  both	  demonstrated	  that	  in	  insulin-­‐resistant	  	  CHF	  patients,	  C-­‐reactive	  protein,	  interleukin-­‐6,	  TNF-­‐α	  and	  its	  soluble	  receptors	  were	  all	  significantly	  elevated	  secondary	  to	  neuro-­‐hormonal	  activation.	  High	  level	  of	  circulating	   TNF-­‐α	   has	   been	   detected	   in	   cachectic	   patients	   with	   severe	   CHF	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(44,45),	   and	   it	   has	  been	   shown	   to	   correlate	  with	   leptin	   level,	   disease	   severity	  and	  poorer	   exercise	   tolerance	   (46).	   At	   a	  molecular	   level,	   TNF-­‐α	   increases	   the	  Ser	  phosphorylation	  of	  insulin	  receptor	  substrates	  results	  in	  reduction	  of	  auto-­‐phosphorylation	   of	   tyrosine	   and	   tyrosine	   kinase	   activities.	   The	   docking	   and	  interaction	   of	   IRS	   to	   its	   downstream	   effectors	   and	   kinase	   such	   as	   PI3-­‐K	   are	  markedly	  reduced,	  resulting	  in	  reduced	  glucose	  transport	  (47).	  These	  lead	  to	  IR	  and	   reduce	   myocytes'	   ability	   to	   utilize	   glucose	   as	   a	   substrate	   for	   ATP	  production.	   These	   maladaptive	   stress	   responses	   of	   IR	   and	   CHF	   have	   been	  recognized	   by	   Lip	   et	   al	   as	   a	   pro-­‐thrombotic	   state,	   and	   can	   lead	   to	  thrombogenesis	   and	   poorer	   clinical	   outcome	   (48).	   They	   concluded	   in	   their	  study	   that	   IL-­‐6	   and	   tissue	   factors	   (but	   not	   vascular	   endothelial	   growth	   factor	  (VEGF),	   plasma	   viscosity,	   von-­‐Willebrand	   factor,	   fibrinogen	   or	   soluble	   P-­‐selectin)	  levels	  were	  predictors	  of	  mortality	  and	  poor	  prognosis	  in	  patients	  with	  CHF.	  	  
(3)	   ALTERED	  ADIPOKINES	  LEVELS	  
LEPTIN	  	   Leptin,	   a	   product	   of	   ob-­‐gene,	   has	   received	   a	   great	   deal	   of	   attention	   in	  recent	  research	  on	  metabolic	  syndrome	  and	  heart	  failure.	  Leptin	  is	  an	  adipose	  tissue	   specific	   protein	   with	   immune-­‐modulatory	   properties.	   It	   plays	   an	  important	   role	   in	  weight	   regulations	  and	  energy	  expenditure.	  Leptin	  deficient	  mice	  have	  been	  shown	  to	  be	  susceptible	  to	  infections	  (49).	  Leptin	  release	  can	  be	  induced	   by	   pro-­‐inflammatory	   cytokines	   and	   catecholamines	   (50,51).	   Besides	  IR/	   diabetes	   (52,53)	   and	   CHF,	   elevated	   	   leptin	   levels	   were	   found	   in	   other	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conditions	   with	   a	   high	   level	   of	   circulating	   proinflammatory	   cytokines	   and	  catecholamines	   such	   as	   obesity	   (54),	   sepsis	   (55,56)	   and	   chronic	   obstructive	  airway	   disease	   (57).	   Leptin	   stimulates	   fatty	   acid	   oxidation	   (58)	   and	   glucose	  uptake	   (59).	   It	   prevents	   lipid	   accumulation	   in	   non	   adipose	   tissue,	   which	   can	  otherwise	   lead	   to	   lipotoxicity	   (60).	   Lipotoxicity	   of	   pancreatic	   beta-­‐cells,	  myocardium,	   and	   skeletal	   muscle	   leads,	   respectively,	   to	   type	   2	   diabetes,	  cardiomyopathy,	   and	   insulin	   resistance.	   High	   level	   of	   leptin	   has	   been	  consistently	   observed	   in	   patients	   with	   CHF	   (61,62)	   and	   correlates	   positively	  with	   IR	   (63)	   and	   levels	   of	   TNF-­‐α	   (64).	   Doehner	   et	   al	   hypothesized	   that	  hyperleptinaemia	  may	   result	   in	   impaired	   cardiac	   energy	  metabolism.	   	   Serum	  level	   of	   leptin	   also	   correlates	   with	   the	   progressive	   functional	   impairment	   of	  advanced	   CHF	   (46).	   But	   interestingly	   leptin	   level	   was	   found	   to	   be	   low	   in	  patients	  with	   advanced	   CHF	   and	   cachexia	   (65,66).	   These	   findings	  may	   be	   the	  end	  results	  of	  excessive	  loss	  of	  muscle	  and	  fat	  mass	  in	  patients	  with	  advanced	  CHF.	  	  
ADIPONECTIN	  	   Adiponectin,	  an	  adipocyte	  derived	  protein,	  which	  has	  anti-­‐inflammatory,	  	  insulin	  sensitizing,	  anti-­‐atherogenic	  properties	  (67).	  It	  also	  plays	  an	  important	  role	   in	   vascular	   remodeling.	   It	   has	   been	   researched	   extensively	   in	   various	  disease	  states	  lately	  particularly	  in	  patients	  with	  metabolic	  syndrome	  and	  CHF.	  Overweight	  individuals	  have	  reduced	  serum	  adiponectin	  levels.	  .	  Clinical	  studies	  have	   shown	   that	   adiponectin	   levels	  were	   low	   in	  patients	  with	   acute	   coronary	  syndrome	  (68)	  and	  T2DM	  (69),	  and	  were	  more	  closely	  related	  to	  the	  severity	  of	  insulin	   resistance	   and	   hyperinsulinaemia	   than	   to	   the	   degree	   of	   adiposity.	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Paradoxically,	   adiponectin	   levels	   are	   higher	   in	   patients	   with	   CHF.	   It	   was	   not	  related	   to	  BMI	   in	   these	  patients	   (64).	   The	   levels	   of	   adiponectin	   also	   correlate	  positively	  with	  severity	  of	  CHF	  determined	  by	  NYHA	  functional	  class	  and	  serum	  NT-­‐pro	  BNP	  levels.	  More	  importantly,	  elevated	  adiponectin	  levels	  were	  found	  to	  be	  a	  predictor	  of	  morbidity	  and	  mortality	  in	  CHF	  (70-­‐72).	  As	  stated	  earlier,	  CHF	  is	   an	   inflammatory	   condition	   associated	  with	   elevated	   inflammatory	  markers.	  Of	  particular	  interest,	  serum	  adiponectin	  levels	  were	  negatively	  correlated	  with	  serum	   inflammatory	  markers	   such	   as	   highly	   sensitive	   C-­‐reactive	   protein	   (hs-­‐CRP)	   (73,74).	   Why	   are	   adiponectin	   levels	   high	   in	   CHF	   rather	   than	   low	   as	   in	  other	   disease	   states	   such	   as	   atherosclerosis	   and	   acute	   coronary	   syndrome?	  Owing	   to	   its	   anti-­‐inflammatory	   and	   anti-­‐diabetic	   properties,	   it	   has	   been	  speculated	  that	  the	  elevated	  adiponectin	  levels	  parallel	  the	  neurohormonal	  and	  inflammatory	   axes	   in	   the	   pathophysiology	   of	   CHF	   (71,75),	   as	   part	   of	   the	  physiological	   protective	   response	   to	   counteract	   inflammation	   and	  neurohormonal	  activation	   (71).	  Recent	  clinical	   studies	  have	  demonstrated	   the	  significance	  of	  adipocytokines	  modulation	  in	  HF	  patients	  (76).	  Van	  Berendoncks	  et	   al	   have	   shown	   that	   adiponectin	   mRNA	   expression	   was	   increased	   in	   CHF	  patients.	  Whereas	  its	  receptors	  (AdipoR1)	  and	  its	  downstream	  metabolic	  genes	  (i.e.	   PPAR–α	   and	   AMPK)	   expressions	   were	   decreased	   in	   CHF	   patients.	   More	  importantly,	   they	   have	   shown	   that	   four	   months	   of	   endurance	   resistance	  exercise	   training	  normalized	   these	   levels,	   suggesting	   that	  modulation	  of	   these	  adipocytokines	  altered	  glucose	  and	  lipids	  metabolism	  at	  the	  muscle	  level.	  This	  further	   consolidates	   our	   understanding	   of	   the	   beneficial	   effects	   of	   exercise	  training	  in	  CHF.	  	  




We	  have	  now	  known	  that	  the	  adipose	  tissues	  play	  an	  essential	  part	  in	  the	  regulation	   of	   glucose	   and	   insulin	   metabolism	   through	   the	   release	   of	  adipocytokines.	  The	  adipocytokines	  also	  plays	  an	   important	   role	   in	   regulation	  of	  endothelial	  function	  and	  inflammation.	  Resistin	  has	  attracted	  a	  great	  deal	  of	  interest	   and	   attention	   in	   recent	   years.	  Resistin	  was	  originally	  described	   as	   an	  adipocyte-­‐secreted	   peptide	   that	   induced	   insulin	   resistance	   in	   rodents	   (77).	  Administration	  of	  resistin	  to	  healthy	  rats	  impairs	  glucose	  tolerance	  and	  insulin	  action.	  Resistin	   has	   recently	   been	   shown	   to	   induce	   beta	   cell	   apoptosis	   in	   rats	  (78).	  There	  is	  increasing	  recognition	  of	  its	  role	  in	  the	  inflammation	  (79).	  Recent	  study	  has	  shown	  that	  resistin	  activates	  human	  endothelial	  cells	  through	  the	  up-­‐regulation	  of	  cell	  adhesion	  molecules	  (80)	  and	  is	  a	  significant	  local	  and	  systemic	  regulatory	   cytokine	   involved	   in	   inflammation	   on	   vessels'	   walls	   in	   a	   rodent	  model	   (81).	   Serum	   resistin	   levels	   are	   increased	   in	   patients	   with	   T2DM.	   It	   is	  strongly	   associated	  with	   body	  mass	   index,	   and	   the	   degree	   of	   IR	  measured	   by	  HOMA-­‐IR	   and	   various	   ED	   and	   inflammatory	  markers	   (82).	  More	   importantly,	  there	   is	   a	   strong	   positive	   correlation	   between	   resistin	   level	   and	   the	  development	   and	   degree	   of	   mircoangiopathies	   	   (i.e.	   retinopathy,	   neuropathy	  and	  nephropathy)	  in	  patients	  with	  T2DM	  independent	  of	  age,	  gender,	  BMI,	  and	  either	  the	  duration	  of	  T2DM	  (P	  =	  0.0318)	  or	  serum	  creatinine	  (P	  =	  0.0092)	  (83).	  
In	  a	  correlation	  study	  of	  the	  serum	  level	  of	  resistin	  and	  exercise	  capacity	  in	  patients	  with	  stable	  coronary	  artery	  disease,	  elevated	  serum	  resistin	  was	  also	  associated	  with	  poor	  exercise	  capacity	  and	  exercise-­‐induced	  cardiac	  ischaemia.	  Adjustment	  for	  inflammatory	  markers	  attenuated	  these	  associations,	  suggesting	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a	  possible	  role	  for	  resistin	  in	  inflammation	  and	  the	  pathophysiology	  of	  coronary	  heart	   disease	   (84).	   Long-­‐term	   resistin	   over-­‐expression	  was	   associated	  with	   a	  complex	   phenotype	   of	   oxidative	   stress,	   inflammation,	   fibrosis,	   apoptosis	   and	  myocardial	  remodeling	  and	  dysfunction	  in	  a	  rodent	  model	  (85).	  Therefore,	  with	  increased	   understanding	   of	   the	   pathophysiological	   role	   of	   resistin,	   it	   is	   not	   a	  surprise	   to	   see	   that	   serum	   resistin	   levels	  were	   associated	  with	   incident	   heart	  failure,	  even	  after	  accounting	  for	  prevalent	  coronary	  heart	  disease,	  obesity,	  and	  measures	   of	   insulin	   resistance	   and	   inflammation	   from	   the	   Framingham	  Offspring	   study	   (86).	   This	   study	   suggested	   the	   pathophysiological	   role	   of	  resistin	   in	   HF.	   Similar	   findings	   were	   shown	   from	   the	   Heart	   and	   Soul	   Study	  where	  patients	  with	   coronary	  heart	  disease	  with	   resistin	   levels	   in	   the	  highest	  quartile	  were	  at	  an	  increased	  risk	  of	  heart	  failure	  (hazard	  ratio	  [HR],	  2.06;	  95%	  confidence	   interval	   [CI],	   1.26–3.39)	   and	   death	   (HR,	   1.56;	   95%	   CI,	   1.11–2.18),	  adjusted	   for	   age,	   sex,	   and	   race.	   However,	   these	   effects	  were	   neutralised	   after	  adjusting	   for	   traditional	   cardiovascular	   risk	   factors	   such	   as	   obesity,	  hypertension,	   insulin	   resistance,	   dyslipidaemia,	   and	   renal	   dysfunction	   (87).	  Nonetheless,	   the	   current	   literatures	   seem	   to	   suggest	   that	   resistin	   plays	   an	  important	   role	   in	   vascular	   biology,	   inflammation	   and	   is	   highly	   related	   to	   the	  development	  of	  IR	  and	  the	  development	  of	  HF.	  	  	  	  
(4)	  	   FORMATION	  OF	  ADVANCED	  GLYCOSYLATION	  END	  PRODUCTS	  
	   This	   process	   is	   greatly	   accelerated	   in	   diabetic	   patients.	   High	   level	   of	  advanced	   glycosylation	   end	   products	   in	   the	   myocardium	   leads	   to	   increased	  collagen	   cross-­‐linking	   and	   myocardial	   stiffness	   (88).	   This	   causes	   further	  deterioration	   of	   ventricular	   relaxation	   and	   contraction	   in	   patients	   with	   CHF.	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Chronic	   metformin	   use	   has	   been	   shown	   to	   prevent	   the	   above	   process	   and	  improve	  ventricular	  function	  in	  canine	  diabetic	  models	  (89).	  	  
	  
(5)	   HYPERINSULINAEMIA	  
	   Insulin	  is	  a	  catabolic	  hormone,	  and	  chronic	  hyperinsulinaemic	  state	  has	  been	   shown	   to	   increase	  myocardial	  mass	   and	   reduced	   cardiac	   output	   in	   rats	  (90).	  It	  can	  also	  lead	  to	  sodium	  retention	  (91)	  and	  subsequently	  decompensated	  heart	   failure.	   Besides	   that,	   hyperinsulinaemia	   also	   leads	   to	   activation	   of	   SNS	  (37),	   and	   increased	   pressor	   response	   to	   angiotensin	   II	   (38).	   Elevated	  catecholamine	  levels	   in	   CHF	   further	   antagonized	   insulin’s	   actions,	   which	  promote	   lipolysis,	   results	   in	   increased	   free	   fatty	   acid	   and	   worsened	   insulin	  resistance	  (92)	  and	  cardiac	  energy	  metabolism.	  The	  results	  of	  these	  effects	  are	  increased	   cardiac	   hypertrophy,	   collagen	   formation,	   myocardial	   fibrosis	   (93),	  and	  eventually	  worsening	  of	  CHF.	  	  
(6)	  	   SUBSTRATE	  UTILIZATION	  
	   In	   a	   normal,	   unstressed	   heart,	   energy	   in	   the	   form	   of	   ATP	   is	   mainly	  derived	   from	   free	   fatty	   acids	   (FFA)	   oxidation	   (94).	   Under	   pathological	   stress,	  the	   heart	   will	   switch	   from	   FFA	   oxidation	   to	   more	   fuel-­‐efficient	   glucose	  metabolism	  (95)	  (amount	  of	  ATP	  generated	  per	  molecule	  of	  oxygen	  consumed).	  IR	  is	  associated	  with	  a	  high	  level	  of	  circulating	  FFA.	  High	  supply	  of	  FFA	  exceeds	  the	   heart’s	   oxidative	   capacity,	   leading	   to	   accumulation	   of	   intra-­‐myocardial	  triglycerides,	   and	   hence	   lipotoxicity	   that	   worsens	   CHF	   (95-­‐98).	   High	   level	   of	  
CHAPTER	  3	  IR	  and	  CHF	  
	  
53	  
FFA	   impairs	   the	   heart’s	   ability	   to	   utilize	   glucose	   as	   a	   main	   source	   of	   ATP	  generation	  in	  different	  ways:	  	  
1. It	  impairs	  insulin	  mediated	  glucose	  uptake	  through	  inhibition	  of	  insulin	  receptor	  substrates	  and	  protein	  kinase-­‐B.	  	  	  2. PPAR-­‐α	   is	  activated,	  and	  this	  leads	  to	  the	  promotion	  of	  genes	  involved	  in	  FFA	  oxidation	  and	  pyruvate	  dehydrogenase	  kinase-­‐4	  (PDK-­‐4),	  which	  inhibits	   pyruvate	   dehydrogenase	   (PDH)	   and	   influx	   of	   pyruvate	   into	  mitochondrial.	  	  3. High	  level	  of	  acetyl-­‐CoA	  from	  β-­‐oxidation	  of	  FFA	  further	  activates	  PDK-­‐4,	  leading	  to	  further	  inhibition	  of	  PDH,	  hence	  pyruvate	  influx.	  	  4. Augmented	   acetyl-­‐CoA	   also	   leads	   to	   accumulation	   of	   citrate,	   which	  subsequently	   inhibits	   phosphofructose	   kinase-­‐1	   (PK1),	   a	   rate-­‐limiting	  enzyme	  of	  glycolysis.	  	  5. Increased	   FFA	   level	   also	   correlates	   with	   decreased	   myocardial	  phosphocreatinine-­‐to-­‐ATP	   (PCr/ATP)	   ratios,	   suggesting	   impaired	   ATP	  production	   (99).	   ATP	  production	   depends	   on	   the	   energy	   of	   the	   proton	  gradient	   across	   the	   mitochondrial	   inner	   membrane.	   High	   level	   of	   FFA	  activates	   the	   transcription	   factors	   of	   PPAR,	   leading	   to	   increased	  expression	   of	   mitochondrial	   uncoupling	   proteins	   (UCPs)	   expression	  (100).	   UCPs	   are	   also	   being	   up	   regulated	   in	   heart	   failure	   (100).	   UCP	  lowers	   the	   proton	   gradient	   by	   allowing	   protons	   to	   re-­‐enter	   the	  mitochondrial	  matrix	  with	  the	  production	  of	  heat	  rather	  than	  ATP	  (101).	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In	  severe	  CHF,	  myocardial	  IR	  results	  in	  reduced	  membrane	  translocation	  of	  GLUT-­‐4	  (decreased	  glucose	  uptake)	  and	  decreased	  phosphorylation	  of	  Akt-­‐1	  (decreased	   glucose	   metabolism)	   resulting	   in	   decreased	   ATP	   production.	   It	  further	   prevents	   the	   heart	   adaptive	   response	   to	   stress	   (deriving	   ATP	   from	  glucose	   metabolism	   rather	   than	   FFA	   oxidation).	   CHF	   in	   the	   setting	   of	   IR	   is	  probably	  the	  worst	  of	  all	  possibilities	   for	  energy	  metabolism.	  Gene	  expression	  for	  metabolizing	  FFA	  is	  down	  regulated	  due	  to	  CHF,	  and	  genes	  for	  metabolizing	  	  glucose	  are	  down	  regulated	  secondary	  to	  IR,	  preventing	  the	  heart	  from	  utilizing	  either	  fuel	  (102,103).	  
(7)	  	   ENDOTHELIAL	  DYSFUNCTION	  (ED)	  
The	   endothelium	   represents	   an	   active	   and	   reactive	   single	   layer	   cells	  	  	  	  	  	  	  that	  line	  all	  the	  blood	  vessels	  in	  the	  body	  (104).	  A	  healthy	  endothelium	  should	  consist	   of	   a	   smooth	   surface	   that	   limits	   the	   activation	   of	   clotting	   cascades	   and	  pro-­‐inflammation.	   Endothelial	   dysfunction	   is	   defined	   as	   inadequate	   or	  abnormal	   endothelial-­‐mediated	   vasodilatation,	   which	   eventually	   leads	   to	  activation	   of	   coagulation	   and	   clotting	   cascades	   and	   inflammation,	   and	  eventually	  development	  of	  atherosclerosis.	  It	  was	  first	  observed	  in	  patients	  who	  underwent	   diagnostic	   coronary	   angiography	   (105).	   ED	   and	   IR	   often	   co-­‐exist,	  and	  the	  combination	  of	  ED	  and	  IR	  were	  found	  among	  the	  individuals	  who	  are	  at	  higher	  risk	  of	  developing	  cardiovascular	  event	  (106).	   IR	  and	  ED	  represent	   the	  fundamental	   pathophysiological	   disturbance	   responsible	   for	   the	   clusters	   of	  metabolic	   and	   cardiovascular	   disease	   (107,108).	   The	   presence	   IR	   and	   ED	   are	  increasing	   recognised	   as	   a	   precursor	   to	   the	   development	   of	   atherosclerosis	  (109).	   ED	   leads	   to	   inadequate	   vasodilatation	   and/or	   paradoxical	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vasoconstriction	  in	  coronary	  and	  peripheral	  arteries	  in	  response	  to	  stimuli	  that	  release	  nitric	  oxide	  (NO).	  Deficiency	  of	  endothelial-­‐derived	  NO	  is	  believed	  to	  be	  the	  primary	  defect	  that	  links	  insulin	  resistance	  and	  endothelial	  dysfunction.	  NO	  deficiency	   can	   result	   from	   either	   decreased	   synthesis	   or	   accelerated	  degradation	  by	  high	  levels	  of	  reactive	  oxygen	  (ROS)	  and	  nitrogen	  (RNS)	  species,	  which	   are	   produced	   by	   cellular	   disturbances	   in	   glucose	   and	   lipid	  metabolism	  (110).	  ED	  is	  found	  in	  patients	  with	  insulin	  resistance	  prior	  to	  the	  development	  of	  diabetes,	  and	  is	  well	  described	  in	  obese	  patients,	  metabolic	  syndrome	  and	  in	  patients	  with	  gestational	  diabetes	  (111-­‐113).	  ED	  was	  detected	  in	  patients	  with	  early	  asymptomatic	  HF	  (114)	  as	  well	  as	  symptomatic	  HF	  (115).	  The	  presence	  of	  IR	  was	  associated	  with	  ED	  in	  patients	  with	  CHF	  (116).	  Deficiency	  in	  endothelial-­‐derived	  nitric	  oxide	  is	  believed	  to	  be	  the	  link	  between	  IR	  and	  ED	  (117).	  IR	  and	  ED	  have	  an	  impact	  on	  each	  other	  in	  terms	  of	  causation	  and	  outcome.	  There	  is	  a	  large	   body	   of	   evidence	   to	   show	   that	   IR	   is	   associated	  with	   ED	   (118,119).	   The	  exact	   mechanisms	   of	   how	   IR	   affects	   ED	   are	   not	   fully	   understood.	   Oxidative	  stress,	   hyperglycaemia,	   attenuation	   of	   insulin	   medicated	   NO	   release	   from	  vascular	   bed;	   dyslipidaemia	   and	   increased	   arginase	   activity	   have	   been	  suggested	  (120-­‐122).	  
ED	  can	  impact	  on	  insulin	  action	  by	  altering	  its	  trans-­‐capillary	  passage	  of	  insulin	   to	   target	   tissues,	   which	   results	   in	   abnormal	   tissues	  metabolisms,	   and	  accumulation	  of	  toxic	  metabolites,	  which	  in	  turns	  worsen	  IR.	  Vascular	  damage	  from	   oxidative	   stress	   and	   lipids	   deposition	   further	   induce	   localised	  inflammatory	  process	  that	  worsens	  IR	  and	  ED.	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The	  presence	  of	  ED	  is	  also	  an	  important	  prognosticator	  in	  patients	  with	  established	   cardiovascular	   disease	   independent	   of	   other	   established	  cardiovascular	   risk	   factors	   (123).	   Therefore,	   improving	   ED	   and	   IR	   may	  represent	   therapeutic	   targets	   to	   prevent	   the	   development	   of	   atherosclerosis	  and	  cardiovascular	  disease.	  	  
	  
CHAPTER	  SUMMARY	  
	   IR	  and	  CHF	  are	  an	  intricate	  pair	  of	  disease.	  There	  is	  increasing	  evidence	  to	  suggest	  that	  IR	  plays	  an	  important	  role	  in	  the	  pathophysiological	  processes	  in	  CHF.	  Activation	  of	  SNS	  and	  RAS,	  inflammation,	  altered	  adipocytokines	  levels,	  formation	  of	  advanced	  glycosylation	  products,	  changes	  of	  substrate	  utilization	  in	  the	  myocardium	  and	  endothelial	  dysfunction	  are	  possible	  explanations	  of	  how	  IR	  affecting	  disease	  process	  in	  CHF.	  With	  increased	  understanding	  of	  the	  pathophysiological	  role	  of	  IR	  in	  CHF,	  improving	  IR	  may	  potentially	  result	  in	  improvement	  of	  CHF.	  
	   CHAPTER	  4:	  PHARMACOLOGICAL	  TREATMENT	  FOR	  INSULIN	  RESISTANCE	  AND	  CHRONIC	  HEART	  FAILURE	  
	   In	   this	   section,	   we	   will	   consider	   pharmacological	   tools	   that	   can	   be	  utilized	  to	  reverse	  IR	  in	  patients	  with	  CHF.	  We	  are	  mindful	  that	  lifestyle	  changes	  are	   important,	  most	  notably	  exercise	  which	  has	  been	   shown	   to	   improve	   IR	   in	  patients	  with	   impaired	   glucose	   tolerance	   in	   the	  Diabetes	   Prevention	  Program	  (DPP)	  study	  (124).	  	  
CHF	  DRUGS	  THAT	  IMPACT	  ON	  IR	  
	   A	   recent	   meta-­‐analysis	   showed	   that	   drugs	   that	   inhibit	   the	   renin-­‐angiotensin	  system	  might	  prevent	  the	  onset	  of	  diabetes	  mellitus	  (DM).	  In	  their	  meta-­‐analysis,	   Andraws	   and	   Brown	   showed	   that	   in	   angiotensin	   converting	  enzyme	  (ACE)	  inhibitor	  trials,	  the	  odds	  of	  developing	  DM	  were	  reduced	  by	  28%	  (OR	  0.72,	  95%	  CI	  0.63	  to	  0.84,	  p<0.001),	  and	  in	  the	  angiotensin	  receptor	  blocker	  trials,	  there	  was	  a	  27%	  reduction	  (OR	  0.73,	  95%	  CI	  0.64	  to	  0.84,	  p<0.001)	  in	  the	  odds	   (125)	   compared	   to	   placebo	   or	   other	   antihypertensive	   agents	   such	   as	  calcium	   channel	   blockers	   and	   diuretics.	   With	   respect	   to	   beta-­‐blockers,	   there	  may	  be	  differences	  between	  beta-­‐blockers	  in	  their	  impact	  on	  insulin	  resistance	  (126).	  In	  the	  setting	  of	  CHF,	  carvedilol	  has	  shown	  superior	  effects	  in	  prevention	  of	  diabetes	  when	  compared	  with	  metoprolol	  in	  the	  COMET	  study	  (127).	  	  
Mineralocorticoid	  receptors	  are	  expressed	  in	  non-­‐epithelial	  tissues,	  such	  as	   blood	   vessels,	   the	   heart	   and	   adipose	   tissue.	   Mineralocorticoid	   receptors	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antagonist	   (MRA)	   had	   been	   shown	   to	   be	   beneficial	   in	   HF	   trials.	   There	   is	  increasing	   body	   of	   evidence	   to	   suggest	   the	   role	   of	   aldosterone	   in	   the	  pathophysiological	   process	   of	   HF,	   it	   is	   associated	   with	   fibrosis,	   worsening	  catecholamine	   process,	   inflammation	   and	   endothelial	   dysfunction	   (128).	   The	  Randomized	   Aldactone	   Evaluation	   Study	   (RALES)	   has	   shown	   mortality	   and	  morbidity	  benefit	   of	   adding	   spironolactone	   in	   addition	   to	   existing	  HF	   therapy	  during	  that	  time	  (129).	  Additionally,	  the	  newer	  MCA	  Eplerenone	  has	  also	  been	  shown	   to	   have	   striking	   mortality	   benefit	   in	   patients	   with	   LVSD	   following	  myocardial	  infarction	  (130)	  and	  also	  in	  milder	  HF	  population	  (131)	  in	  addition	  to	   RAS	   modulators	   (ACEi	   or	   ARB).	   Although	   both	   spironolactone	   and	  eplerenone	   are	   both	   MCAs,	   they	   have	   very	   different	   metabolic	   effects,	  particularly	   on	   IR	   or	   glycaemic	   control.	   In	   an	   animal	   model,	   the	   use	   of	  spironolactone	  was	   associated	  with	   an	   increased	   level	   of	   plasma	   aldosterone	  and	   impaired	   glucose	   tolerance	   compared	   to	   eplerenone	   (132).	  Whereas	   in	   a	  study	   examining	   the	   effects	   of	   eplerenone	   and	   spironolactone	  on	   cortisol	   and	  HbA1c	   levels	   in	   patients	   with	   chronic	   stable	   HF,	   plasma	   cortisol	   levels	   and	  HbA1c	  were	  significant	  higher,	  and	  adiponectin	  levels	  significantly	  decreased	  in	  patients	  taking	  spironolactone	  but	  remains	  unchanged	  in	  the	  eplerenone	  group	  (133).	   Eplerenone	   seems	   to	   have	   neutral	   metabolic	   effects	   on	   IR	   whereas	  spironolactone	   has	   been	   shown	   to	   upset	   glycaemic	   control	   in	   HF	   patients.	  Therefore,	  these	  metabolic	  effects	  should	  be	  considered	  when	  prescribing	  MCA	  to	  CHF	  patients	  with	  DM	  or	  IR.	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59	  DIABETIC	  DRUGS	  THAT	  IMPROVE	  IR	  
THIAZOLIDINEDIONE	  (TZDS)	  
TZDs	   (e.g.	   rosiglitazone	   and	   pioglitazone)	   belong	   to	   the	   high	   affinity	  ligands	  for	  the	  nuclear	  hormone	  receptor	  family	  member	  PPAR-­‐γ	  (134).	   	  They	  modulate	  the	  transcription	  of	  the	  insulin-­‐sensitive	  genes	  involved	  in	  the	  control	  of	   glucose	   and	   lipid	  metabolism	   in	   adipose,	   muscular	   tissue	   and	   in	   the	   liver.	  They	   improve	   insulin	  sensitivity	   in	   the	   liver	  and	  peripheral	   tissue,	  and	  reduce	  plasma	  insulin	  level	  and	  glycated	  haemoglobin.	  TZDs	  also	  improve	  lipid	  profiles	  and	  are	  associated	  with	  anti-­‐inflammatory	  and	  anti-­‐atherosclerotic	  properties	  (135).	  However,	   there	   have	   been	   reports	   of	   adverse	   cardiovascular	   outcomes	  associated	  with	   the	  use	  of	  TZDs,	  most	  notably	  with	  CHF	  hospitalizations.	   In	   a	  recent	  meta-­‐analysis,	  Lago	  and	  colleagues	  reported	  that	  TZDs	  increased	  risk	  for	  development	   of	   CHF,	   probably	   as	   a	   result	   of	   fluid	   retention,	   across	   a	   wide	  background	  of	  cardiac	  risk	  (relative	  risk	  [RR]	  1.72,	  95%	  CI	  1.21-­‐2.42,	  p=0.002)	  (136).	  At	  this	  time,	  the	  Food	  and	  Drug	  Administration	  (FDA)	  indicates	  that	  TZDs	  are	  not	  recommended	  for	  use	  in	  patients	  with	  NYHA	  functional	  class	  III/IV	  CHF,	  and	  have	  introduced	  a	  ‘black	  box’	  warning	  regarding	  the	  increased	  risk	  of	  CHF.	  There	  are	  additional	  concerns	  regarding	  the	  risk	  of	  myocardial	  infraction	  with	  TZDs	   especially	   with	   rosiglitazone.	   	   Recent	   results	   of	   different	  meta-­‐analyses	  were	   inconclusive	   as	   to	   whether	   rosiglitazone	   caused	   real	   adverse	   effects	   of	  myocardial	  infarction	  (137,138).	  The	  US	  FDA	  have	  placed	  a	  ‘black	  box’	  warning	  on	   rosiglitazone	   to	   signal	   potential	   of	  myocardial	   infarction	   and	  heart-­‐related	  deaths	  until	  additional	  safety	  data	  is	  available.	  The	  UK	  Commission	  on	  Human	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Medicines	  has	  reviewed	  the	  available	  data	  in	  year	  2010	  and	  has	  concluded	  that	  there	  is	  an	  increased	  cardiovascular	  risk	  for	  rosiglitazone.	  The	  Commission	  has	  therefore	   concluded	   that	   the	   benefits	   of	   rosiglitazone	   no	   longer	   outweigh	   its	  risks.	   The	   European	   Committee	   on	   Medicinal	   Products	   for	   Human	   Use	   has	  recommended	  the	  suspension	  of	   the	  marketing	  authorisations	  of	  rosiglitazone	  (Avandia,	  Avandamet)	  across	  the	  European	  Union.	  
METFORMIN	   	  
Another	   insulin	   sensitizing	  drug	   that	  may	  have	  potential	   use	   in	   CHF	   is	  metformin.	  Metformin	  has	  been	  on	  the	  market	  for	  almost	  50	  years	  and	  is	  widely	  prescribed	   in	   diabetic	   population.	   It	   was	   first	   described	   in	   the	   scientific	  literature	  in	  1957	  (139)	  and	  was	  first	  marketed	  in	  France	  in	  1979,	  but	  did	  not	  receive	  approval	  by	  FDA	  for	  the	  treatment	  of	  Type	  2	  diabetes	  until	  1994	  in	  the	  USA	   .	   It	   is	   cheap	   and	   has	   potent	   insulin	   sensitizing	   effect	   (140).	   Metformin,	  according	   to	   the	   package	   insert,	   is	   contraindicated	   in	   all	   patients	  with	   ‘’heart	  failure	   requiring	   pharmacologic	   treatment’’	   because	   of	   increased	   risk	   of	  potentially	   lethal	   lactic	   acidosis	   (LA)	   (141).	   This	   stems	   from	   the	   previous	  reports	   of	   severe	   LA	  with	   phenformin,	   another	   biaguanide	   that	  was	   removed	  from	  the	  market	  after	  306	  cases	  of	  LA	  were	  reported	  in	  the	  1970s.	  However,	  the	  available	   evidence	   of	   the	   risk	   of	   LA	   with	   metformin	   is	   somewhat	   lacking	  (142,143).	  Indeed,	  the	  reported	  incidence	  of	  LA	  related	  to	  metformin	  have	  been	  extremely	   low	   in	   large	   observational	   studies	   and	   metformin	   levels	   do	   not	  correlate	  with	  lactate	  levels	  in	  individuals	  who	  develop	  LA	  which	  may	  support	  the	   notion	   that	   metformin	   may	   be	   ‘an	   innocent	   bystander’’	   in	   sick	   patients	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rather	  than	  the	  causal	  agent	  (144,145).	  	  The	  overall	  rate	  of	  LA	  with	  metformin	  has	  been	  estimated	  at	  6.3	  cases	  per	  100,000	  patient-­‐years	  (143).	  
With	  respect	  to	  studies	  reporting	  the	  use	  of	  metformin	  in	  CHF,	  there	  has	  been	   several	   analyses	   of	   prescribing	   databases.	   In	   a	   retrospective	   cohort	  analysis	   by	   Masoudi	   et	   al	   (28),	   16417	   Medicare	   beneficiaries	   with	   diabetes	  discharged	  after	  hospitalization	  with	  the	  principle	  discharge	  diagnosis	  of	  heart	  failure	  were	  assessed.	  The	  primary	  outcome	  of	  the	  study	  was	  time	  to	  death	  due	  to	  all	  causes.	  Secondary	  outcomes	  included	  time	  to	  readmission	  for	  all	  causes	  or	  for	   heart	   failure.	   Crude	   1-­‐year	   mortality	   rates	   were	   lower	   among	   the	   2226	  patients	   treated	   with	   TZDs	   (30.1%)	   or	   the	   1861	   treated	   with	   metformin	  (24.7%)	   compared	   with	   that	   among	   the	   12069	   treated	   with	   neither	   insulin-­‐sensitizing	  drug	  (36%,	  P=<0.0001	  for	  both	  comparisons)(Figure	  10).	  The	  study	  concluded	   that	   these	   treatments	   are	   not	   associated	   with	   increased	   mortality	  and	  may	   improve	   outcomes	   in	   older	   patients	  with	   diabetes	   and	   heart	   failure.	  Admissions	  for	  all	  causes	  did	  not	  differ	  with	  either	  insulin	  sensitizer.	  There	  was	  a	   higher	   risk	   of	   readmission	   for	   heart	   failure	  with	   TZDs	   treatment	   (HR	   1.06,	  95%	  CI	  1.00	  to	  1.09)	  and	  lower	  risk	  with	  metformin	  treatment	  (HR	  0.92,	  95%	  CI	  0.92-­‐0.99).	   Notably,	   there	   was	   no	   excess	   of	   admissions	   for	   LA	   in	   patients	  treated	  with	  metformin.	  




Figure	  10:	  Observation	  data	  suggests	  that	  metformin	  may	  have	  mortality	  benefit	  in	  Type	  
2	  Diabetes	  Mellitus.	  Masoudi	  et	  al.	  Circulation	  2005;111:583-­‐90	  
	   	  Eurich	   DT	   and	   colleagues	   had	   analyzed	   the	   Saskatchewan	   Health	  database	  to	  identify	  patients	  with	  CHF	  and	  diabetes	  for	  a	  retrospective	  analysis	  (146).	   12272	   new	   users	   of	   oral	   anti-­‐diabetic	   agents	   were	   identified.	   The	  average	   follow-­‐up	   was	   2.5	   years.	   Compared	   with	   sulfonylurea	   monotherapy,	  fewer	   deaths	   occurred	   in	   subjects	   receiving	   metformin:	   404	   (52%)	   for	  sulfonylurea	  monotherapy	   versus	   69	   (33%)	   for	  metformin	  monotherapy	   (HR	  0.70	   [95%	   CI	   0.54-­‐0.91])	   and	   263	   (31%)	   for	   combination	   therapy	   (0.61	   [CI	  0.52-­‐0.72]).	   Reductions	   in	   deaths	   or	   hospitalization	   were	   also	   noted	   in	  metformin	   treated	   groups.	   Therefore,	   metformin,	   alone	   or	   in	   combination,	   in	  subjects	   with	   heart	   failure	   and	   Type	   2	   diabetes	   was	   associated	   with	   lower	  morbidity	  and	  mortality	  compared	  with	  sulfonylurea	  monotherapy.	  
	  
	  	  
Metformin associated with lower mortality 
Masoudi FA et al. Circulation. 2005;111:583-90. 
N = 16,417 with diabetes and HF  
Metformin (n = 1861)  
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GLUCAGON	  LIKE	  PEPTIDE	  (GLP-­‐1)	  AND	  DIPEPTIDYL-­‐PEPTIDASE-­‐4	  INHIBITORS	  
	   The	   incretin	   system	   has	   received	   a	   great	   deal	   of	   attention	   in	   the	  treatment	  of	  diabetes	  mellitus.	  Glucagon	   like	  peptide	   (GLP-­‐1)	   is	   a	   gut	  derived	  incretin	   hormone	   that	   has	   glucose-­‐dependent	   insulinotropic	   effects.	   GLP-­‐1	  stimulates	   insulin	   release,	   suppresses	   glucagon	   secretion,	   inhibits	   gastric	  emptying	   and	   reduces	   appetite	   and	   food	   intake.	   The	   current	   approach	   to	  enhance	   incretin	   system	   is	   either	   to	   increase	   the	   incretin	   level	   (incretin	  mimetic,	   i.e.	   GLP-­‐1)	   or	   to	   reduce	   the	   degradation	   of	   incretin	   (dipeptidyl-­‐peptidase-­‐4	   inhibitors	   (DPP-­‐4),	   i.e.	   sitagliptin	   and	   vildagliptin).	   	   The	   incretin	  concept	  was	  developed	  from	  an	  observational	  study	  in	  the	  1960’s,	  when	  enteral	  nutrition	   was	   shown	   to	   be	   a	   more	   potent	   insulinotropic	   stimulus	   than	   iso-­‐glycaemic	   intravenous	   challenge	   (147).	   GLP-­‐1	   levels	   increase	   rapidly	   after	  eating	  but	  also	  inactivated	  swiftly	  by	  DPP-­‐4.	  Activation	  of	  incretin	  systems	  lead	  to	   insulin	   biosynthesis,	   stimulation	   of	   β-­‐	   cell	   proliferation	   (148),	   promote	  resistance	  to	  apoptosis	  and	  enhanced	  β-­‐cell	  survival	  (149,150).	  Nikolaidis	  et	  al	  shared	   some	   insights	   into	   how	   GLP-­‐1	   affects	   cardiac	   function	   from	   canine	  models.	  He	  demonstrated	  that	  recombinant	  GLP-­‐1	  infusion	  resulted	  in	  dramatic	  improvement	   of	   LV	   and	   systemic	   haemodynamics	   in	   conscious	   dogs	   with	  advanced	   dilated	   cardiomyopathy	   induced	   by	   rapid	   pacing	   (151).	   This	   was	  followed	  by	  a	  clinical	  study,	  which	  showed	  improvement	  of	  LV	  ejection	  fraction,	  functional	  status,	  and	  reduced	  brain	  natriuretic	  peptide	  (BNP)	  in	  patients	  with	  CHF	   (95).	   The	   expected	   insulinotropic	   effects	   of	   GLP-­‐1	  were	   observed	   in	   this	  study.	  Plasma	  glucose	  and	  non-­‐esterified	   fatty	  acid	  were	  significantly	   reduced	  in	   GLP-­‐1	   group,	   in	   association	   with	   an	   increase	   in	   plasma	   insulin	   levels	   but	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measurement	  of	  insulin	  resistance	  (insulin-­‐mediated	  glucose	  uptake)	  were	  not	  performed	   in	   this	   study.	  GLP-­‐1	  and	  DDP-­‐4	   inhibitors	  have	  not	  been	   shown	   to	  ameliorate	  IR	  directly	  to	  date.	  Therefore,	  improvement	  of	  cardiac	  function	  may	  not	  be	  a	  direct	  effect	  of	  GLP-­‐1	  on	   IR.	   It	  may	  be	   the	  results	  of	   improvement	  of	  endothelial	   function	  (152,153),	  GLP-­‐1	  variable	   inotropic	  effects	  (154,155)	  and	  more	  efficient	  myocardial	  ATP	  production	  from	  reduced	  myocardial	  FFA.	  	  
It	   should	   be	   noted	   that	   the	   available	   DPP-­‐IV	   inhibitors,	   which	   are	  currently	  used	  in	  the	  treatment	  of	  diabetes	  mellitus,	  could	  increase	  GLP-­‐1	  levels	  (156).	  To	  date,	  it	  has	  not	  been	  shown	  to	  have	  any	  cardioprotective	  effects	  post	  myocardial	   infarction	   (157)	   although	   smaller	   animals	   studies	   have	   show	  positive	   effects	   on	   BNP	   expression	   (158)	   and	   improvement	   of	   cardio-­‐renal	  function	  in	  a	  porcine	  models	  (159).	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  CHAPTER	  SUMMARY	  
	   Lifestyles	  changes	  such	  as	  diet	  and	  exercise	  are	  important	  in	  improving	  IR	  in	  CHF	  patients	  but	  difficult	  to	  achieve	  and	  prescribe.	  CHF	  trials	  seem	  to	  suggest	  that	  most	  conventional	  CHF	  medications	  have	  favourable	  impact	  on	  glycaemic	  control	  or	  prevent	  the	  development	  of	  diabetes.	  In	  terms	  of	  diabetic	  medications,	  insulin	  sensitizers	  are	  limited	  to	  TZDs	  and	  metformin.	  The	  use	  of	  TZDs	  have	  reduced	  greatly	  because	  of	  risk	  of	  exacerbating	  HF	  and	  its	  association	  with	  increased	  risk	  of	  myocardial	  infarction,	  whereas	  metformin	  is	  increasing	  recognised	  as	  a	  safe	  and	  beneficial	  drug	  in	  T2DM	  and	  CHF	  from	  large	  observational	  studies.	  Lastly,	  our	  increased	  insights	  and	  understanding	  of	  the	  incretins	  system	  has	  opened	  a	  new	  horizon	  in	  the	  potential	  treatment	  options	  in	  CHF,	  and	  outcome	  trials	  are	  awaiting.
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INTRODUCTION	  	  
Chronic	   heart	   failure	   (CHF)	   and	   type	   2	   diabetes	   mellitus	   (T2DM)	  frequently	  coexist	  (160-­‐162).	  In	  population	  based	  studies	  and	  in	  CHF	  trials,	  the	  prevalence	  of	  T2DM	  in	  patients	  with	  CHF	  is	  estimated	  to	  be	  between	  11%	  and	  28%	  and	  among	  all	  patients	  hospitalized	  for	  CHF	  it	  has	  been	  reported	  that	  25-­‐30%	   have	   T2DM.	   	   	   This	   combination	   can	   be	   lethal	   since	   diabetes	   has	  consistently	  been	  shown	  to	  be	  an	  independent	  predictor	  of	  increased	  morbidity	  and	   mortality	   in	   patients	   with	   either	   symptomatic	   heart	   failure	   or	  asymptomatic	  left	  ventricular	  dysfunction	  (163,164).	  
Unfortunately,	   patients	   with	   a	   combination	   of	   CHF	   and	   T2DM	   have	  limited	  drug	  therapy	  options	  for	  their	  diabetes.	  Because	  insulin	  resistance	  is	  a	  key	  pathophysiological	  process	  in	  these	  patients	  (165),	  it	  would	  seem	  intuitive	  to	   administer	   an	   insulin-­‐sensitizing	   agent	   such	   as	   a	   thiazolidinedione	   or	  metformin.	  However,	   thiazolidinediones	  have	   the	  potential	   to	   exacerbate	  CHF	  in	  patients	  with	  poor	  cardiac	  reserve	  and	  are	  currently	  contraindicated	  in	  CHF	  patients	   with	   New	   York	   Heart	   Association	   (NYHA)	   functional	   class	   III	   or	   IV.	  While	  metformin	   is	  a	  widely	  prescribed	  drug	   in	   the	  management	  of	  T2DM,	   its	  use	   in	   patients	   with	   T2DM	   and	   CHF	   has	   previously	   been	   discouraged	   due	   to	  concerns	  over	  the	  risk	  of	  lactic	  acidosis	  originating	  from	  earlier	  experience	  with	  phenformin.	   This	   was	   withdrawn	   from	   U.S.	   market	   in	   the	   1970s	   due	   to	   case	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reports	   of	   fatal	   lactic	   acidosis.	   However,	   both	   clinical	   experience	   and	   the	  literature	   suggest	   that	   the	   risk	  of	  metformin–associated	   lactic	   acidosis	   is	   very	  low,	   and	   similar	   to	   that	   of	   other	   anti-­‐diabetic	   drugs	   (28,166).	   	   In	   fact,	  observational	   data	   suggest	   that	  metformin	  may	   actually	   be	  beneficial	   for	  CHF	  through	   its	   insulin	   sensitizing	   properties.	   A	   retrospective	   cohort	   study	   in	   a	  group	   of	   Medicare	   recipients	   discharged	   from	   U.S.	   hospitals	   with	   a	   principal	  diagnosis	   of	   CHF,	   suggests	   that	  metformin	   (and	   thiazolidinediones)	   were	   not	  associated	   with	   increased	   mortality	   and	   may	   improve	   outcomes	   in	   older	  patients	  with	  T2DM	  and	  CHF	  (28).	  It	  has	  been	  proposed	  by	  several	  groups	  that	  compensated	  CHF	   can	  no	   longer	  be	  upheld	   as	   contraindication	   for	  metformin	  (167-­‐169).	   The	   beneficial	   effect	   of	   metformin	   in	   CHF	  may	   extend	   to	   patients	  with	  other	  manifestations	  of	  cardiovascular	  disease;	  an	  observational	  study	   in	  the	   UK	   demonstrated	   that	   cardiovascular	   risk	   was	   lower	   among	   metformin	  users	   compared	   to	   sulphonylureas	   users	   (169).	   Further	   evidence	   for	   the	  potential	  benefit	  of	  metformin	  in	  patients	  with	  both	  T2DM	  and	  CHF	  may	  result	  in	  expanding	  the	  therapeutic	  options	  for	  managing	  this	  important	  common	  and	  complex	  group	  of	  patients.	  Therefore,	   the	  aim	  of	   this	   study	  was	   to	   add	   to	   the	  growing	  body	  of	  evidence	  on	  the	  safety	  of	  metformin,	  and	  to	  explore	  benefits	  of	  its	  use	  among	  patients	  with	  T2DM	  and	  CHF	  in	  Tayside,	  Scotland.	  	  
AIMS	  AND	  OBJECTIVES	  
To	  investigate	  the	  use	  of	  metformin	  therapy	  for	  treating	  type	  2	  diabetes	  mellitus	  (T2DM)	  with	  Chronic	  Heart	  Failure	  (CHF)	  in	  a	  large	  population-­‐based	  cohort	  study.	  





This	  study	  was	  carried	  out	  in	  the	  population	  (approximately	  400,000)	  of	  Tayside	  in	  Scotland,	  using	  the	  Diabetes	  Audit	  and	  Research	  in	  Tayside	  Scotland	  (DARTS)	   (171)	   information	   system	   and	   the	   dispensed	   prescribing	   database	  maintained	  by	  the	  Health	  Informatics	  Centre	  (HIC)	  of	  the	  University	  of	  Dundee	  (formerly	  known	  as	  the	  MEMO	  database).	  This	  contains	  records	  of	  all	  dispensed	  community	   prescriptions	   dating	   back	   to	   1993.	   The	   DARTS	   dataset	   contains	  detailed	   clinical	   information	   on	   every	   patient	   diagnosed	   with	   diabetes	   in	  Tayside.	   Clinical	   information	   is	   collected	   according	   to	   the	   national	   clinical	  dataset	   for	   the	  care	  of	  diabetic	  people	   in	  Scotland,	  and	   includes	  diabetes	  type,	  date	   of	   diagnosis,	   duration,	   therapy,	   HbA1c,	   presence	   (and	   date)	   of	  microvascular	   and	   macrovascular	   diabetic	   complications	   and	   cardiovascular	  risk	  factors.	  	  
Datasets	   available	   from	   HIC	   also	   include	   hospital	   discharge	   data,	  biochemistry	   data,	   mortality	   data,	   socio-­‐demographic	   descriptors,	   and	   other	  data	   that	   are	   linked	   by	   a	   unique	   10	   digit	   patient	   identifier,	   the	   community	  health	  index	  (CHI)	  number	  that	  is	  used	  for	  all	  health	  care	  activities	  in	  Tayside.	  The	  first	  six	  digits	  are	  the	  date	  of	  birth,	  with	  a	  figure	  coding	  sex	  (odd	  male,	  even	  female)	  in	  the	  remaining	  four	  distinguishing	  digits.	  	  This	  number	  facilitates	  high	  accuracy	   record	   linkage	   at	   the	   level	   of	   the	   individual	   across	   the	   region.	   All	  research	   data	   are	   robustly	   anonymised	   and	   approved	   by	   the	   Tayside	   NHS	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Caldicott	   Guardians.	   The	   study	   was	   granted	   ethical	   approved	   by	   the	   Tayside	  Committee	  on	  Medical	  Research	  Ethics.	  	  	  	  	  	  	  
STUDY	  POPULATION	  
The	   study	   population	   was	   defined	   as	   residents	   of	   Tayside	   who	   were	  registered	  with	  their	  GP	  during	  the	  study	  period	  1994-­‐2003.	  Using	  the	  DARTS	  database,	  we	   identified	  all	  Tayside	   residents	  who	  were	  diagnosed	  with	  T2DM	  prior	  to	  December	  2003.	  We	  then	  identified	  all	   those	  who	  were	  newly	  treated	  with	   oral	   hypoglycaemic	   agents	   during	   the	   study	   period	   (January	   1994	   to	  December	   2003).	   	   Any	   patients	   who	   received	   oral	   hypoglycaemic	   agent	  prescriptions	   before	   1994	   or	   received	   insulin	   at	   any	   point	   during	   the	   study	  period	  were	  excluded.	  	  
We	   identified	   patients	   who	   had	   incident	   CHF	   during	   the	   study	   period	  and	  defined	  a	  date	  of	  CHF	  diagnosis	  for	  each	  patient.	  This	  was	  the	  earliest	  date	  of	  patients	  fulfilling	  any	  one	  of	  the	  following	  criteria:	  1.	  Patients	  with	  a	  hospital	  admission	  ICD9/10	  diagnostic	  code	  for	  CHF	  during	  the	  study	  period	  (ICD-­‐9	  428	  ICD-­‐10	  50).	  The	  date	  of	  admission	  was	  defined	  as	  the	  date	  of	  CHF	  diagnosis.	  2.	  Patients	   commenced	   on	   CHF	   medications	   defined	   as	   a	   combination	   of	   loop	  diuretics	  and	  ACEi.	  	  Co-­‐prescribing	  had	  to	  occur	  within	  a	  90-­‐day	  period,	  and	  the	  date	  of	   the	   second	  drug	  was	  defined	  as	   the	  date	  of	  CHF	  diagnosis.	   3.	   Patients	  who	   had	   at	   least	   one	   admission	   for	   myocardial	   infarction	   and	   then	   received	  loop	   diuretic	  medication.	   The	   date	   of	   diuretic	  medication	  was	   defined	   as	   the	  date	   of	   CHF	   diagnosis.	   Patients	   were	   excluded	   if	   their	   plasma	   creatinine	  concentration	  was	  >	  200	  μmol/L	  prior	  to	  the	  prescribing	  of	  a	  loop	  diuretic.	  This	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was	   to	   exclude	   patients	   with	   renal	   hypertension	   without	   CHF	   who	  might	  receive	   loop	   diuretics	   and	   ACE	   inhibitors.	  We	   have	   previously	   used	  similar	  criteria	  to	  identify	  CHF	  from	  large	  datasets	  in	  Tayside	  (172).	  	  
To	  be	  eligible	  for	  the	  study,	  the	  date	  of	  CHF	  diagnosis	  had	  to	  occur	  after	  the	   date	   of	   diagnosis	   of	   T2DM.	   The	   patient	   also	   had	   to	   receive	   a	   first	  prescription	   for	   either	  metformin	   or	   sulphonylureas	  within	   1	   year	   after	   their	  date	  of	  CHF	  diagnosis.	  Patients	  were	  then	  divided	  into	  three	  cohorts:	  those	  who	  received	   prescriptions	   for	   metformin	   only	   (metformin	   monotherapy),	   those	  who	   received	   prescriptions	   for	   sulphonylureas	   only	   (sulphonylureas	  monotherapy)	  and	  those	  who	  received	  prescriptions	  for	  both	  (combination).	  	  
STATISTICAL	  ANALYSIS	  
	  All	   subjects	  were	  prospectively	   followed	  up	   from	  their	   index	  date	   (the	  date	   of	   CHF	   diagnosis)	   until	   the	   primary	   outcome,	   termination	   of	   HIC	   health	  care	  coverage,	  or	  termination	  of	  the	  study.	  	  The	  study	  outcomes	  were	  all-­‐cause	  mortality,	  both	  at	  1	  year	   (short	   term),	  and	  by	   the	  end	  of	   the	   follow-­‐up	  period	  (long	   term).	   All	   cause	   mortality	   was	   determined	   from	   death	   certification	  records	  of	  the	  General	  Register	  Office	  (GRO)	  of	  Scotland.	  We	  compared	  survival	  between	  cohorts	  for	  each	  outcome	  using	  Kaplan-­‐Meier	  survival	  plots	  and	  used	  Cox	   regression	   analyses	   to	   estimate	   the	   relative	   risks	   of	   each	   outcome	   for	  patients	   in	   the	   study	   cohorts.	   For	   this	   analysis,	   the	   metformin	   monotherapy	  cohort	  and	  the	  combination	  cohort	  were	  merged	  into	  a	  larger	  cohort,	  with	  the	  sulphonylureas	   monotherapy	   cohort	   as	   the	   reference	   group.	   Survival	   times	  were	   censored	   if	   patients	   left	   Tayside,	   or	   at	   the	   end	   of	   the	   study	   period.	   The	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following	   confounding	   variables	   were	   investigated:	   sex,	   age	   at	   index	   date,	  duration	   of	   diabetes	   at	   index	   date,	   creatinine	   (divided	   into	   quartiles	   in	  ascending	  orders)	  and	  HbA1c.	  We	  also	  accounted	   for	  whether	   the	  patient	  had	  been	   admitted	   to	   hospital	   with	   an	   ICD9/10	   diagnostic	   code	   for	   a	   major	  cardiovascular	  event	  (myocardial	   infarction,	  coronary	  heart	  disease	  or	  stroke)	  prior	   to	   their	   diagnosis	   with	   CHF.	   Finally,	   we	   calculated	   the	   proportions	   of	  patients	   in	   each	   cohort	   who	   had	   received	   prescriptions	   for	   any	   of	   four	   drug	  types:	   angiotensin-­‐converting	   enzyme	   inhibitors	   aspirin,	   diuretics	   or	   beta-­‐adrenoceptor	   blocking	   drugs	   (beta	   blockers).	   	   Continuous	   covariates	   were	  categorised	   into	   quartile	   groups	   where	   appropriate,	   and	   all	   covariates	   were	  included	   in	   the	   final	   models	   only	   if	   they	   were	   statistically	   significant	   in	  univariate	   analyses	   (p	   <	   0.05),	   to	   produce	   adjusted	   risk	   estimates	   for	   all	  covariates.	  All	  analyses	  were	  conducted	  using	  SPSS	  version	  16.0	  (Chicago,	  USA).	  
RESULTS	  	  
There	   were	   1,141	   patients	   who	   were	   diagnosed	   with	   T2DM	   prior	   to	  December	   2003,	   who	   received	   oral	   hypoglycaemic	   agents	   during	   the	   study	  period	  (1994	  to	  2003)	  but	  were	  not	  on	   insulin.	  All	  of	   these	  patients	  had	  been	  admitted	  to	  hospital	  with	  a	  diagnostic	  code	  for	  CHF,	  although	  218	  patients	  were	  not	   eligible	   for	   the	   study	   as	   their	   hospital	   admissions	   occurred	   out	   with	   the	  study	   period.	   It	  was	   not	   possible	   to	   identify	   a	   date	   of	   diagnosis	   of	   CHF	   for	   9	  patients	   who	   were	   also	   excluded	   from	   the	   study.	   From	   the	   remaining	   914	  patients,	  we	  identified	  769	  whose	  date	  of	  CHF	  diagnosis	  occurred	  after	  date	  of	  diagnosis	  of	  T2DM.	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Four	  hundred	  and	  ninety	  patients	  were	  prescribed	  either	  metformin	  or	  sulphonylureas	   after	   their	   date	   of	   CHF	   diagnosis.	   However,	   we	   excluded	   a	  further	  59	  patients	  whose	  first	  oral	  hypoglycaemic	  agent	  was	  prescribed	  more	  than	   365	   days	   after	   date	   of	   CHF	   diagnosis,	   and	   9	   without	   a	   valid	   date	   of	  diagnosis	  of	  T2DM.	  Of	  the	  remaining	  422	  patients	  (mean	  age	  75.4	  ±	  0.56yrs),	  68	  were	  prescribed	  metformin	  only,	  217	  were	  prescribed	  sulphonylureas	  only	  and	  137	   received	   prescriptions	   for	   both.	   The	   characteristics	   of	   these	   patients	   are	  presented	  in	  Table	  5.	  We	  compared	  patients	  who	  had	  received	  any	  metformin	  (metformin	  monotherapy	   cohort	   or	   combination	   cohort)	   with	   patients	   in	   the	  sulphonylureas	  monotherapy	  cohort.	  Although	  they	  were	  slightly	  younger	  and	  more	  likely	  to	  be	  female,	  the	  only	  statistically	  significant	  differences	  were	  that	  they	   had	   lower	   mean	   creatinine	   and	   a	   higher	   proportion	   was	   treated	   with	  aspirin	  and	  ACE	  inhibitors.	  	  
Both	  1-­‐year	  and	  long-­‐term	  mortality	  were	  higher	  in	  the	  sulphonylureas	  monotherapy	  cohort	  compared	  with	  patients	  prescribed	  metformin.	  In	  the	  Cox	  regression	  analysis,	  the	  unadjusted	  hazard	  ratios	  were	  0.56	  (95%	  CI	  0.38-­‐0.84)	  and	   0.53	   (95%	  CI	   0.33-­‐0.67)	   for	   1	   year	   and	   long-­‐term	  mortality	   respectively,	  when	   the	   metformin	   and	   combination	   cohorts	   were	   grouped	   together	   and	  compared	   with	   the	   sulphonylurea	   monotherapy	   cohort	   (Table	   6).	   After	  adjusting	  for	  baseline	  differences	  between	  the	  two	  groups,	  users	  of	  metformin,	  alone	  or	  in	  combination	  had	  a	  30-­‐40%	  lower	  risk	  of	  the	  outcomes	  (Table	  6	  and	  Figure	  11).	  	  
	  




Metformin	  is	  a	  widely	  prescribed	  potent	  insulin-­‐sensitizing	  drug,	  which	  is	   cheap,	   and	   has	   been	   on	   the	   market	   for	   almost	   50	   years.	   However,	   in	   the	  relatively	   large	   group	   of	   T2DM	   patients	   with	   concomitant	   CHF,	   it	   is	   largely	  contraindicated.	  According	  to	  the	  package	  insert,	  metformin	  is	  contraindicated	  in	   patients	   with	   CHF	   requiring	   pharmacological	   therapy	   due	   to	   a	   possible	  increased	   risk	   of	   lactic	   acidosis.	   This	   is	   due	   to	   historical	   experience	   of	   lactic	  acidosis	  with	  phenformin,	  despite	  the	  fact	  that	  metformin	  dose	  not	  predispose	  to	   this	   when	   compared	   with	   other	   therapies	   (167).	   Other	   contraindications	  such	   as	   old	   age,	   renal	   impairment	   and	   CHF	   are	   increasingly	   disregarded	   in	  clinical	  practice.	  The	  key	   finding	  of	   this	   study	   is	   that	  patients	  with	  T2DM	  and	  CHF	   who	   were	   treated	   with	   metformin	   alone	   or	   in	   combination	   with	  sulphonylureas	  were	  at	  significantly	   lower	  risk	  of	  all	  cause	  mortality	  during	  1	  year	   and	   long-­‐term	   follow-­‐up	   than	   those	  who	  were	   treated	  with	   sulfonylurea	  alone.	   This	   remained	   so	   even	   after	   full	   correction	   for	   multiple	   possible	  confounding	   influences.	  This	   reduces	   the	  possibility	   that	   this	   finding	  might	  be	  due	   to	   differences	   in	   baseline	   co-­‐morbidities,	   medication	   or	   other	   patient	  characteristics	  that	  may	  influence	  channelling	  bias.	  	  
How	   does	   metformin	   mediate	   these	   beneficial	   cardiovascular	   effects?	  Metformin	   has	   potent	   insulin	   sensitizing	   effects	   although	   its	   precise	  mechanisms	   of	   action	   are	   not	   fully	   understood	   (140).	   Arguably,	   the	   insulin	  sensitizing	  properties	  might	  confer	  in	  part	  some	  of	  the	  beneficial	  effects.	  CHF	  is	  increasingly	   recognized	   as	   an	   insulin	   resistant	   state	   (165,173).	   Studies	   that	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have	   demonstrated	   an	   association	   between	   CHF	   and	   insulin	   resistance	   have	  found	  that	  the	  degree	  of	  insulin	  resistance	  is	  independently	  associated	  with	  the	  severity	  and	  exercise	  intolerance	  in	  CHF	  in	  terms	  of	  exercise	  capacity	  and	  peak	  oxygen	   consumption	   (VO2)	   or	   the	   6-­‐min	   walk	   test	   (116,174,175).	   Insulin	  resistance	  also	  predicted	  mortality	   in	  patients	  with	  CHF,	   independent	  of	  body	  composition	   and	   other	   established	   prognostic	   indicators	   (35).	   These	   findings	  support	   the	   notion	   that	   insulin	   resistance	   is	   pathophysiologically	   linked	  with	  CHF	  and	  is	  implicated	  in	  the	  disease	  progression.	  This	  is	  likely	  because	  insulin	  resistance	   is	   associated	  with	   endothelial	   dysfunction,	   inflammation,	   increased	  oxidative	   stress	   and	   myocardial	   remodelling;	   processes	   that	   accelerate	   the	  progression	  of	  disease	  in	  CHF.	  Therefore,	  it	  is	  likely	  that	  the	  observed	  beneficial	  effects	   of	   metformin	  might	   be	   related	   to	   its	   potent	   insulin	   sensitizing	   effects	  (176,177).	   Indeed,	   metformin	   has	   been	   shown	   to	   offer	   protection	   from	  cardiovascular	  disease	  in	  general	  (140,177,178).	  In	  the	  UK	  Prospective	  Diabetes	  Study	   (UKPDS),	   metformin	   decreased	   the	   risk	   of	   mortality	   and	   morbidity	  among	  obese	  patients	  with	   type	  2	  diabetes	  who	  had	  cardiac	  disease	   (179).	   In	  keeping	   with	   our	   finding	   that	   CHF	   patients	   in	   the	   metformin	   monotherapy	  group	  or	  in	  combination	  had	  better	  survival	  compared	  to	  those	  on	  sulfonylurea	  alone,	  evidence	  from	  previous	  studies	  showed	  clearly	  that	  its	  benefits	  outweigh	  its	   risks	   in	  patients	  with	  haemodynamically	   stable	  heart	   failure	   and	   adequate	  renal	  function	  (28,166).	  	  
It	   should	   also	   be	   noted	   that	   metformin	   activates	   5'-­‐AMP-­‐activated	  protein	   kinase	   (AMPK),	   a	   heterotrimeric	   enzyme	   that	   is	   expressed	   in	   many	  tissues,	   including	   the	   heart	   and	   vasculature	   (137).	   In	   animal	   models,	   cardiac	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AMPK	  has	  been	  shown	  to	  mediate	  ischaemic	  glucose	  uptake	  and	  prevent	  post-­‐ischaemic	  cardiac	  dysfunction	  (180).	  	  Metformin	  may	  also	  have	  specific	  vasculo-­‐protective	  effects	  and	  can	  improve	  endothelial	  function	  (181).	  	  
Our	  study	  is	  observational	  and	  in	  common	  with	  all	  studies	  of	  this	  nature,	  it	  is	  impossible	  to	  account	  for	  all	  possible	  confounding	  influences	  that	  may	  have	  biased	   the	  observed	  differences	  between	   the	  groups	  considered.	  For	  example,	  patients	   in	   the	   sulphonylurea	  monotherapy	   group	  were	   somewhat	   older	   and	  have	  more	  prevalent	  use	  of	  loop	  diuretics.	  This	  may	  imply	  that	  this	  group	  have	  greater	   prevalence	   of	   left	   ventricular	   dysfunction	   and	   degree	   of	   heart	   failure	  than	   the	   metformin	   cohort.	   This	   may	   well	   have	   led	   to	   non-­‐prescription	   of	  metformin	  given	  the	  well-­‐known	  perception	  of	  contraindication	  of	  this	  agent	  in	  patients	   with	   heart	   failure.	   In	   this	   context,	   the	   presence	   of	   left	   ventricular	  dysfunction	  could	  easily	   lead	   to	  non-­‐prescription	  of	  metformin,	  and	  therefore,	  confounding	   by	   contraindication.	   Patients	   in	   the	   sulphonylurea	   group	   have	  higher	   creatinine	   level,	   which	   is	   another	   potential	   confounder.	   Metformin	   is	  contraindicated	   in	   patients	   with	   renal	   impairment	   and	   physicians	   would	   be	  likely	  to	  withhold	  metformin	  from	  patients	  with	  the	  worse	  renal	  function,	  a	  well	  recognised	   independent	   predictor	   of	   adverse	   outcome	   in	   patients	   with	   heart	  failure.	   Lastly,	   the	   findings	   of	   lower	   hazard	   ratios	   in	   patients	   with	   higher	  creatinine	   is	   counterintuitive,	   this	   may	   be	   a	   reflection	   of	   higher	   usage	   of	  diuretics	  and	  ACE	  inhibitors.	  However,	  this	  analysis	  is	  based	  on	  one	  creatinine	  measurement	  and	  therefore,	  evidence	  of	  higher	  creatinine	  level	  associated	  with	  better	   outcome	   in	   heart	   failure	   patients	  with	   T2DM	  must	   remain	   speculative	  and	   cannot	   be	   inferred	   directly	   from	   this	   study.	   Clearly,	   further	   randomised	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placebo	   controlled	   trials	   in	   this	   area	  would	   be	   required	   to	   provide	   definitive	  evidence	  of	  the	  benefit	  of	  metformin	  in	  this	  group	  of	  patients	  and	  further	  define	  the	  underlying	  mechanisms.	  
CONCLUSION	  	  
This	   large	   observational	   data	   suggest	   that	   the	   insulin	   sensitizer	  metformin	   is	  probably	  more	  effective	   than	  sulphonylurea	  based	  monotherapy	  in	  the	  treatment	  of	  CHF	  in	  patients	  with	  T2DM.	  A	  clinical	  trial	  of	  metformin	  in	  CHF	  is	  warranted	  to	  corroborate	  the	  observational	  study	  results	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Table	  5:	  Characteristics	  of	  patients	  in	  the	  study	  cohorts	  with	  p	  values	  for	  differences	  
between	  the	  ‘any	  metformin’	  cohort	  and	  the	  sulphonylureas	  monotherapy	  cohort.	  	  	  	   Sulphonylureas	  monotherapy	   Metformin	  monotherapy	   Metformin	  +	  Sulphonylurea	  Combination	   Any	  metformin:	  Metformin	  monotherapy	  	  AND	  Combination	  
p*	  
Total	   217	  	   68	  	   137	   205	   	  
%	  female	   45.2	   48.5	   46.7	   47.3	   0.661	  
Age	  in	  yrs	  (SD)	  	   76.7	  (SD	  9.8)	  	   75.5	  (SD	  8.9)	  	   73.4	  (SD	  8.7)	  	   74.1	  (SD	  8.8)	   0.192	  
Mean	   diabetes	  duration	   in	  yrs.	  (SD)	  
6.7	  (SD	  6.2)	  	   6.7	  (SD	  6.2)	   7.7	  (SD	  5.8)	  	   7.4	  (SD	  5.9)	   0.862	  
Previous	  hospital	  admission	  (%)	  	  
72	  (33.2%)	   23	  (33.8%)	   37	  (27.0%)	   60	  (29.3%)	   0.391	  










Mean	   last	  HbA1c	  (SD)	   7.20	  (SD	  1.6)	  	   7.35	  (SD	  1.5)	   7.59	  (SD	  1.9)	   7.51	  (SD	  1.8)	   0.562	  
%	   on	   ACE	  inhibitor	   32.6	   41.8	   43.3	   42.9	   0.031	  
%	  on	  aspirin	   51.6	   68.7	   67.6	   68.0	   0.0011	  
%	  on	  diuretic	   21.9	   14.9	   17.6	   16.7	   0.131	  
%	  on	  beta-­‐
blocker	  
11.6	   19.4	   15.4	   16.7	   0.131	  
Pearson	  Chi	  square1.	  Independent	  samples	  t	  test2	  
*	  p	  comparison	  is	  between	  sulphonylurea	  monotherapy	  vs	  'Any	  metformin:	  Metformin	  monotherapy	  and	  Combination'	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Table	  6:	  Cox	  regression	  analysis	  showing	  unadjusted	  and	  adjusted	  odds	  ratios	  (with	  95%	  
confidence	  intervals)	  for	  all	  covariates	  for	  1-­‐	  year	  and	  long-­‐term	  mortality.	  	   1-­‐ Year	  mortality	   Long-­‐term	  mortality	  
Cohort	   Unadjusted	   Adjusted1	   Unadjusted	   Adjusted1	  Sulphonylurea	  monotherapy	   1.00	   1.00	   1.00	   1.00	  Metformin	  monotherapy	   +	  Combination	  	   0.56	  (0.38-­‐0.84)	   0.60	  (0.37-­‐0.97)	   0.53	  (0.33-­‐0.67)	   0.67	  (0.51-­‐0.88)	  
Sex	   	   	   	   	  Male	   1.00	   1.00	   1.00	   1.00	  Female	   0.82	  (0.67-­‐1.00)	   0.47	  (0.29-­‐0.77)	   1.16	  (0.93-­‐1.45)	   0.64	  (0.49-­‐0.84)	  
Age	   	   	   	   	  <	  60	  yrs.	   1.00	   1.00	   1.00	   1.00	  60-­‐69	  yrs.	   5.60	  (0.76-­‐41.4)	   4.62	  (0.62-­‐34.64)	   1.15	  (0.57-­‐2.32)	   1.11	  (0.52-­‐2.39)	  70-­‐79	  yrs.	   5.07	  (0.70-­‐36.9)	   4.20	  (0.59-­‐34.64)	   1.66	  (0.85-­‐3.28)	   1.57	  (0.75-­‐3.25)	  80-­‐89	  yrs.	   7.06	  (0.97-­‐51.5)	   7.33	  (0.98-­‐54.86)	   2.82	  (1.43-­‐5.56)	   2.61	  (1.24-­‐5.49)	  >89	  yrs.	   8.57	  (1.09-­‐67.7)	   12.39	  (1.52-­‐101.06)	   3.24	  (1.51-­‐6.94)	   3.44	  (1.47-­‐8.05)	  
Duration	   	   	   	   	  <	  5	  yrs.	   1.00	   -­‐	   1.00	   1.00	  5-­‐9	  yrs.	   1.44	  (0.91-­‐2.28)	   -­‐	   1.26	  (0.97-­‐1.64)	   0.92	  (0.67-­‐1.26)	  10-­‐14	  yrs.	   1.70	  (1.00-­‐2.91)	   -­‐	   1.28	  (0.92-­‐1.78)	   1.13	  (0.77-­‐1.64)	  >14	  yrs.	   1.38	  (0.74-­‐2.58)	   -­‐	   1.80	  (1.25-­‐2.58)	   1.77	  (1.17–2.65)	  
Previous	  hospital	  admission	   	   	   	  Yes	  v	  No	   1.23	  (0.83-­‐1.83)	   1.08	  (0.67-­‐1.74)	   1.01	  (0.79-­‐1.28)	   0.97	  (0.73-­‐1.27)	  
Creatinine1	   	   	   	   	  Quartile	  1	   1.00	   1.00	   1.00	   1.00	  Quartile	  2	   0.54	  (0.30-­‐0.96)	   0.46	  (0.26-­‐0.84)	   0.55	  (0.38-­‐0.80)	   0.52	  (0.35-­‐0.76)	  Quartile	  3	   0.29	  (0.14-­‐0.59)	   0.23	  (0.11-­‐0.47)	   0.62	  (0.43-­‐0.88)	   0.53	  (0.36-­‐0.77)	  Quartile	  4	  	   0.67	  (0.38-­‐1.17)	   0.51	  (0.28-­‐0.91)	   1.09	  (0.78-­‐1.53)	   0.87	  (0.61-­‐1.23)	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HbA1c2	   	   	   	   	  <	  7.5	  	   1.00	   -­‐	   1.00	   -­‐	  7.5	  –	  9.49	   1.14	  (0.70-­‐1.83)	   -­‐	   1.08	  (0.83-­‐1.40)	   -­‐	  >9.49	   1.06	  (0.48-­‐2.34)	   -­‐	   1.03	  (0.67-­‐1.57)	   -­‐	  
ACE	   	   	   	   	  Yes	  v	  No	   0.56	  (0.36-­‐0.86)	   0.57	  (0.34-­‐0.97)	   0.66	  (0.52-­‐0.84)	   0.76	  (0.58-­‐1.00)	  
Aspirin	   	   	   	   	  Yes	  v	  No	   0.61	  (0.41-­‐0.89)	   0.67	  (0.42-­‐1.08)	   0.65	  (0.52-­‐0.82)	   0.80	  (0.61-­‐1.05)	  
Diuretic	   	   	   	   	  Yes	  v	  No	   1.14	  (0.72-­‐1.81)	   -­‐	   1.09	  (0.83-­‐1.43)	   -­‐	  
Betablocker	   	   	   	   	  Yes	  v	  No	   0.46	  (0.22-­‐0.94)	   0.41	  (0.16-­‐1.04)	   0.52	  (0.36-­‐0.74)	   0.52	  (0.34-­‐0.80)	  Available	  for	  3461	  and	  3632	  patients	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Figure	   11:	   Kaplan-­‐Meier	   plot	   for	   1-­‐year	   follow-­‐up,	   comparing	   mortality	   in	   the	  









	   Insulin	  resistance	  and	  CHF	  is	  an	  intricate	  pair	  that	  forms	  a	  vicious	  cycle	  that	  worsens	  each	  other	  at	  both	  tissue	  and	  cellular	  levels.	  Our	  increased	  understanding	  of	  the	  relationships	  between	  IR	  and	  CHF	  provides	  the	  rationale	  for	  targeting	  IR	  in	  the	  development	  of	  new	  CHF	  therapy.	  However,	  there	  appear	  to	  be	  some	  conundrum	  in	  the	  choice	  of	  available	  insulin	  sensitizers	  as	  there	  are	  safety	  issues	  of	  regarding	  TZDs	  and	  metformin.	  While	  the	  concerns	  regarding	  TZDs	  appear	  to	  be	  justified,	  there	  is	  now	  emerging	  evidence	  that	  metformin	  may	  not	  only	  be	  safe	  in	  CHF	  but	  may	  indeed	  be	  good	  in	  CHF.	  	  However,	  prospective	  trials	  are	  needed	  to	  prove	  this.	  TAYSIDE	  study	  (MeTformin	  in	  Insulin	  ResistAnt	  LV	  DYSfunctIon,	  Double	  blind,	  placEbo-­‐controlled	  trial)	  will	  determine	  if	  reversing	  IR	  with	  metformin	  will	  have	  beneficial	  effects	  in	  patients	  with	  CHF.	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INTRODUCTION	  
Chronic	   heart	   failure	   (CHF)	   is	   an	   insulin	   resistant	   (IR)	   state	   (165).	  We	  and	  others	  have	  shown	  that	  IR	  is	  highly	  prevalent	  among	  non-­‐diabetic	  patients	  with	  CHF	  (116,174,182),	  and	  the	  degree	  of	   IR	  correlates	  with	  disease	  severity	  and	   outcome	   (35,116).	   	   Furthermore,	   it	   is	   associated	   with	   reduced	   exercise	  capacity	   (116,175).	   	   It	   is	   unclear	  whether	   IR	   is	   a	   bystander	   reflecting	  disease	  severity	  or	  whether	   it	   is	  a	  culprit	   contributing	   to	   the	  pathophysiology	  of	  CHF.	  Previous	  association	  studies	  did	  not	  distinguish	  the	  cause	  and	  effect.	  Therefore,	  a	  proof	  of	  concept	  study	   is	  required	   to	   test	   the	  hypothesis	   that	   IR	   is	  a	  culprit,	  and	   that	   reversing	   IR	  will	   lead	   to	   clinical	   improvement	   in	   CHF.	  However,	   the	  numbers	   of	   insulin	   sensitizers	   that	   are	   suitable	   to	   be	   tested	   are	   limited.	  	  Thiazolidinediones	   have	   the	   potential	   to	   exacerbate	   CHF	   in	   patients	   with	  reduced	  cardiac	  reserve.	  	  Although	  metformin	  is	  a	  widely	  prescribed	  drug	  in	  the	  management	  of	  T2DM,	  and	  its	  use	  in	  diabetic	  patients	  with	  CHF	  has	  previously	  been	   discouraged	   due	   to	   concerns	   over	   the	   risk	   of	   lactic	   acidosis	   originating	  from	   earlier	   experience	   with	   phenformin.	   	   However,	   clinical	   experience	  suggests	   that	   the	   risk	   of	  metformin–associated	   lactic	   acidosis	   is	   very	   low	  and	  similar	  to	  that	  of	  other	  anti-­‐diabetic	  drugs	  (183).	  	  Indeed,	  there	  is	  observational	  data	  to	  suggest	  that	  metformin	  may	  actually	  be	  beneficial	  for	  CHF	  (18,184).	  We	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have	   therefore	   conducted	   a	   proof	   of	   concept	   study	   to	   evaluate	   the	   impact	   of	  metformin	   on	   IR	   and	   its	   effects	   on	   exercise	   capacity	   in	   non-­‐diabetic	   patients	  with	  CHF.	  	  
RESEARCH	  DESIGN	  AND	  METHODS	  
This	  is	  a	  randomized,	  placebo-­‐controlled	  trial	  designed	  to	  evaluate	  the	  impact	  of	  metformin	  on	  IR	  and	  its	  effects	  on	  exercise	  capacity	  in	  non-­‐diabetic	  patients	  with	  CHF.	  The	  primary	  endpoint	  of	  the	  trial	  was	  to	  determine	  if	  improvement	  of	  IR	  with	  metformin	  lead	  to	  improvement	  of	  peak	  VO2.	  However,	  many	  patients	  with	  CHF	  are	  unable	  to	  perform	  maximal	  exercise,	  and	  oxygen	  requirements	  for	  activities	  of	  daily	  living	  rarely	  approach	  maximal	  levels	  (185).	  Therefore,	  we	  have	  included	  the	  sub-­‐maximal	  derived	  exercise	  variable	  of	  the	  slope	  of	  the	  ratio	  of	  minute	  ventilation	  to	  carbon	  dioxide	  production	  (VE/VCO2)	  as	  a	  secondary	  end-­‐point	  of	  this	  study.	  VE/VCO2	  slope	  is	  an	  index	  of	  ventilatory	  response	  to	  exercise,	  unlike	  peak	  VO2,	  VE/VCO2	  	  is	  not	  influenced	  by	  the	  mechanical	  work	  done	  during	  exercise	  testing	  but	  reflects	  alterations	  in	  the	  peripheries	  caused	  by	  the	  disease	  in	  CHF,	  which	  can	  in	  turn	  lead	  to	  the	  progression	  and	  symptomatology	  of	  CHF	  (186).	  Furthermore,	  we	  have	  also	  explored	  possible	  mechanisms	  of	  improvement	  of	  exercise	  capacity	  by	  measuring	  left	  ventricular	  ejection	  fraction	  by	  echocardiography,	  endothelial	  function	  and	  related	  biomarkers.	  The	  study	  was	  approved	  by	  the	  East	  of	  Scotland	  Research	  Ethics	  Service	  (07/S1401/59).	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Every	  patient	  provided	  written	   informed	  consent	  prior	   to	  participation	  in	   this	   study.	   Patients	   with	   CHF	   were	   recruited	   from	   out	   patient	   cardiology	  clinics	  and	  local	  echocardiography	  database.	  Patients	  with	  a	  history	  of	  CHF	  and	  left	   ventricular	   systolic	   dysfunction	   on	   echocardiography	   had	   enrolled	   for	   a	  fasting	   blood	   test	   to	   determine	   IR	   status	   by	   an	   empirical	   fasting	   insulin	  resistance	  index	  (FIRI),	  consisting	  of	  the	  product	  of	  plasma	  insulin	  and	  glucose	  divided	  by	  25.	  	  CHF	  patients	  with	  a	  FIRI	  >2.7	  were	  considered	  to	  have	  IR	  (116)	  and	  invited	  to	  participate	  in	  the	  study.	  Exclusion	  criteria	  included:	  patients	  with	  history	   of	   type	   2	   diabetes	   or	   fasting	   glucose	   of	  more	   than	   7mmol/L;	   patients	  aged	   >80	   years;	   patients	   with	   NYHA	   functional	   class	   IV	   and	   decompensated	  CHF;	   renal	   dysfunction	   (serum	   creatinine	   >	   160	   µmol/L);	   patients	   unable	   to	  exercise	  including	  patients	  that	  were	  excluded	  for	  reasons	  of	  safety	  or	  potential	  effects	   on	   exercise	   performance.	   Patients	   had	   to	   be	   on	   stable	   dose	   of	   CHF	  medications	  at	  least	  one	  month	  prior	  to	  screening.	  127	  patients	  were	  screened	  (Figure	  12)	  and	  53	  patients	  were	  excluded	  based	  on	  exclusion	  criteria,	  and	  21	  were	   found	   to	   be	   non-­‐IR.	   	   62	   patients	   with	   evidence	   of	   CHF	   and	   IR	   were	  randomised	   to	   receive	   metformin	   or	   placebo	   (2:1	   ratio)	   with	   39	   patients	  randomised	   to	   receive	   metformin	   and	   23	   to	   receive	   a	   placebo.	   Treatment	  allocation	  was	  masked	   for	  patients	  and	   investigators	  until	  after	  database	   lock.	  Compliance	  was	  assessed	  by	  tablet	  counting.	  	  




Figure	  12:	  The	  CONSORT	  (Consolidated	  Standards	  of	  Reporting	  Trial)	  diagram	  describing	  
outcomes	  of	  all	  patients	  within	  the	  study	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Infirmary,	  Glasgow).	  	  The	  dose	  and	  duration	  of	  metformin	  therapy	  was	  based	  on	  a	   previous	   study	   in	   patients	   with	   impaired	   glucose	   tolerance,	   which	   showed	  that	   this	   dose	   regimen	   was	   well	   tolerated	   and	   had	   a	   beneficial	   effect	   on	  endothelial	   function	   (187).	   	   The	   metformin	   study	   drug	   was	   commenced	   at	  500mg	   b.d.	   for	   two	   weeks	   and	   was	   up	   titrated	   if	   well	   tolerated	   based	   on	  symptoms	   and	   measurement	   of	   plasma	   lactate	   and	   renal	   function.	   At	  subsequent	   visits,	   patients	   were	   reassessed	   and	   doses	   of	   study	   drug	   altered	  according	   to	   tolerability.	  All	  measurements	  of	   interests	  were	   repeated	  after	  4	  months	  of	  intervention.	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CARDIOPULMONARY	  EXERCISE	  TESTING	  (CPET)	  
CPET	  was	  performed	  in	  the	  fasting	  state	  as	  previously	  described	  (188).	  	  Prior	  to	  exercise,	  the	  patient	  was	  instructed	  on	  the	  re-­‐breathing	  technique.	  An	  incremental	  symptom-­‐limited	  bicycle	  exercise	  testing	  was	  performed	  using	  an	  upright,	  braked	  cycle	  ergometer.	  After	  3	  minutes	  rest,	  exercise	  was	  begun	  at	  0	  Watts	   (W)	   and	   increased	   every	   3	   minutes	   by	   25W	   until	   symptom-­‐limited	  maximal	   exercise	   was	   achieved.	   Patients	   were	   instructed	   to	   signal	  approximately	  1	  minute	  before	  peak	  exercise.	  ECG	  was	  monitored	  continuously	  during	  the	  test.	  Cuff	  blood	  pressure	  was	  measured	  at	  rest	  and	  every	  3	  minutes.	  Expired	  gas	  analysis	  was	  performed	  continuously	  throughout	  the	  test	  with	  the	  Innocor	   system	   (Innovision	  A/S,	  Odense,	  Denmark).	   Peak	  VO2	  was	   defined	   as	  the	  highest	  value	  of	  VO2	  achieved	  in	  the	  final	  20	  seconds	  of	  exercise.	  VE/VCO2	  slope	   was	   calculated	   from	   the	   start	   of	   incremental	   exercise	   to	   the	   anaerobic	  threshold,	   by	   least	   squares	   linear	   regression.	   Cardiac	   output	   (CO)	  measurements	  were	  made	   at	   the	   end	  of	   the	   rest	   period	   and	   at	   peak	   exercise.	  VO2	   (ml/kg/min),	   VCO2	   (L/min),	   and	   VE	   (L/min)	   (minute	   ventilation)	   were	  measured	   on	  a	   breath-­‐by-­‐breath	   basis.	   CPETs	   were	   performed	   at	   visit	   1	   and	  visit	   2	   to	   achieve	   a	   variation	   of	   exercise	   duration	   of	   less	   than	   15%	   prior	   to	  randomisation	   to	   minimise	   the	   “learning	   effect”.	   If	   variation	   was	   more	   than	  15%,	   a	   further	   CPET	   was	   repeated	   and	   the	   highest	   value	   of	   peak	   VO2	   was	  chosen	  to	  be	  the	  baseline.	  	  
	  
	  




A	  number	  of	  non-­‐invasive	  methods	  of	  assessing	  endothelial	  function	  are	  available.	   	   We	   have	   chosen	   Reactive	   Hyperaemia	   Peripheral	   Arterial	  Tonometry,	   RH-­‐PAT	   (Itamar	   Medical	   Ltd.	   Caesarea,	   Israel)	   (Figure	   14)	   and	  	  Flow-­‐Mediated	   Dilatation	   (FMD)	   (116,189)	   (Figure	   15)	   to	   assess	   vascular	  function	  in	  different	  vascular	  beds.	  	  
	  
FLOW-­‐MEDIATED	  DILATATION	  (FMD)	  	   Endothelial	   function	   has	   been	   shown	   to	   predict	   future	   cardiovascular	  events	  (190).	  Flow-­‐mediated	  dilatation	  (FMD),	  available	  since	  1992,	  is	  currently	  viewed	  as	  the	  gold	  standard	  for	  assessing	  endothelial	   function	  non-­‐	   invasively	  (109).	   FMD	  provides	  useful	  prognostic	   information	  based	  on	   the	   concept	   that	  direct	  assessment	  of	  the	  function	  of	  the	  arterial	  wall	  has	  more	  predictive	  power	  compared	  to	  assessing	  traditional	  risk	  factors.	  Table	  7	  summarises	  the	  studies	  using	  FMD	  as	  a	  prognosticator	   in	  subjects	  with	  cardiovascular	  disease	  or	  high	  risk	  for	  developing	  cardiovascular	  disease	  (191).	  FMD	  has	  been	  documented	  to	  correlate	  with	  invasively	  assessed	  endothelial	  function	  in	  the	  coronary	  arteries.	  (192).	   Endothelial	   function	   in	   the	   brachial	   circulation	   is	   impaired	   as	   in	   the	  coronary	   circulation	   in	   the	   setting	   of	   traditional	   and	   novel	   risk	   factors	   and	  responds	   to	   interventions	   known	   to	   reduce	   CVD	   risk	   (190)	   .	   FMD	   measures	  change	  in	  diameter	  of	  a	  conduit	  vessel	  following	  a	  period	  of	  ischaemia,	  and	  the	  brachial	   artery	   is	   the	   most	   commonly	   studied	   vessel.	   A	   sphygmomanometer	  cuff	  is	  placed	  on	  the	  forearm	  distal	  to	  the	  brachial	  artery	  and	  inflated	  to	  supra-­‐
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Table	  7:	  FMD	  as	  a	  prognosticator	  in	  subjects	  with	  cardiovascular	  disease	  or	  at	  high	  risk	  
for	  cardiovascular	  disease.	  Green	  D	  et	  al.	  Hypertension	  2011;57:363-­‐369	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Figure	   14:	   Reactive	   hyperaemic	   tomography	   (Adopted	   from	   ITamar	   Medical)
	  
	  
Figure	  15:	  	  Flow	  mediated	  dilatation.	  (Adopted	  from	  BMPE,	  University	  of	  Tokyo)	  
	  	  	  
	  




Standard	  2-­‐D	  echo	  was	  performed	  in	  all	  patients.	  Biplane	  left	  ventricular	  ejection	  fraction	  (LVEF)	  was	  calculated	  using	  the	  Simpson’s	  method.	  
6MWT	  WAS	  PERFORMED	  USING	  A	  STANDARDISED	  APPROACH	  OVER	  A	  25	  METERS	  COURSE.	  	  
MINNESOTA	  LIVING	  WITH	  HEART	  FAILURE	  QUESTIONNAIRE	  (MLHF)	  This	   is	   a	   21-­‐item	   questionnaire,	   which	   assesses	   physical	   activity,	  subjective	  symptoms	  and	  psychosocial	  issues.	  	  
BIOMARKERS	  
Venous	   blood	   samples	   were	   obtained	   following	   a	   20	   min	   semi-­‐recumbent	   rest	   in	   the	   fasting	   state	   at	   baseline,	   and	   at	   end	   of	   study	   for	  measurement	  of	  full	  blood	  count,	  renal	  function,	  glycated	  haemoglobin	  (HbA1c),	  glucose,	  lipids,	  lactate,	  insulin	  (INSIK-­‐5,	  DiaSorin,	  UK),	  brain	  natriuretic	  peptide	  (BNP),	   adiponectin	   (Quantikine,	   R&D	   System,	   UK),	   leptin	   (Quantikine,	   R&D	  System,	  UK)	  and	  resistin.	  	  
SAFETY	  ASSESSMENTS	  
Safety	   was	   assessed	   via	   monitoring	   for	   adverse	   events	   (AEs),	   clinical	  examination,	   standard	   laboratory	   testing,	   ECG	   recordings	   and	   regular	  measurements	   of	   vital	   signs.	   Lactate	   levels	   were	   measured	   2	   weeks	   after	  initiation	  of	  study	  treatment,	  and	  at	  the	  end	  of	  study	  visit.	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We	  targeted	  66	  subjects	  and	  the	  power	  calculations	  were	  based	  on	  our	  previous	   observational	   study	   of	   CHF	   with	   IR	   with	   a	   mean	   peak	   VO2	   of	   11	  ml/min/kg	  and	  standard	  deviation	  of	  1.8ml/min/kg,	  	  which	  would	  provide	  80%	  power	   to	  detect	   a	  13.5%	  change	   in	  peak	  VO2	   in	   the	  2	  groups	  of	  patients	  with	  CHF	   (alpha=0.05)	   allowing	   for	   a	   10%	   drop	   out	   rate.	   Statistical	   analysis	   was	  performed	  using	  SPSS	  for	  Windows	  version	  16	  (SPSS	  Inc.,	  Chicago,	  IL).	  Numeric	  values	   were	   expressed	   as	   mean	   ±	   standard	   deviation.	   An	   intention	   to	   treat	  analysis	   was	   used.	   The	   significant	   of	   differences	   between	   the	   two	   treatment	  groups	   of	   changes	   from	   baseline	  was	   analyzed	   using	   independent	   t-­‐tests	   and	  chi-­‐square	   tests.	   	   Correlations	   were	   made	   using	   Pearson	   product	   moment	  correlation	   coefficients.	   P	   value	   of	   less	   than	   0.05	  was	   considered	   statistically	  significant.	  	  
	  
RESULTS	  
Baseline	  characteristics	  were	  well	  matched	  between	  the	  2	  study	  groups	  (Table	  8).	  Baseline	  measurements	  of	  interests	  are	  shown	  in	  Table	  9.	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Table	  8:	  Baseline	  characteristics	  of	  TAYSIDE	  Study	  	  
	  
	  
	   Metformin	   Placebo	   All	  Patients	  	   P	  Value	  
	   N=39	   N=23	   N=62	   	  
Age	   64	  ±	  8	   68	  ±	  7	   65	  ±	  8	   0.063	  
Sex	  (Male/Female)	   35/4	   22/1	   57	  /	  5	   0.409	  
Systolic	  Blood	  Pressure	  (mmHg)	   113	  ±	  16	   114	  ±	  17	   113	  ±	  16	   0.761	  
Diastolic	  Blood	  Pressure	  (mmHg)	   71	  ±	  9	   73	  ±	  10	   72	  ±	  9	   0.563	  
Mean	  Heart	  Rate	  (bpm)	   74	  ±	  16	   71	  ±	  19	   73	  ±	  16	   0.597	  
Body	  Mass	  Index	  (BMI)	   30	  ±	  5	   29	  ±	  4	   29.7	  ±	  4.6	   0.224	  
LV	  Ejection	  Fraction	  (%)	   34	  ±	  8	   30	  ±	  8	   33	  ±	  8	   0.083	  
NYHA	  (I/II/III/IV)	   7/29/3/0	   3/17/3/0	   10	  /	  46	  /	  6	  /	  0	   0.725	  
Aetiology	  of	  Heart	  Failure	   	   	   	   	  
	  	  	  	  Ischaemic	   28	   21	   49	   0.068	  
	  	  	  	  Non-­‐ischaemic	   11	   2	   13	   	  
Past	  Medical	  History	  (%)	   	   	   	   	  
	  	  	  	  	  Ischaemic	  Heart	  Disease	   80	   91	   63	   0.036	  
	  Atrial	  fibrillation	   31	   17	   26	   0.245	  
	  	  	  	  Revascularisation	   33	   35	   34	   0.944	  
Peripheral	  vascular	  disease	   3	   9	   5	   0.277	  
Hypertension	   41	   43	   55	   0.850	  
Chronic	  Obstructive	  Pulmonary	  Disease	   3	   13	   7	   0.105	  
Medications	  (%)	   	   	   	   	  
	  	  	  	  	  Diuretics	   51	   52	   53	   0.946	  
	  	  	  	  Angiotension	  Converting	  Enzyme	  	  	  inhibitors	   74	   82	   74	   0.473	  
	  	  	  	  Angiotensin	  receptor	  blockers	   21	   14	   18	   0.474	  
	  	  	  	  	  Betablockers	   82	   91	   82	   0.329	  
	  	  	  	  Aldosterone	  antagonist	   37	   14	   27	   0.055	  
	  	  	  	  Digoxin	   8	   14	   10	   0.475	  
	  	  	  	  Calcium	  channel	  blocker	   11	   18	   13	   0.401	  
	  	  	  	  HMG	  Co-­‐A	  reductase	  Inhibitors	  (Statin)	   82	   100	   91	   0.031	  
	  	  	  	  Isosorbide	  Mononitrate	   18	   36	   12	   0.122	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   Metformin	   Placebo	   P	  Value	  	   N=39	   N=23	   	  
Exercise	  Parameters	   	   	   	  
 Peak	  VO2	  (ml/kg/min)	   19.5	  ±4.9	   18.5	  ±5.1	   0.312	  
 Peak	  Cardiac	  Output	  (L/min)	   8.3	  ±2.9	   7.8	  ±2.6	   0.631	  
 VE/VCO2	  Slope	   32.9	  ±15.9	   32±	  5.9	   0.821	  
 Ventilatory	  Class	  I/II/III/IV	   13/12/7/1	   8/7/5/0	   0.845	  
 Respiratory	  Gas	  Exchange	  Ratio	  (R)	   0.9	  ±0.1	   0.8	  ±0.1	   0.088	  
 Total	  exercise	  duration	  (secs)	   1049	  ±207	   940	  ±288	   0.091	  
 6	  Minute	  Walk	  Test	  (meters)	   438	  ±76	   414±86	   0.280	  
Endothelial	  Function	   	   	   	  
 Reactive	  Hyperaemic	  Index	  (RHI)	   1.8	  ±0.3	   1.9	  ±0.6	   0.264	  
 Flow	  Mediated	  Dilatation	  (FMD)	  (%)	   7.1	  ±3.7	   5.4	  ±3.7	   0.119	  
Laboratory	  Parameters	   	   	   	  
 Haemoglobin	  (g/dL)	   14.8	  ±1.4	   14.5	  ±1.3	   0.361	  
 Creatinine	  (µmol/L)	   87.8	  ±	  16.3	   88.3	  ±	  19.5	   0.912	  
 Glucose	  (mmol/L)	   5.6	  ±	  0.6	   5.3	  ±	  0.4	   0.029	  
 Insulin	  (mU/L)	   26.8	  ±	  14.3	   23.2	  ±	  10.5	   0.198	  
 Fasting	  Insulin	  Resistance	  Index	  (FIRI)	   6.6	  ±	  3.9	   6.5	  ±	  4.6	   0.116	  
 Total	  Cholesterol	  (mmol/L)	   4.3	  ±	  1.0	   3.8	  ±	  0.6	   0.023	  
 Adiponectin	  (mg/ml)	   8.4	  ±	  6.7	   8.7	  ±	  5.5	   0.879	  
 Leptin	  (ng/ml)	   16.6	  ±	  23.2	   10.9	  ±	  6.4	   0.265	  
 BNP	  (pg/ml)	   131.7±	  158.5	   187.1	  ±	  251.3	   0.362	  
 Resistin	  (ng/ml)	   5.1	  ±	  2.3	   4.0	  ±	  1.1	   0.054	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CHANGES	  IN	  WEIGHT,	  FIRI	  AND	  BIOMARKERS	  
Compared	   to	   placebo,	  metformin	   resulted	   in	   a	   significant	   reduction	   in	  weight	   and	   BMI	   (p<	   0.001,	   p=0.037	   respectively).	   Metformin	   significantly	  decreased	   FIRI	   (p<0.001)	   and	   serum	   HbA1c	   (p=0.002).	   Serum	   leptin	   levels	  were	   significant	   reduced	   with	   metformin	   (metformin,	   -­‐4.56	   ±	   11.0	   ng/ml	   vs	  placebo,	  0.58±	  3.5	  ng/ml,	  p=0.038).	  There	  was	  no	  significant	  change	  in	  plasma	  BNP	  with	  metformin	   (metformin,	   -­‐20.2	   ±	   78.7	   pg/ml	   vs	   placebo,	   7.5	   ±	   131.2	  pg/ml).	  	  
	  
MAXIMAL	  AND	  SUB-­‐MAXIMAL	  EXERCISE	  PARAMETERS	  AND	  6MWT	  
Peak	   exercise	   parameters	   did	   not	   differ	   between	   treatment	   groups	  (Table	   10).	   Compared	   to	   placebo,	   metformin	   decreased	   the	   sub-­‐maximal	  parameters	   of	   VE/VCO2	   slope	   (from	   32.9±15.9	   to	   28.1±	   8.8,	   p=0.034)	   and	  ventilatory	  class	  (χ-­‐square	  test,	  p=0.008).	  There	  was	  no	  difference	  in	  6MWT.	  
	  
CORRELATIONS	  BETWEEN	  VE/VCO2	  SLOPE,	  WEIGHT	  AND	  FIRI	  
Pearson	   correlations	   and	   linear	   regression	   model	   showed	   that	   weight	  reduction	  on	   its	  own	  was	  not	  correlated	  with	   the	  reduction	  of	  VE/VCO2	  slope	  (p=0.801).	   In	   the	  metformin	   treated	  group,	  FIRI	  and	  serum	   leptin	   levels	  were	  significantly	   related	   to	   the	   reduction	   of	   VE/VCO2	   slope	   (R=0.41,	   Difference	   in	  FIRI:	  Beta:	  -­‐14.07,	  p=0.036;	  Difference	  in	  leptin:	  Beta=0.29,	  p=0.023).	  	  




There	  was	  no	   significant	   change	   in	  NYHA	   functional	   class	   between	   the	  treatment	   groups	   (χ-­‐square	   test,	   p=0.124).	   Although	   it	   was	   noted	   that	   4	  patients	   in	   the	  metformin	   arm	   reported	   an	   improvement	   in	   NYHA	   functional	  class	  with	  a	  drop	  of	  one	  NYHA	  functional	  class	  whereas	  1	  patient	  in	  the	  placebo	  arm	  had	  an	  increase	  in	  one	  NYHA	  functional	  class.	  MNLHF	  Questionnaire	  scores	  did	  not	  differ	  between	  the	  groups.	  Heart	  failure	  medications	  including	  diuretic	  dosage	  remained	  unchanged	  throughout	  the	  study.	  
ECHOCARDIOGRAPHY	  AND	  ENDOTHELIAL	  FUNCTION	  
There	   was	   no	   significant	   change	   in	   LVEF.	   Changes	   in	   RH-­‐PAT	  (metformin,	  0.12	  ±	  0.4	  vs.	  placebo,	  0.06	  ±	  0.70)	  and	  FMD	  (metformin,	   -­‐0.38	  ±	  4.46	  vs.	  placebo,	  -­‐1.74±	  2.71)	  were	  not	  statistically	  significant.	  
TOLERABILITY	  AND	  SAFETY	  OF	  METFORMIN	  
There	  were	  no	  SAEs	  in	  either	  treatment	  groups.	  AEs	  were	  more	  frequent	  with	  metformin	  treatment	  although	  majority	  of	  these	  AEs	  were	  transient,	  and	  were	  mild	  to	  moderate	  in	  severity.	  The	  main	  AEs	  were	  abdominal	  discomfort	  (16%	  metformin,	  4%	  placebo,	  p=	  0.18),	  diarrhoea	  (47%	  metformin,	  13%	  placebo,	  p=	  0.008),	  nausea	  (29%	  metformin,	  0%	  placebo,	  p=	  0.005),	  and	  anorexia	  (21%	  metformin,	  0%	  placebo,	  p=	  0.021).	  AEs	  led	  to	  premature	  discontinuation	  in	  five	  metformin	  treated	  patients.	  The	  average	  tolerable	  dose	  of	  metformin	  was	  1675mg	  daily.	  Lactate	  levels	  did	  not	  differ	  between	  treatment	  groups	  and	  no	  lactic	  acidosis	  was	  reported.	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Table	  10:	  	  TAYSIDE	  study.	  Changes	  after	  4	  months	  of	  metformin	  treatment	  
	  
	   Metformin	   Placebo	   P	  value	  
	   N=36	   N=22	   	  
Peak	  Exercise	  Parameters	   	   	   	  
Peak	  VO2	  (ml/kg/min)	   -­‐0.38	  ±	  1.40	   3.60	  ±	  3.90	   0.08	  
Peak	  CO	  (L/min)	   0.03	  ±	  3.10	   -­‐0.35	  ±	  2.10	   0.682	  
Sub-­‐maximal	  Exercise	  Parameters	   	   	   	  
VE/VCO2	  Slope	   -­‐4.45	  ±	  10.72	   -­‐0.23	  ±	  3.54	   0.034	  
Ventilatory	  Class	  I/II/III/IV	   21/8/2/2	   8/6/7/1	   0.008	  
NYHA	  Functional	  Class	  I/II/III/IV	   10/25/1/0	   3/15/4/0	   0.124	  
Heart	  Failure	  Questionnaires	   1.58	  ±	  14.78	   0.45	  ±	  8.57	   0.746	  
6	  Minute	  Walk	  Test	  (meters)	   6	  ±	  40	   6	  ±	  32	   0.988	  
Biomarkers	  and	  laboratory	  parameters	   	   	   	  
HbA1c	  (%)	   -­‐0.12	  ±	  0.19	   0.08	  ±	  0.17	   0.035	  
Glucose	  (mmol/L)	   -­‐0.36	  ±	  0.45	   0.09	  ±	  0.71	   0.005	  
Insulin	  (mU/L)	   -­‐6.60	  ±	  8.80	   4.10	  ±	  13.10	   0.000	  
FIRI	  (Log)	   -­‐1.44	  ±	  0.16	   0.05	  ±	  0.18	   0.000	  
Leptin	  (ng/ml)	   -­‐4.56	  ±	  11.0	   0.58	  ±	  3.50	   0.038	  
Adiponectin	  (mg/ml)	   -­‐0.44	  ±	  2.16	   0.43	  ±	  2.54	   0.168	  
Resistin	  (ng/ml)	   0.01	  ±	  0.08	   0.04	  ±	  0.06	   0.094	  
BNP	  (pg/ml)	   -­‐20.2	  ±	  78.7	   17.5	  ±	  131.2	   0.184	  
Creatinine	  (µmol/L)	   0.50	  ±	  12.46	   1.41	  ±	  7.39	   0.758	  
Lactate	  (mmol/L)	   0.09	  ±	  0.63	   0.00	  ±	  0.42	   0.562	  
Cholesterol	  (mmol/L)	   -­‐0.32	  ±	  0.54	   -­‐0.01	  ±	  0.65	   0.055	  
Triglyceride	  (mmol/L)	   -­‐0.17	  ±	  0.60	   -­‐0.04	  ±	  0.80	   0.467	  
Weight	  (Kg)	   -­‐1.9	  ±	  2.3	   1.1	  ±	  2.5	   0.000	  
Body	  Mass	  Index	   -­‐2.03	  ±	  6.07	   0.39	  ±	  0.89	   0.037	  
Waist	  Hip	  Ratio	   -­‐0.08	  ±	  0.03	   -­‐0.49	  ±	  2.02	   0.341	  
Ejection	  Fraction	  (%)	   0.35	  ±	  5.50	   -­‐1.10	  ±	  4.20	   0.356	  
Endothelial	  Function	   	   	   	  
Reactive	  Hyperaemic	  Index	  (Endo-­‐PAT)	   0.12	  ±	  0.54	   0.06	  ±	  0.70	   0.743	  
Flow	  Mediated	  Dilatation	  (%)	   -­‐0.38	  ±	  4.36	   -­‐1.74	  ±	  2.71	   0.201	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This	   study	   had	   two	  main	   findings,	   Firstly,	   we	   showed	   that	   in	   patients	  identified	  to	  have	  insulin	  resistance	  and	  CHF,	  metformin	  treatment	  significantly	  reduced	  FIRI	  and	  that	  this	  treatment	  was	  associated	  with	  a	  weight	  loss	  of	  1.9	  kg.	  Secondly,	   although	   metformin	   had	   no	   effect	   on	   peak	   exercise	   parameters	  including	   peak	   VO2,	   metformin	   treatment	   did	   result	   in	   a	   significant	  improvement	   in	   VE/VCO2	   slope,	   a	   pre-­‐specified	   endpoint	   of	   this	   proof	   of	  concept	  study.	  	  
Although	  diabetes	  predispose	  to	  the	  development	  of	  CHF,	  CHF	  may	  also	  lead	   to	   the	   development	   of	   IR	   and	  diabetes.	   Previous	   clinical	   studies	   utilizing	  the	   hyperinsulinaemic-­‐euglycaemic	   clamps	   have	   demonstrated	   fasting	  hyperinsulinaemia	   and	   insulin	   resistance	   in	   patients	  with	   both	   ischaemic	   and	  non-­‐ischaemic	   CHF	   (174).	   	   IR	   is	   highly	   prevalent	   amongst	   patients	  with	   CHF.	  We	  and	  others	  have	  showed	  that	  close	  to	  two	  thirds	  of	  patients	  with	  CHF	  has	  IR	  determined	   by	   either	   FIRI	   or	   oral	   glucose	   tolerance	   test	   (116,182).	   IR	   is	  associated	  with	  decreased	  exercise	  capacity,	  endothelial	  dysfunction	  (116)	  and	  more	  importantly	  worse	  prognosis	  in	  CHF	  (2,3).	  The	  prognostic	  impact	  of	  IR	  is	  independent	  of	  other	  variables,	  including	  peak	  VO2	  and	  left	  ventricular	  ejection	  fraction,	   which	   may	   imply	   that	   IR	   maybe	   pathogenic	   rather	   than	   simply	   a	  marker	  for	  worsened	  CHF	  (175,194).	  These	  findings	  support	  the	  notion	  that	  IR	  may	  be	  pathophysiologically	   linked	  with	  CHF,	  and	   is	   implicated	   in	   the	  disease	  progression	   in	   CHF	   (195).	   This	   is	   likely	   because	   IR	   is	   associated	   with	  endothelial	   dysfunction,	   inflammation,	   increased	   oxidative	   stress,	   changes	   in	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cardiac	  metabolism	  and	  myocardial	  remodelling,	  processes	   that	  accelerate	   the	  progression	  of	  disease	  in	  CHF	  (195).	  
If	   IR	   is	   important	   to	   the	   pathogenesis	   of	   CHF,	   it	   could	   be	   argued	   that	  therapies	  directed	  toward	  improving	  IR	  could	  be	  beneficial.	  To	  the	  best	  of	  our	  knowledge,	   this	   is	   the	   first	   proof	   of	   concept	   study	   to	   examine	   the	   impact	   of	  metformin	   on	   IR	   and	   exercise	   parameters	   in	   patients	   with	   CHF	   identified	   to	  have	  IR.	  In	  this	  study,	  we	  have	  chosen	  to	  use	  metformin	  although	  we	  recognize	  that	  the	  precise	  mechanisms	  of	  metformin’s	  action	  are	  not	  entirely	  understood	  (176).	   	   However,	   there	   is	   increasing	   evidence	   to	   suggest	   that	  metformin	  may	  have	  cardio-­‐protective	  effects	  in	  the	  setting	  of	  CHF	  that	  are	  not	  attributed	  to	  the	  glucose	   lowering	   effects	   alone.	   Recent	   experimental	   studies	   suggest	   ancillary	  potential	   mechanisms.	   These	   protective	   effects	   may	   be	   conferred	   via	   the	   5'-­‐AMP-­‐activated	   protein	   kinase	   (AMPK)	   pathway,	   which	   is	   activated	   by	  metformin	   (165,196,197).	   Metformin	   has	   also	   been	   shown	   to	   improve	  endothelial	  function	  by	  increasing	  nitric	  oxide	  production	  (198).	  Clinical	  studies	  show	   that	  metformin	  may	   reduce	   plasma	   dipeptidyl	   peptidase-­‐4	   activity	   and	  increase	   circulating	   levels	   of	   glucagon-­‐like	   peptide	   1	   (GLP-­‐1),	   which	   is	   an	  incretin	  hormone	   that	  has	  protective	   effects	   on	   the	  heart	   and	   the	   vasculature	  (199,200).	   Finally,	   there	   are	   observational	   studies	   of	   patients	   with	   CHF	   and	  type	   2	   diabetes	   mellitus	   taking	   metformin	   that	   suggest	   a	   morbidity	   and	  mortality	   benefit	   (18,184).	   Although	   these	   data	   were	   encouraging,	   the	   main	  limitations	  of	   these	  observational	  studies	  were	   the	  potential	   for	  selection	  bias	  imposed	   by	   different	   therapies.	   What	   is	   needed	   are	   prospective	   placebo	  controlled	  studies	  such	  as	  our	  study.	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  In	   this	   study,	   we	   were	   interested	   in	   determining	   if	   reversing	   IR	   with	  metformin	   in	   patients	   with	   CHF	  would	   result	   in	   an	   improvement	   in	   exercise	  capacity.	   In	   this	   study,	   we	   did	   not	   observe	   an	   effect	   of	   metformin	   on	   peak	  exercise	   parameters	   including	   peak	   VO2,	   the	   primary	   endpoint	   of	   our	   study.	  However,	   metformin	   treatment	   did	   result	   in	   VE/VCO2	   slope	   and	   ventilatory	  class.	   The	   VE/VCO2	   slope	   reduced	   from	   32.9	   to	   28.1.	   The	   VE/VCO2	  slope	   had	  been	   reported	   to	   be	   a	   more	   accurate	   prognostic	   index	   for	   cardiac	   related	  mortality	   and	   hospitalization	   than	   peak	   VO2	   (201,202),	   and	   the	   ventilatory	  classification	  system	  has	  been	  proposed	  to	  guide	  therapy	  in	  patients	  with	  CHF	  (203).	   We	   acknowledge	   that	   there	   are	   several	   possible	   explanations	   for	   our	  findings.	  One	  possible	   explanation	   for	   the	   improvement	   in	   functional	   capacity	  might	  be	  the	  weight	  loss	  of	  1.9	  kg	  associated	  with	  metformin	  therapy.	  Studies	  of	  both	  diet	  and	  drug-­‐induced	  weight	  loss	  have	  been	  shown	  to	  improve	  functional	  status	   in	  CHF	  patients	   (204).	  However,	   it	   should	  be	  noted	   that	  our	   regression	  model	   showed	   that	   weight	   reduction	   did	   not	   correlate	   with	   the	   reduction	   in	  VE/VCO2	  slope.	  Another	  consideration	  is	  that	  the	  insulin	  sensitizing	  properties	  of	   metformin	   might	   confer	   some	   beneficial	   effects	   on	   exercise	   capacity.	  Improving	   insulin	   sensitivity	   has	   been	   shown	   to	   improve	   exercise	   capacity.	  Regensteiner	   and	   colleagues	   have	   previously	   shown	   that	   improvement	   in	  insulin	   sensitivity	  with	   rosiglitazone	   resulted	   in	   a	   significant	   improvement	   in	  exercise	  capacity	  and	  peak	  VO2	  in	  diabetic	  individuals	  (205).	  	  In	  this	  regard,	  we	  found	  that	  with	  metformin	  treatment,	  reduction	  of	  FIRI	  and	  serum	  leptin	  level	  was	  significantly	  correlated	  with	  the	  reduction	  of	  VE/VCO2	  slope.	  Doehner	  et	  al	  had	   previously	   demonstrated	   that	   hyperleptinaemia	   is	   an	   independent	  predictor	   of	   IR	   in	   patients	   with	   CHF,	   	   and	   it	   may	   play	   an	   important	   role	   in	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energy	  metabolism	  in	  these	  patients	  (63).	  Reduction	  of	  serum	  leptin	  levels	  have	  been	   previously	   reported	   following	   chronic	   metformin	   therapy	   (206),	   and	  might	  be	  due	   to	  a	  direct	  effect	  of	  metformin	  on	   leptin	  secretion	  (207).	  Recent	  studies	   have	   shown	   the	   significance	   of	   adipocytokines	   modulation	   in	   HF	  patients;	  and	  high	  levels	  of	  adiponectin	  were	  associated	  with	  adverse	  outcomes	  in	  CHF	   (75,76).	  There	  were	  no	   significant	   change	  of	   adiponectin	   levels	   in	   our	  study	  (p=0.168).	  However,	  we	  did	  notice	  that	  patients	  in	  the	  metformin	  treated	  group	  have	  decreased	  adiponectin	  level	  whereas	  adiponectin	  levels	  were	  higher	  in	   the	   placebo	   group.	   Therefore,	   the	   improvement	   of	   sub-­‐maximal	   exercise	  capacity	   in	   our	   cohort	   may	   in	   part	   be	   due	   to	   an	   improvement	   of	   IR	   and	   the	  reduction	  of	  serum	  leptin	   level.	  A	   third	  consideration	   is	  metformin’s	  ability	   to	  activate	   AMPK,	   which	   is	   expressed	   in	   various	   tissues	   including	   the	   skeletal	  muscle,	   myocardium	   as	   well	   as	   the	   vascular	   endothelium	   (165).	   Therefore,	  activation	   of	   AMPK	   could	   impact	   on	   central	   as	   well	   as	   peripheral	  haemodynamic	  mechanisms,	  which	   in	   turn	   leads	   to	  changes	   in	  VE/VCO2	  slope	  and	   hence,	   ventilatory	   class.	   Improvement	   of	  myocardial	   substrate	   utilization	  and	   glucose	   uptake	   through	   activation	   of	   AMPK	   may	   improve	   myocardial	  contraction	   and	   increase	   cardiac	   output	   (196).	   In	   animal	   models	   of	   heart	  failure,	   metformin	   has	   been	   shown	   to	   activate	   AMPK	   and	   improve	   left	  ventricular	   function	   and	   to	   attenuate	   oxidative	   stress-­‐induced	   cardiomyocyte	  apoptosis,	   resulting	   in	   improved	  survival	   (197).	  However,	  we	  did	  not	  observe	  an	   effect	   of	   metformin	   on	   echo	   derived	   LVEF	   or	   CO	   at	   rest	   and	   during	   peak	  exercise.	   With	   respect	   to	   peripherally	   mediated	   mechanisms,	   an	   effect	   of	  metformin	  on	  exercising	  skeletal	  muscles	  could	  account	  for	  the	  improvement	  in	  VE/VCO2	   slope.	   	   Alterations	   in	   skeletal	   muscle	   energy	   metabolism,	   IR	   and	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functional	   adiponectin	   resistance	   have	   been	   reported,	   and	   linked	   to	   exercise	  intolerance	   in	  patients	  with	  CHF	   (208).	  A	   study	  of	   the	   effect	   of	  metformin	  on	  skeletal	  muscle	   enzyme	   activities	   in	   our	   subjects	  would	   be	   of	   interest.	   In	   our	  original	   proposal,	  we	  had	  planned	   to	   do	   this	   but	   this	   invasive	   procedure	  was	  offered	  as	  an	  option	  and	  no	  patient	  consented	  to	  the	  procedure.	  We	  did	  not	  see	  an	   effect	   of	   metformin	   on	   endothelial	   function.	   Obviously	   any	   evidence	   that	  metformin	   improves	   exercise	   capacity	   through	   central	   cardiac	   or	   peripheral	  mechanisms	   in	   patients	   with	   CHF	   must	   remain	   speculative	   and	   cannot	   be	  inferred	  directly	  from	  this	  study.	  Clearly,	  further	  studies	  are	  required	  to	  define	  the	  mechanisms	  underlying	  these	  effects	  of	  metformin	  in	  CHF.	  
In	  this	  study,	  we	  did	  not	  record	  any	  incidence	  of	  lactic	  acidosis	  and	  SAEs.	  The	  most	  common	  AE	  was	  diarrhoea,	  which	   is	  well	  described	  with	  metformin	  use.	  The	  2	  kg	  reduction	  in	  weight	  is	  consistent	  with	  findings	  of	  previous	  studies	  of	  metformin	  when	  used	  in	  non-­‐diabetic	  populations	  (209).	  
LIMITATIONS	  OF	  STUDY	  
In	  order	   to	   comply	  with	  our	   strict	   inclusion	   criteria,	   patients	   recruited	  had	  to	  be	  able	  to	  perform	  repeated	  CPETs.	  We	  believe	  that	  these	  strict	  inclusion	  criteria	  might	   have	   resulted	   in	   us	   recruiting	   a	   cohort	   of	   patients	  with	  milder	  CHF	  as	  our	  patients	  had	  a	  higher	  peak	  VO2	  (19	  ml/kg/min)	  than	  the	  peak	  VO2	  (11	  ml/kg/min)	   that	  we	  based	   our	   power	   calculations	   on.	   This	  might	   explain	  why	  we	  did	  not	  observe	  an	  effect	  of	  metformin	  on	  the	  primary	  endpoint	  of	  the	  study,	  peak	  VO2.	  Even	  though	  this	  is	  a	  randomised	  controlled	  study,	  there	  were	  inevitable	   potential	   confounding	   factors	   noted	   although	   they	   were	   not	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statistically	  significant	  between	  groups.	  Patients	   in	   the	  metformin	  group	  were	  somewhat	  younger,	  LVEF	  was	  higher	  and	  with	  more	  non-­‐ischaemic	  aetiology	  of	  heart	   failure.	  Therefore,	   they	  may	  have	  been	  able	   to	  exercise	  more	  within	   the	  period	  of	  the	  study.	  	  
CONCLUSIONS	  
This	  proof	  of	  concept	  study	  has	  shown	  that	  in	  non-­‐diabetic	  CHF	  patients	  identified	   to	   have	   IR,	   treatment	   with	   metformin	   significantly	   improved	   IR,	  VE/VCO2	  slope	  and	  resulted	  in	  significant	  weight	  loss,	  but	  did	  not	  improve	  peak	  VO2,	  the	  primary	  endpoint	  of	  the	  study.	  Although	  the	  improvement	  of	  VE/VCO2	  slope	  was	  correlated	  with	  the	  improvement	  of	  IR,	  we	  were	  not	  able	  to	  ascertain	  if	   this	   was	   the	   cause	   of	   improvement	   of	   sub-­‐maximal	   exercise	   performance	  owing	   to	   the	   complexity	   of	   action	   of	   metformin.	   Our	   findings	   are	   however	  hypothesis	  generating,	  and	  further	  studies	  are	  clearly	  required	  to	  determine	  the	  effects	  of	  metformin	  on	  exercise	  performance	  in	  patients	  with	  CHF.	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ABSTRACT	  
	   The	  5’-­‐AMP-­‐activated	  protein	  kinase	  (AMPK)	  is	  a	  heterotrimeric	  enzyme	  that	  is	  expressed	  in	  many	  tissues	  including	  the	  heart	  and	  vasculature,	  and	  plays	  a	  central	  role	  in	  the	  regulation	  of	  energy	  homeostasis.	  It	  is	  activated	  in	  response	  to	  stresses	  that	  lead	  to	  an	  increase	  in	  the	  cellular	  AMP:	  ATP	  ratio	  caused	  either	  by	  inhibition	  of	  ATP	  production	  (i.e.	  anoxia,	  ischaemia)	  or	  by	  accelerating	  ATP	  consumption	   (i.e.	   muscle	   contraction,	   fasting).	   In	   the	   heart,	   AMPK	   activity	  increases	  during	   ischaemia	  and	   functions	  to	  sustain	  ATP,	  cardiac	   function	  and	  myocardial	   viability.	   There	   is	   increasing	   evidence	   that	   AMPK	   is	   implicated	   in	  the	  pathophysiology	  of	  cardiovascular	  and	  metabolic	  diseases.	  A	  principle	  mode	  of	  AMPK	  activation	  is	  phosphorylation	  by	  upstream	  kinases	  (e.g.	  LKB1,	  calcium	  calmodulin	  dependent	  protein	  kinase),	  which	   leads	   to	  direct	  effects	  on	  tissues	  and	  phosphorylation	  of	  various	  downstream	  kinases	  (i.e.	  eEF2	  kinase,	  p70S6).	  These	  upstream	  and	  downstream	  kinases	  of	  AMPK	  have	   fundamental	   roles	   in	  glucose	   metabolism,	   fatty	   acid	   oxidation,	   protein	   synthesis	   and	   tumour	  suppression;	   consequently,	   they	   have	   been	   implicated	   in	   cardiac	   ischaemia,	  arrhythmias	   and	   hypertrophy.	   Recent	   mechanistic	   studies	   have	   shown	   that	  AMPK	   has	   an	   important	   role	   in	   the	   mechanism	   of	   action	   of	   metformin,	  thiazolidinediones	  and	  statins.	  Increased	  understanding	  of	  the	  beneficial	  effects	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of	   AMPK	   activation	   provides	   the	   rationale	   for	   targeting	   AMPK	   in	   the	  development	  of	  new	  therapeutic	  strategies	  for	  cardio-­‐metabolic	  disease.	  	  	  
INTRODUCTION	  
	   The	   prevalence	   of	   cardiometabolic	   diseases	   is	   reaching	   epidemic	  proportions	   in	   industrialized	   nations	   and	   in	   developing	   countries	   (210-­‐212).	  Despite	   aggressive	   treatment	   of	   the	   individual	   cardiometabolic	   risk	   factors,	  death	   from	   cardiometabolic	   conditions	   remains	   unacceptably	   high.	   Therefore,	  there	   is	   an	  urgent	  need	   to	   identify	  new	  strategies	   for	   treating	  and	  preventing	  cardiometabolic	   diseases.	   In	   this	   respect,	   the	   AMP-­‐activated	   protein	   kinase	  (AMPK)	  pathway	  has	  become	   the	   focus	  of	   a	  great	  deal	  of	   attention	  as	  a	  novel	  therapeutic	   target	   in	   cardiometabolic	   disease,	   because	   it	   has	   been	  demonstrated	   to	   mediate,	   at	   least	   in	   part,	   the	   effects	   of	   a	   number	   of	  physiological	   and	   pharmacological	   factors	   that	   exert	   beneficial	   effects	   on	   the	  vasculature	   and	   the	   heart.	   AMPK	   has	   several	   important	   metabolic	   effects	  including	   increasing	   muscle	   glucose	   uptake	   (213)	   (214),	   and	   ameliorating	  insulin	   resistance	   (215).	   It	   regulates	   cardiac	   muscle	   glucose	   and	   lipid	  metabolism	  both	  directly	  and	  indirectly	  in	  order	  to	  provide	  ATP	  in	  response	  to	  energy	  depletion	  (specifically	  a	  rise	  in	  the	  AMP:	  ATP	  ratio).	  AMPK	  activity	  can	  also	  be	  modulated	  by	  hormones	  and	  adipocytokines,	  which	  may	  have	  protective	  effects	   against	   cardiovascular	  disease.	  AMPK	  has	   also	  been	   shown	   to	   regulate	  transcription	   of	   genes	   involved	   in	   lipid	   and	   glucose	   metabolism	   (216,217).	  Dysregulation	   of	   this	   process	   (e.g.	   in	   obesity)	   can	   lead	   to	   the	   development	   of	  insulin	  resistance	  and	  dyslipidaemia,	  both	  of	  which	  are	  major	  risks	   factors	   for	  
Chapter	  7	  The	  Future	  IR	  Modulators:	  AMPK	  activators	  	  
	  
108	  
CVD.	  Thus,	  the	  identification	  of	  a	  compound	  that	  specifically	  and	  safely	  activates	  the	   AMPK	   pathway	   might	   contribute	   significantly	   to	   the	   treatment,	  management	   and	   even	   prevention	   of	   CVD.	   We	   aim	   to	   discuss	   the	   direct	   and	  indirect	   role	   of	   AMPK	   in	   normal	   cardiac	   physiology	   and	   in	   cardiometabolic	  disease,	  and	  therapeutic	  strategies	  in	  modulating	  APMK	  activity.	  
STRUCTURE	  AND	  REGULATION	  OF	  AMPK	  
Understanding	   of	   the	   role	   of	   AMPK	   in	   key	   physiological	   pathways	   has	  increased	  several	  folds	  in	  recent	  years.	  Its	  discovery	  can	  be	  traced	  back	  to	  two	  independent	   findings	   reported	   in	   1973	   (218)	   which	   observed	   that	   crude	  preparations	  of	  acetyl-­‐CoA	  carboxylase	  (ACC)	  and	  3-­‐hydroxy-­‐3-­‐methyl	  (HMG)-­‐CoA	   reductase	   became	   inactivated	   when	   incubated	   with	   ATP.	   Both	   groups	  predicted	   that	   the	   effects	   were	   due	   to	   phosphorylation	   of	   the	   enzyme	   by	   an	  endogenous	   protein	   kinase	   that	   contaminated	   their	   preparations.	   It	   was	  subsequently	   shown	   that	   this	   protein	   kinase	   was	   itself	   activated	   by	  phosphorylation	  by	  an	  upstream	  kinase	  (219).	   	  In	  1987,	  Hardie	  et	  al	  made	  the	  discovery	   that	   the	   inactivation	   of	   ACC	   and	   HMG-­‐CoA	   reductase	   were	   both	  catalyzed	  by	  a	  single	  protein	  kinase	  (220).	  	  As	  it	  became	  clear	  that	  it	  was	  a	  true	  multi-­‐substrate	  kinase,	   they	  renamed	   it	  AMP-­‐activated	  protein	  kinase	  after	   its	  allosteric	  activator,	  5’-­‐AMP	  (221).	  Hardie	  et	  al	  have	  described	  AMPK	  as	  a	   ‘fuel	  gauge’	  and	  ‘guardian	  of	  energy	  status’,	  implying	  the	  fundamental	  role	  of	  AMPK	  in	   energy	   metabolism	   and	   maintaining	   body	   energy	   balance.	   AMPK	   is	   a	  heterotrimetric	  enzyme	  complex	  which	  consists	  of	  α,	  β,	  and	  γ	  subunits,	  each	  of	  which	   has	   two	   or	  more	   isoforms	   that	   are	   encoded	   by	   distinct	   genes	   and	   are	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differentially	   expressed	   in	   various	   tissues	   (222).	   The	   α	   subunit	   contains	   the	  catalytic	  domain,	  including	  the	  important	  regulatory	  Thr-­‐172	  residue,	  which	  is	  phosphorylated	   by	   upstream	  kinase.	   The	   β	   subunit	   has	   a	   glycogen-­‐binding	   C-­‐	  terminal	  domains	  that	  are	  sufficient	  on	  their	  own	  to	  form	  a	  complex	  with	  α	  and	  γ	  subunits.	  High	  cellular	  glycogen	  content	  exerts	  an	  inhibitory	  effect	  on	  AMPK	  through	   interaction	  with	   the	   β	   subunit	   in	   skeletal	  muscle,	   although	   the	   exact	  mechanism	  is	  unknown	  (223).	  The	  γ	  subunit	  of	  AMPK	  was	  first	  recognized	  by	  Bateman	   (224)	   and	   contains	   4	   repeats,	   forming	   two	   domains.	   Each	   of	   these	  domains	  binds	  one	  molecule	  of	  AMP	  or	  ATP	  ion	  in	  a	  mutually	  exclusive	  manner	  (225),	  consistent	  with	  the	  findings	  that	  high	  concentrations	  of	  ATP	  antagonize	  activation	  of	  AMPK	  by	  AMP.	  
	   For	  many	  years,	  the	  upstream	  kinases(s)	  that	  phosphorylate	  Thr-­‐172	  on	  the	   α	   subunit	   of	   AMPK	   remained	   unidentified.	   In	   recent	   years,	   it	   has	   been	  established	  that	  the	  major	  upstream	  kinase	  in	  mammalian	  cells	  is	  a	  complex	  of	  protein	  kinase	  LKB1	  and	  two	  accessory	  subunits,	  STRAD	  and	  MO25	  (226-­‐228).	  LKB1	  also	  acts	  as	  an	  upstream	  kinase	  of	  at	  least	  12	  other	  AMPK-­‐related	  kinases	  (229,230).	  It	  has	  also	  been	  found	  to	  be	  a	  tumour	  suppressor	  and	  was	  identified	  in	  humans	  as	  a	  gene	  carrying	  an	  autosomal	  dominant	  mutation	  in	  Peutz-­‐Jeghers	  syndrome	  (228,231).	  	  The	  STRAD	  subunit	  is	  essential	  for	  the	  ability	  of	  the	  LKB1	  complex	  to	  phosphorylate	  Thr-­‐172	  on	  AMPK	  (227).	  Besides	  LKB1,	  STRAD	  and	  MO25,	   AMPK	   can	   also	   be	   activated	   by	   an	   LKB1-­‐independent	   mechanism	  involving	  Ca2+/calmodulin	  dependent	  protein	  kinases.	  
AMPK	  exerts	   its	  metabolic	   effects	   through	   its	   interactions	  with	  various	  metabolic	   pathways.	   Activation	   of	   these	   metabolic	   pathways	   via	   AMPK	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activation	   leads	   to	   remodeling	   of	   various	   components	   of	  metabolic	   syndrome	  (232)	   (Figure	   16).	   AMPK	  plays	   a	  major	   role	   in	   providing	  ATP	   in	   the	  midst	   of	  energy	  depletion	  via	   its	   interactions	  with	  various	  metabolic	  pathways	   (Figure	  17).	  Furthermore,	  AMPK	  also	  has	  direct	  and	   indirect	  effects	  on	  cardiovascular	  system.	   	   The	   understanding	   of	   such	   effects	   provide	   the	   rationale	   of	   targeting	  AMPK	  as	  a	  new	  therapeutic	  modality	  for	  the	  treatment	  and	  prevention	  of	  CVD.	  	  
	  
Figure	   16:	   Activation	   of	   various	   metabolic	   pathways	   via	   AMPK	   activation	   leads	   to	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Figure	  17:	  	  AMPK	  activation	  leads	  to	  activation	  of	  different	  metabolic	  pathways	  
AMPK	  plays	  an	  important	  role	  in	  whole	  body	  energy	  homeostasis.	  It	  regulates	  and	  
interacts	  with	  different	  key	  metabolic	  pathways.	  Activation	  of	  AMPK	  secondary	  to	  
change	  of	  AMP:ATP	  ratio	  or	  activation	  by	  upstream	  kinases	  such	  as	  CAMKK,	  LKB1	  
leads	   to	   leads	   to	   switching	   on	   energy	   production	   pathways	   such	   as	   glucose	   and	  
lipids	   metabolism	   and	   turning	   off	   energy	   metabolic	   process	   such	   as	   protein	  
synthesis,	  which	  is	  not	  required	  for	  immediate	  cell	  survival.	  	  	  
Fatty	  Acid	  metabolism.	  AMPK	  activation	  leads	  to	  increased	  translocation	  of	  CD36,	  a	  fatty	  acid	   transport	   protein.	   It	   increases	   fatty	   acid	   into	   cells	   and	   subsequent	   uptake	   into	  mitochondria	  for	  β-­‐oxidation.	  Carnitine	  palmitoyl	  transferase	  (CPT-­‐1)	  inhibits	  fatty	  acid	  influx	  and	  acts	  as	  a	  gatekeeper	  for	  mitochondrial	  uptake	  of	  fatty	  acid.	  Activation	  of	  AMPK	  leads	   to	   inhibition	   of	   acetyl	   CoA	   carboxylase	   (ACC2	   isoform),	  which	   normally	   converts	  acetyl	   CoA	   to	   malonyl	   CoA.	   The	   inhibitory	   effect	   of	   malonyl	   CoA	   of	   CPT-­‐1	   is	   hence	  removed,	   leading	   to	   unopposed	   intake	   of	   fatty	   acid	   into	   mitochondria.	   	   Furthermore,	  phosphorylating	  and	  inactivation	  of	  the	  ACC1	  isoform	  of	  ACC	  by	  AMPK	  activation	  reduces	  fatty	   acid	   synthesis	   and	   turning	   off	   expression	   of	   lipogenic	   genes	   such	   as	   fatty	   acid	  synthase.	  
Glucose	  metabolism.	  Activation	  of	  AMPK	  increases	  translocation	  and	  retention	  of	  glucose	  transporter-­‐4	   (GLUT-­‐4)	   in	   the	   plasma	  membrane	   as	  well	   as	   increased	   transcription	   of	  GLUT-­‐4	   gene,	   leading	   to	   increased	   glucose	   uptake.	   It	   also	   enhances	   glycolysis	   via	  activation	  and	  phosphorylation	  of	  phosphofructokinase	  (PFK2).	  	  
Protein	  metabolism.	  p70	  ribosomal	  protein	  kinase	  6	  (p70S6K)	   is	  a	  one	  of	   the	  key	  kinase	  involved	   in	   protein	   synthesis.	   mTOR	   activates	   p70S6K	   and	   leads	   to	   increased	   protein	  synthesis.	  When	   AMPK	   is	   activated,	   the	   activation	   of	   p70S6K	   is	   blocked	   as	   a	   result	   of	  inhibition	  of	  mTOR.	  Activation	  of	  AMPK	  also	  results	  in	  phosphorylation	  and	  inactivation	  of	  eEF2,	  subsequent	  inhibition	  of	  protein	  synthesis.	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(A)	   AMPK	  AND	  CARDIAC	  ISCHAEMIA	  
During	  cardiac	  ischaemia,	  the	  AMP/ATP	  ratio	  is	  increased	  as	  a	  result	  of	  decreased	   oxidative	   metabolism	   of	   both	   free	   fatty	   acids	   and	   glucose	   due	   to	  diminished	   oxygen	   supply	   in	   the	   face	   of	   increased	   glycolytic	   ATP	   production	  and	   glucose	   transport	   (237).	   Russell	   et	   al	   have	   shown	   that	   AMPK	   activation	  using	  5’	  aminoimidazole-­‐4-­‐carboxamide-­‐1-­‐β-­‐4-­‐ribofuranoside	  (AICAR)	  in	  an	   in	  
vitro	   rat	  model	   increased	   translocation	   of	   glucose	   transporters	   (i.e.	   GLUT	   -­‐4)	  into	   the	   sarcolemma,	   and	  hence	   increased	   glucose	  uptake(214).	   Furthermore,	  AMPK	  also	  phosphorylates	  and	  activates	  phosphofructokinase	  (PFK-­‐2),	  leading	  to	  the	  production	  of	  fructose	  2,6-­‐bisphosphate,	  a	  potent	  stimulator	  of	  glycolysis.	  AMPK	   may	   be	   necessary	   for	   adiponectin	   to	   exert	   its	   cardio-­‐protective	   effect	  against	  ischaemia-­‐perfusion	  injury	  (238).	  Both	  the	  α1	  and	  α2	  subunits	  of	  AMPK	  are	   activated	   during	   myocardial	   ischaemia,	   with	   α	   2	   activated	   to	   a	   greater	  extent	   (180,239).	   Previous	   studies	   in	   transgenic	   mice	   have	   shown	   that	  decreased	   α	   2	   activities	   resulted	   in	   reduced	   cardiac	   glucose	   uptake	   following	  ischaemia	   (240)	   and	   impaired	   recovery	   of	   left	   ventricular	   systolic	   function	  (180).	  Additionally,	   in	   transgenic	  mice	  expressing	  a	  kinase	  dead	   (KD)	   form	  of	  the	  enzyme,	  phosphocreatinine	  was	  also	   lower	  after	   reperfusion	   (180).	  These	  observations	   suggested	   that	   activation	   of	   AMPK	   following	   ischaemia	   has	   a	  cardio-­‐protective	  effect,	  and	  results	  in	  lesser	  cardiac	  injury	  and	  faster	  recovery.	  Calvert	  et	  al	  have	  also	  shown	  that	  activation	  of	  AMPK	  with	  metformin	  resulted	  in	   decreased	  myocardial	   injury	   in	   both	   diabetic	   and	   non-­‐diabetic	  mice	   (241).	  This	   may	   be	   a	   result	   of	   deriving	   ATP	   from	   more	   energy	   efficient	   glucose	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metabolism	  from	  increased	  AMPK-­‐mediated	  glucose	  uptake	  and	  glycolytic	  flux	  in	  the	  face	  of	  oxygen	  deprivation	  (242,243).	  	  
However,	   ischaemic-­‐induced	  activation	  of	  AMPK	  may	  be	  detrimental	   to	  the	   ischaemic	   heart,	   as	   suggested	   by	   Dyck	   and	   Lopaschuk	   (244).	   During	  ischaemia,	   circulating	   fatty	   acid	   levels	   are	   elevated	   (245),	   which	   may	   be	  detrimental	   to	   the	   ischaemic	   heart	   (246,247).	   Activation	   of	   AMPK	   leads	   to	  increased	  fatty	  acid	  uptake	  and	  inhibition	  of	  malonyl-­‐CoA,	  a	  potent	  endogenous	  inhibitor	   of	   mitochondrial	   fatty	   acid	   uptake.	   This	   results	   in	   accelerated	  mitochondrial	   fatty	  acid	  uptake	  and	  hence	  increased	  mitochondrial	  acetyl	  CoA	  production	  from	  β-­‐oxidation.	  High	  level	  of	  acetyl	  CoA	  has	  an	  inhibitory	  effect	  on	  pyruvate	   dehydrogenase	   (PDH),	   reducing	   the	   amount	   of	   pyruvate	   being	  converted	   into	   acetyl-­‐CoA,	   hence	   reduced	   glucose	   oxidation	   (the	   exact	  mechanisms	   remain	   undefined).	   The	   proposed	   mechanisms	   of	   these	  detrimental	   effects	   of	   high	   circulating	   fatty	   acids	   include:	   (1)	   accumulation	   of	  toxic	   intermediates	   of	   fatty	   acid	   oxidation	   such	   as	   long	   chain	   acyl-­‐CoA	  thioesters	   and	   long	   chain	   acylcarnitines	   (246),	   (2)	   inhibition	   of	   glucose	  oxidation	   via	   inhibition	   of	   PDH	   complex	   by	   fatty-­‐acid-­‐derived	   acetyl	   CoA,	   (3)	  accumulation	   of	   glycolytic	   by-­‐products	   such	   as	   protons	   and	   lactate.	   These	  valuable	  observations	  have	  affirmed	  the	  role	  of	  AMPK	  in	  cardiac	  ischaemia	  and	  implicated	   a	   potential	   role	   for	   therapeutic	   targeting	   in	   the	   treatment	   of	  myocardial	  ischaemia	  and	  infarction.	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(B)	   AMPK	  AND	  CARDIAC	  ARRHYTHMIAS	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(C)	   AMPK	  AND	  CARDIAC	  HYPERTROPHY,	  CELL	  GROWTH	  AND	  GENE	  TRANSCRIPTION	  
	   AMPK	  may	   play	   a	   further	   role	   in	   the	   regulation	   of	   normal	   cardiac	   cell	  growth	   (180,240)	  and	  energy	   regulation	   in	   the	  hypertrophied	  heart	   (254)	  via	  its	  effects	  on	  protein	  synthesis	  (255,256).	  γ2	  mutations	  not	  only	  cause	  glycogen	  overload	   in	   the	   heart	   and	   the	   Wolff-­‐Parkinson-­‐White	   syndrome,	   but	   also	  hypertrophy	   and	   heart	   failure	   (248,257-­‐259).	   Severity	   of	   the	   defect	   also	  correlates	  with	  severity	  of	  the	  disease.	  Eukaryotic	  elongation	  factor-­‐2	  (eEF2)	  is	  the	  main	  mediator	  of	  the	  translocation	  step	  in	  protein	  synthesis	  and	  is	  inhibited	  through	   phosphorylation	   of	   eEF2	   kinase.	   p70S6	   kinase	   regulates	   protein	  synthesis	   through	   the	   same	   pathway	   or	   via	   phosphorylation	   of	   ribosomal	  protein	  S6.	  Chan	  et	  al	  have	  shown	   that	  AMPK	  not	  only	   regulates	  eEF2	  kinase,	  but	   also	   exerts	   effects	   on	   protein	   synthesis	   via	   the	   mammalian	   target	   of	  rapamycin	   (mTOR)	   pathway,	   ultimately	   leading	   to	   inhibition	   of	   p70S6	   (256).	  Furthermore,	  Chan	  et	  al	  have	  shown	  that	  activation	  of	  AMPK	  using	  metformin	  and	   AICAR	   results	   in	   inhibition	   of	   protein	   synthesis,	   and	   is	   associated	   with	  prevention	   and	   regression	   of	   cardiac	   hypertrophy.	   However,	   studies	   in	  transgenic	   mice	   have	   shown	   that	   elevated	   AMPK	   activity	   is	   associated	   with	  accumulation	  of	   large	  amount	  of	  glycogen,	   leading	   to	  dramatic	   left	  ventricular	  hypertrophy	   and	   arrhythmias	   (254,260).	   	   	   It	   remains	   uncertain	   therefore	  whether	  AMPK	  activation	  in	  the	  hypertrophied	  heart	  is	  beneficial	  (256,261)	  or	  deleterious	  and	  further	  studies	  are	  required.	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(D)	   AMPK	  AND	  VASCULAR	  AND	  ENDOTHELIAL	  FUNCTION	  
	   AMPK	  also	  plays	  an	  important	  role	  in	  the	  regulation	  of	  vascular	  function	  and	   structure.	   It	   activates	   endothelial	   nitric	   oxide	   synthase	   (eNOS)	   in	  endothelial	  cells	  and	  cardiac	  myocytes	  by	  phosphorylation	  at	  Ser-­‐1177	  (human	  sequence)	   (262,263).	   eNOS	  activation	   leads	   to	   augmentation	  of	   vascular	   tone,	  platelet	   aggregation,	   leukocyte	   adherence	   and	   vascular	   smooth	   muscle	  proliferation	  (264).	  	  
	   Using	   a	   diabetic	   rat	   model,	   Suzuki	   et	   al	   has	   shown	   that	   activation	   of	  AMPK	   using	   a	   cyclic	   AMP	   (cAMP)	   phosphodiesterase	   inhibitor,	   cilostazol,	  restores	  endothelial	   function	  independently	  of	  cAMP	  (265).	   	  Administration	  of	  cilostazol	  leads	  to	  phosphorylation	  of	  AMPK	  and	  subsequent	  phosphorylation	  of	  eNOS	   and	   increased	   nitric	   oxide	   (NO)	   production.	   Other	   AMPK	   activators,	   5-­‐aminoimidazole-­‐4-­‐carboxamide	   riboside	   (AICAR)	   (266),	  metformin	   (267)	   and	  rosiglitazone	   (268)	  have	   all	   been	   shown	   to	   increase	  NO	  production	   in	  human	  aortic	  endothelial	  cells	  via	  the	  AMPK	  pathway.	  Additionally,	  AMPK	  also	  appears	  to	   have	   a	   role	   in	   angiogenesis,	   promoting	   the	   action	   of	   the	   HIF-­‐1α/	   vascular	  endothelial	   growth	   factor	   VEGF	   pathway	   (269)	   (270),	   and	   inhibiting	  angiotensin	   II-­‐induced	   smooth	   muscle	   cell	   proliferation	   (271).	   Furthermore,	  activation	  of	  AMPK	  activation	  using	  AICAR	  has	  been	  shown	  to	  inhibit	  palmitate-­‐induced	   endothelial	   cells	   apoptosis	   through	   suppression	   of	   reactive	   oxygen	  species	  (272).	  	  It	  is	  clear	  that	  AMPK	  plays	  a	  central	  role	  in	  vascular	  biology.	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  EFFECTS	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Recent	   data	   have	   shown	   that	   levels	   of	   adipocytokines	   such	   as	  adiponectin	  and	  leptin	  correlate	  with	  the	  development	  of	  different	  components	  of	   metabolic	   syndrome	   (273).	   AMPK	   has	   been	   suggested	   to	   play	   a	   role	   in	  mediating	   the	   metabolic	   and	   vascular	   effects	   of	   the	   key	   adipocytokines	  (274,275).	  	  	  
(A)	   AMPK	  AND	  LEPTIN	  
Leptin	  is	  an	  adipocyte-­‐secreted	  hormone	  that	  plays	  a	  pivotal	  role	  in	  the	  regulation	  of	  food	  intake,	  energy	  expenditure,	  body	  weight,	  and	  neuroendocrine	  function	  (276).	  Leptin	  stimulates	   fatty	  acid	  oxidation	  (58),	  and	  glucose	  uptake	  (59),	   and	   prevents	   lipid	   accumulation	   out	   with	   adipose	   tissue,	   preventing	  lipotoxicity	  (60).	  	  Deposition	  of	  ectopic	  fat	  in	  pancreatic	  beta	  cells,	  myocardium,	  and	  skeletal	  muscle	  contributes	  to	  the	  pathogenesis	  of	  type	  2	  diabetes	  mellitus,	  cardiomyopathy,	   and	   insulin	   resistance	   respectively.	   Leptin	   is	   known	   to	   exert	  effects	   via	   the	   AMPK	   pathway,	   stimulating	   phosphorylation	   and	   activation	   of	  the	  α2	  catalytic	  subunit	  of	  AMPK	  selectively	  in	  skeletal	  muscle	  (58).	  	  Leptin	  also	  suppresses	   ACC2	   activity,	   thereby	   stimulating	   fatty	   acid	   oxidation	   in	   muscle.	  AMPK	   also	   inhibits	   lipogenesis	   and	   ectopic	   fat	   deposition	   in	   the	   liver	   (277).	  AMPK	  is	  also	  a	  key	  regulator	  of	  leptin	  action	  in	  the	  hypothalamus	  and	  a	  “master	  regulator”	  of	   food	  intake.	  Minokoshi	  et	  al	  have	  shown	  that	   inhibition	  of	  AMPK	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activity	   by	   leptin	   specifically	   in	   the	   arcuate	   and	   paraventricular	   nuclei	   is	  essential	  for	  its	  anorexigenic	  and	  weight	  loss	  effects	  (278).	  	  
	  
	  (B)	   AMPK	  AND	  ADIPONECTIN	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  AND	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   As	  we	  have	  seen,	  AMPK	  is	  a	  pivotal	  enzyme	  that	  regulates	  diverse	  signals	  in	   metabolic	   pathways	   and	   has	   direct	   and	   indirect	   effects	   on	   the	   heart	   and	  vasculature.	   	   AMPK	   activation	   has	   not	   only	   been	   shown	   to	   alleviate	   various	  components	  of	   the	  metabolic	  syndrome,	  but	  may	  also	   improve	   left	  ventricular	  hypertrophy	   and	   reduce	   cardiac	   injury	   in	   ischaemia.	   AMPK	   is	   also	   a	   key	  mediator	   of	   the	   anti-­‐atherosclerotic	   and	   insulin-­‐sensitizing	   effects	   of	  adiponectin.	   	  Therefore,	   it	   is	   clearly	  an	  attractive	   therapeutic	   target	   in	  cardio-­‐metabolic	   disease.	   A	   number	   of	   AMPK	   activators	   are	   available	   as	  pharmacological	  tools	  and	  some	  are	  in	  clinical	  use	  (Table	  11).	  	  	  
	  
(1)	   	  5-­‐AMINOIMIDAZOLE-­‐4-­‐CARBOXAMIDE	  RIBOSIDE	  (AICAR)	  
AICAR	   is	   an	   adenosine	   analogue,	  which	   activates	  AMPK	   through	  direct	  binding	  followed	  by	  allosteric	  modification.	  It	  is	  initially	  taken	  up	  by	  adenosine	  transporters	   and	   subsequently	   phosphorylated	   to	   5-­‐aminoimidazole-­‐4-­‐carboxamide-­‐1-­‐ß-­‐D-­‐ribofuranotide	  (ZMP)	  within	  the	  cell,	  which	  mimics	  AMP	  in	  AMPK	  signalling	  (281).	  AICAR	  was	  first	  developed	  to	  block	  adenosine	  reuptake	  in	   the	   ischaemic	   heart,	   promoting	   stimulation	   of	   adenosine	   membrane	  receptors.	   In	   1997,	   treatment	   with	   acadesine	   (AICAR)	   before	   and	   during	  surgery	  was	  showed	   to	   reduce	  early	  cardiac	  death,	  myocardial	   infarction,	  and	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combined	  adverse	  cardiovascular	  outcomes	  (282),	  although	  the	  mode	  of	  action	  via	  AMPK	  was	  not	  fully	  appreciated	  at	  that	  time.	  	  
AICAR	   is	   now	   widely	   used	   in	   the	   laboratory	   setting,	   particularly	   in	  experiments	   relating	   to	   glucose	   metabolism,	   insulin	   signalling	   pathways	   and	  lipid	   metabolism.	   In	   recent	   years,	   AICAR	   has	   been	   shown	   to	   reverse	   various	  aspects	   of	   metabolic	   syndrome	   in	   animal	   models	   (232,283-­‐285)	   and	   healthy	  human	   subjects	   (286)(Table	   12).	   AICAR	   has	   also	   been	   shown	   to	   stimulates	  adiponectin	   and	   inhibit	   cytokines	   such	   as	   TNF-­‐α	   and	   IL-­‐6,	   which	   have	   been	  implicated	  in	  the	  development	  of	  obesity-­‐induced	  insulin	  resistance	  (287-­‐290).	  Unfortunately,	  AICAR	  is	  far	  from	  an	  ideal	  activator	  of	  the	  AMPK	  pathway	  in	  the	  clinical	   settings	   because	   of	   its	   short	   half-­‐life,	   requirement	   for	   intravenous	  infusion	  and	  variable	  effectiveness.	   It	   also	  causes	  bradycardia	  and	  can	   lead	   to	  hypoglycaemia	   when	   administered	   intravenously.	   	   Therefore,	   there	   is	   great	  interest	  in	  developing	  a	  more	  potent,	  safer	  and	  more	  specific	  activator.	  	  
(2)	   METFORMIN	  
Metformin	  has	  been	  used	  to	  treat	  diabetes	  for	  more	  than	  50	  years	  and	  is	  associated	   in	   observational	   studies	   with	   reduced	   mortality	   and	   improved	  outcomes	  in	  patients	  with	  chronic	  heart	  failure	  (28,146).	  It	  is	  the	  preferred	  anti-­‐diabetic	  medication	  for	  obese	  patients	  with	  Type	  2	  diabetes	  mellitus	  because	  of	  its	  property	  to	  stabilize	  weight	  and	  reduce	  cardiovascular	  events	  when	  used	  as	  monotherapy	   (291).	   Recent	   clinical	   studies	   have	   shown	   that	   the	   effects	   of	  metformin	  may	   go	   beyond	   improving	   glycated	   haemoglobin	   and	  may	   include	  reductions	   in	   cardiovascular	   endpoints	   in	   Type	   2	   diabetes	  mellitus	   and	   heart	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failure.	   This	   wide	   spectrum	   of	   cardiovascular	   protective	   effects	   may	   be	  attributable	  to	  its	  activation	  of	  AMPK	  and	  its	  downstream	  pathways.	  	  
Metformin	   has	   been	   shown	   to	   activate	   AMPK	   in	   myocytes	   (292-­‐294),	  hepatocytes	  (295)	  and	  skeletal	  muscle	  cells	  (295).	  Metformin	  decreases	  hepatic	  glucose	  production	  and	  increases	  skeletal	  muscle	  glucose	  disposal.	  Therapeutic	  doses	  of	  metformin	  have	  been	   shown	   to	   increase	  AMPK	  α2	  activity	   in	  human	  skeletal	   muscle	   with	   an	   associated	   increase	   in	   phosphorylation	   of	   AMPK	   on	  Thr172	   and	   decreased	   ACC2	   activity	   (296).	   Metformin	   can	   also	   up-­‐regulate	  eNOS	   and	   increases	   nitric	   oxide	   bioactivity	   via	   AMPK	   activation	   (297).	  Furthermore,	   AMPK	   activation	   by	   metformin	   enhances	   fatty	   acid	   oxidation,	  which	   leads	  to	  alleviation	  of	  endothelial	   lipotoxicity	  and	   improved	  endothelial	  function	  (298).	  Moreover,	  metformin	  has	  also	  been	  shown	  to	  have	  anti-­‐cancer	  effects	   in	   recent	   study	   via	   its	   indirect	   AMPK	   activation	   (299).	   However,	   the	  precise	   mechanisms	   of	   how	   metformin	   activates	   AMPK	   are	   still	   poorly	  understood.	  
Even	   though	   metformin	   is	   regarded	   as	   an	   AMPK	   activator,	   it	   has	   not	  been	   shown	   to	   bind	   directly	   to	   AMPK;	   neither	   does	   it	   regulate	   its	   own	  phosphorylation	   and	   dephosphorylation	   in	   cell-­‐free	   assays	   (300).	   	   One	  hypothesis	   is	   that	   it	  activates	  AMPK	  by	   inhibiting	  complex	  I	  of	   the	  respiratory	  chain,	  which	  subsequently	  causes	  a	  rise	  in	  the	  AMP:	  ATP	  ratio	  (301,302).	  In	  fact,	  inhibition	  of	  the	  respiratory	  chain	  in	  the	  intestinal	  mucosa	  may	  account	  for	  the	  gastrointestinal	  side	  effects	  of	   the	  drug	  and	  this	  property	  may	  account	   for	   the	  propensity	   of	   its	   predecessor	   biguanides	   phenformin	   to	   cause	   lactic	   acidosis.	  Metformin	   is	   transported	   into	   intestinal	   cells	   mainly	   by	   the	   organic	   cation	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transporter	  OCT-­‐1,	  but	  phenformin	  penetrates	   cell	  membranes	  without	  active	  transport.	   Recent	   identification	   of	   polymorphisms	   in	   genes	   encoding	   cation	  transporters	   proteins	   may	   ultimately	   explain	   differences	   in	   tolerance	   and	  response	   to	  metformin	   (303).	   Interestingly,	   there	   are	   also	   studies	   suggesting	  that	  AMPK	  can	  be	  activated	  by	  metformin	  without	   changes	  of	  AMP/ATP	  ratio	  (300,304)	   and	   metformin	   can	   also	   exert	   its	   beneficial	   metabolic	   effects	   on	  cardiac	  myocytes	  in	  an	  AMPK-­‐independent	  manner	  (305).	  	  
	   However,	  we	  should	  be	  mindful	  that	  extra	  caution	  is	  required	  if	  we	  are	  to	  use	  these	  results	  to	  extrapolate	  to	  the	  effects	  of	  metformin	  on	  AMPK.	  Firstly,	  variable	   doses	   of	   metformin	   have	   been	   used	   in	   these	   studies.	   The	   plasma	  metformin	  concentration	  in	  clinical	  use	  is	  usually	  around	  10	  µM	  (140)	  whereas	  the	  doses	  used	  in	  vivo	  and	  in	  vitro	  experiments	  are	  consistently	  higher,	   in	  the	  range	   of	   1-­‐10mM	   (Table	   13).	   Saeedi	   et	   al	   has	   shown	   that	   lower	   doses	   of	  metformin	  (i.e.	  2mM)	  failed	  to	  activate	  AMPK	  and	  cause	  no	  changes	  of	  energetic	  state.	  On	  the	  contrary,	  Hardie	  et	  al	  have	  shown	  that	  lower	  doses	  of	  metformin	  can	   actually	   produce	   AMPK	   activation	   without	   significant	   change	   of	   cellular	  AMP:	   ATP	   ratio	   (300).	   Other	   research	   groups	   reported	   that	   AMPK	   activation	  required	   higher	   doses	   of	   metformin	   (i.e.	   5-­‐10mM)	   (292,294)	   (see	   table	   13).	  They	  suggested	  that	  higher	  doses	  of	  metformin	  are	  required	  to	  cause	  changes	  in	  the	   energetic	   state	   and	   hence	   subsequent	   AMPK	   activation.	   However,	   these	  diversified	   results	  may	  be	   the	   result	   of	   different	   exposure	   time	  of	  metformin.	  For	   instance,	   Yang	   et	   al	   has	   shown	   that	   lower	   dose	   of	   MF	   (1mM)	   activated	  AMPK	   and	   increased	   cardiac	   myocytes	   glucose	   uptake	   after	   a	   prolonged	  exposure	  of	  18	  hours	  (293).	  On	  the	  other	  hand,	  Bertrand	  et	  al	  had	  shown	  that	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Table	  11:	  	  Different	  “AMPK	  activators”	  and	  their	  limitations	  in	  clinical	  use	  
	  
Table	  12:	  	  Various	  Studies	  on	  AMPK	  activation	  using	  AICAR	  and	  their	  major	  findings	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Table	  13:	  	  Recent	  studies	  of	  AMPK	  activation	  using	  metformin	  and	  their	  major	  findings	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(3)	   THIAZOLIDINEDIONES	  (TZDS)	  
Thiazolidinediones	   (e.g.	   rosiglitazone	   and	   pioglitazone,	   “TZDs”)	   are	  ligands	   for	   the	  nuclear	  hormone	   receptor	   family	  member	  PPAR-­‐γ	   (134).	  Both	  the	  TZDs	  have	  been	  shown	  to	  activate	  AMPK	  in	  intact	  cells	  (307,308).	  TZDs	  can	  also	   activate	   AMPK	   by	   stimulating	   the	   release	   and	   expression	   of	   circulating	  adiponectin	   from	  adipose	   tissue	  (274,275),	  or	   indirectly	  by	   increasing	  cellular	  AMP/ATP	   ratio,	   possibly	   by	   a	   similar	   mechanism	   to	   biguanides	   (309).	   Both	  rosiglitazone	   and	   pioglitazone	   have	   been	   suggested	   to	   have	   additional	   and	  protective	   beneficial	   anti-­‐atherosclerotic	   and	   anti-­‐inflammatory	   effects	   (310).	  Furthermore,	  TZDs	  have	  also	  been	  shown	  to	  have	  diverse	  beneficial	  effects	  on	  endothelial	   function,	  TNF-­‐α,	  nitric	  oxide	  and	  endothelial	   cell	  proliferations	  via	  AMPK-­‐dependent	   and	   PPARγ-­‐independent	   mechanisms	   (311-­‐315).	   These	  effects	   may	   translate	   into	   improvement	   of	   clinical	   outcomes	   in	   patients	   with	  cardiometabolic	   disease.	   Previous	   studies	   have	   raised	   the	   intriguing	  possibilities	   that	   these	   effects	   may	   be	   mediated	   via	   AMPK	   activation	  (308,316,317).	  However,	  like	  metformin,	  we	  are	  not	  certain	  if	  AMPK	  activation	  is	   the	   key	   to	   these	   clinical	   beneficial	   effects	   on	   cardiovascular	   system.	  Furthermore,	  we	  also	  need	  to	  be	  very	  cautious	  when	  we	  try	  to	  translate	  these	  observations	   in	   animal	   studies	   to	   the	   clinical	   setting.	   The	   doses	   and	   type	   of	  TZDs	   that	   have	   been	   shown	   to	   activate	   AMPK	   vary	   among	   different	   research	  groups	   and	   the	   doses	   used	   in	   these	   animal	   studies	  may	   not	   be	   applicable	   to	  human	   subjects.	   Furthermore,	   the	  majority	   of	   these	   in	   vivo	   studies	   are	   short-­‐term	  studies	  examining	  the	  effects	  of	  acute	  AMPK	  activation	  and	   its	  metabolic	  effects.	  However,	  the	  effects	  of	  long-­‐term	  AMP	  activation	  by	  TZDs	  have	  yet	  to	  be	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determined.	   Nonetheless,	   the	   cardiovascular	   protective	   effects	   of	   TZDs	   are	  evidenced	   in	   the	   recently	   published	   post	   hoc	   analysis	   from	   the	   PROspective	  pioglitAzone	   Clinical	   Trial	   In	   macrovascular	   Events	   (PROactive)	   [116].	   It	  showed	  that	  patient	  who	  has	  chronic	  kidney	  disease	  who	  received	  pioglitazone	  are	  less	  likely	  to	  reach	  composite	  end-­‐points	  of	  all-­‐cause	  death,	  MI,	  and	  stroke,	  independent	  of	  the	  severity	  of	  renal	  impairment.	  
However,	  it	  should	  be	  noted	  that	  TZDs	  use	  is	  associated	  with	  the	  risk	  of	  fluid	  retention,	  which	  may	  exacerbate	  heart	   failure	  (177)	  (PROACTIVE,	  United	  State	   Food	   and	   Drug	   Administration	   (FDA)	   statement).	   In	   a	   recent	   meta-­‐analysis,	   Lago	   and	   colleagues	   reported	   that	   TZDs	   increased	   risk	   for	  development	   of	   CHF,	   probably	   as	   a	   result	   of	   fluid	   retention,	   across	   a	   wide	  background	  of	  cardiac	  risk	  (relative	  risk	  [RR]	  1.72,	  95%	  CI	  1.21-­‐2.42,	  p=0.002)	  (136).	   There	   is	   also	   a	   concern	   that	   these	   agents	   may	   be	   associated	   with	  additional	   cardiovascular	   (MI,	   stroke)	   risk	   in	   patients	   with	   Type	   2	   diabetes	  mellitus	   (T2DM)	   with	   rosiglitazone.	   However,	   it	   should	   be	   noted	   that	   these	  meta-­‐analyses	  which	  included	  many	  small	  trials	  (138),	  while	  large	  clinical	  trial	  data	   have	   shown	   no	   signal	   	   of	   these	   CV	   events	   (RECORD,	   PROACTIVE)	  (177,318).	   The	   European	  Medicines	   Evaluation	   Agency	   (EMEA)	   for	  Medicinal	  Products	   for	   Human	   Use	   has	   adopted	   a	   scientific	   opinion	   in	   January	   2008,	  recommending	   the	   inclusion	   of	   a	   new	   warning	   stating	   that	   the	   use	   of	  rosiglitazone	   in	   patients	   with	   ischaemic	   heart	   disease	   and/or	   peripheral	  arterial	  disease	  is	  not	  recommended.	  A	  recent	  FDA	  review	  suggested	  that	  more	  large	  randomized	  studies	  with	  active	  comparators	  should	  be	  conducted	  (FDA)	  by	  the	  manufacturers.	  In	  2010,	  EMEA	  has	  recommended	  the	  suspension	  of	  the	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marketing	   authorisations	   of	   rosiglitazone	   (Avandia,	   Avandamet)	   across	   the	  European	  Union.	  
(4)	   STATINS	  
	   Statins	   are	   widely	   prescribed	   in	   patients	   with	   metabolic	   syndrome	  owing	  to	  the	  high	  incidence	  of	  hypercholesterolaemia	  in	  this	  group	  of	  patients.	  There	   is	  mounting	   evidence	   to	   suggest	   that	   the	   clinical	   benefits	   of	   statins	   are	  beyond	   its	   lipid	   lowering	   effects.	   The	   clinical	   efficacy	   of	   statins	   treatment	   in	  reducing	  cardiovascular	  mortality	  and	  morbidity	  in	  patients	  with	  diabetes	  and	  without	  diabetes	  are	  well	  proven	  in	  clinical	  trials	  such	  as	  the	  Heart	  Protection	  Study	  and	  the	  Collaborative	  Atorvastatin	  Diabetes	  Study	  (319-­‐322).	  Besides	  its	  cholesterol	   lowering	   effect	   via	   3-­‐hydroxy-­‐3-­‐methylglutaryl-­‐CoA	   (HMG-­‐CoA)	  reductase	   inhibition,	   statins	   has	   also	   been	   shown	   to	   activate	  AMPK	   in	  human	  and	  bovine	  endothelial	  cells	  (323).	  Xenos	  et	  al	  have	  shown	  that	  AMPK	  protein	  levels	   in	   human	   endothelial	   cells	   were	   increased	   after	   being	   treated	   with	  fluvastatin	   for	   2	   days	   (324).	   Sun	   et	   al	   have	   also	   shown	   that	   atorvastatin	   and	  lovastatin	   caused	   rapid	   activation	   of	   AMPK-­‐eNOS/ACC	   in	  mouse	  myocardium	  and	   endothelial	   cells	   [125].	   The	   atorvastatin	   dose	   used	   in	   this	   study	   was	  50mg/kg	  in	  mice,	  which	  is	  equivalent	  to	  80mg	  per	  day	  in	  human.	  This	  study	  has	  shown	   that	   atorvastatin	   did	   not	   alter	   cellular	   AMP:	   ATP	   ratio,	   suggesting	  different	  mechanism	   of	   AMPK	   activation.	   	   The	   beneficial	   effects	   of	   statins	   on	  endothelial	   function	  have	  been	   suggested	   to	   be	   the	   results	   of	   its	   ability	   to	   up	  regulate	   eNOS	   (319,320,325-­‐327),	   and	   its	   anti-­‐inflammatory	   and	   anti-­‐atherogenic	  effects	  (322,328).These	  observations	  have	  all	  suggested	  that	  AMPK	  activation	  might	  be	  the	  key	  to	  the	  pleiotropic	  effects	  of	  statins	  on	  cardiovascular	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protection.	  However,	  further	  mechanistic	  and	  translational	  studies	  are	  required	  to	   show	   that	   AMPK	   activation	   is	   indeed	   the	   key	   these	   effects	   of	   statins	  treatment	   as	  well	   as	   the	   examining	   the	   doses	   of	   different	   statins	   required	   to	  activate	  AMPK.	  	  	  
(5)	   COMPOUND	  A-­‐769662	  
Cool	   et	   al.	   have	   identified	   a	   thienopyridone	   family	   of	   AMPK	   activators	  (329),	  compound	  A-­‐769662.	  It	  stimulates	  AMPK	  directly	  in	  partially	  purified	  rat	  liver	   and	   inhibits	   fatty	   acid	   synthesis	   in	   primary	   rat	   hepatocytes.	   Short-­‐term	  treatment	   of	   normal	   Sprague	   Dawley	   rats	   with	   A-­‐769662	   decreases	   liver	  malonyl	  CoA	  levels	  and	  the	  respiratory	  exchange	  ratio,	  VCO2/VO2,	  indicating	  an	  increased	   rate	   of	   whole-­‐body	   fatty	   acid	   oxidation.	   In	   ob/ob	   mice,	   treatment	  with	   compound	   A-­‐769662	   has	   been	   shown	   to	   decrease	   plasma	   glucose,	  reducing	   weight	   gain	   and	   significantly	   decreasing	   both	   plasma	   and	   liver	  triglyceride	   levels.	   These	   results	   demonstrated	   that	   small	   molecule-­‐mediated	  activation	   of	   AMPK	   in	   vivo	   is	   feasible,	   and	   represent	   therefore	   a	   promising	  approach	   for	   the	   treatment	   of	   Type	   2	   diabetes	   mellitus	   and	   the	   metabolic	  syndrome.	  However,	  the	  compound	  has	  poor	  oral	  bioavailability,	  limiting	  its	  use	  in	  clinical	  settings.	  	  
An	  alternative	  small	  molecule	  compound	  that	  is	  safe,	  potent,	  acts	  directly	  on	   AMPK	   with	   good	   oral	   bioavailability	   would	   be	   an	   attractive	   candidate	   to	  progress	  towards	  clinical	  development.	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   Activation	  of	  AMPK	  pathway	  may	  be	  the	  key	  in	  treating	  and	  preventing	  various	   cardiometabolic	   diseases.	   AMPK	   pathway	   and	   its	   association	  with	   its	  upstream	   and	   downstream	   kinases	   have	   fundamental	   roles	   in	   glucose	  metabolism,	   fatty	   acid	   oxidation,	   and	   protein	   synthesis.	   AMPK	   pathway	   has	  been	   the	   focus	   of	   many	   researches	   of	   late	   owing	   to	   his	   central	   role	   in	  modulating	   cardio-­‐metabolic	   processes,	   and	   recent	   mechanistic	   studies	   have	  shown	   that	   AMPK	   has	   an	   important	   role	   in	   the	   mechanism	   of	   action	   of	  metformin,	   thiazolidinediones	   and	   statins.	   Activation	   of	   AMPK	   may	   be	  responsible	  for	  the	  insulin	  sensitizing	  and	  beneficial	  cardio-­‐metabolic	  effects	  of	  these	  drugs.	  However,	  it	  is	  still	  uncertain	  whether	  direct	  activation	  of	  the	  AMPK	  pathway	  in	  the	  absence	  of	  a	  physiological	  stress	  will	  be	  beneficial	  or	  deleterious	  overall	  in	  humans.	  	  It	  is	  hoped	  that	  chronic	  activation	  of	  AMPK	  will	  not	  result	  in	  “over-­‐compensatory”	  activation	  of	  other	  systems	  such	  as	  the	  renin-­‐angiotensin-­‐aldosterone	   system	   activation	   in	   heart	   failure.	   Alterations	   in	   cardiac	   AMPK	  activity	  are	  associated	  with	  a	  number	  of	  cardiovascular-­‐related	  diseases	  such	  as	  pathological	   cardiac	   hypertrophy	   (258),	   myocardial	   ischemia	   (244),	   glycogen	  storage	   cardiomyopathy	   (260),	   and	   Wolff-­‐Parkinson-­‐White	   syndrome	   (259),	  suggesting	   a	   possible	   maladaptive	   role	   in	   such	   conditions.	   Andersson	   et	   al	  described	   anti-­‐satiety	   effects	   of	   AMPK,	  which	  may	   lead	   to	  weight	   gain	   (330).	  Furthermore,	  McCullough	  et	  al	  also	  demonstrated	  that	  activated	  AMPK	  might	  be	  harmful	   in	   stroke	   (331).	   All	   these	   uncertainties	   will	   need	   to	   be	   clarified	   by	  further	  translational	  studies	  and	  much	  effort	  is	  still	  required	  to	  define	  the	  roles	  of	   AMPK	   activation	   in	   various	   conditions	   that	   we	   have	   already	   discussed.	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   CHAPTER	  8:	  FINAL	  DISCUSSION	  
	  
Diabetes	  Mellitus	  and	  HF	  commonly	  coexist,	  and	  each	  condition	   impact	  on	   each	   other	   in	   terms	   of	   causation	   and	   outcome.	   DM	   is	   highly	   prevalent	  amongst	   HF	   patients	   and	   vice	   versa.	   	   The	   prevalence	   of	   DM	   increases	   with	  severity	   of	  HF.	   	   Up	   to	   one	   third	   of	   patients	  who	   are	   hospitalised	  with	  HF	   are	  found	  to	  be	  diabetic.	  	  
NYHA	   functional	   class	   has	   been	   shown	   to	   be	   a	   predictor	   of	   risk	   of	  developing	   DM	   in	   HF	   from	   population	   based	   study,	   whereas	   HbA1c	  measurements	   are	   predictors	   of	   risk	   of	   developing	   HF	   in	   diabetic	   patients.	  Elevated	  HbA1c	   level	   is	   also	  a	  predictor	  of	   incident	  HF	   in	  diabetics	  as	  well	   as	  non-­‐diabetics.	  More	  importantly,	  suboptimal	  glycaemic	  control	  as	  measured	  by	  HbA1c	   is	   associated	   with	   adverse	   outcome.	   However,	   there	   were	   some	  conflicting	  reports	  regarding	  the	  degree	  of	  glycaemic	  control	  in	  T2DM	  and	  CHF.	  In	  patients	  with	  T2DM	  and	  CHF,	  our	  observational	  study	  shows	  that	  there	  is	  a	  U	  shaped	   relationship	   between	   HbA1c	   and	   mortality	   with	   the	   lowest	   mortality	  risk	   in	   patients	   with	   modest	   glycaemic	   control	   (HbA1c,	   >7 ≤ 9%).	   This	  observational	   data	   adds	   support	   to	   the	   growing	   concern	   that	   we	   need	   to	  redefine	   the	   optimal	   HbA1c	   level	   in	   this	   high-­‐risk	   group	   of	   patients	   with	   co-­‐existing	   T2DM	   and	   CHF.	   These	   findings	   may	   be	   partly	   explained	   by	   the	  differences	   in	   severity	   of	   CHF,	   duration	   of	   diabetes,	   and	   differences	   in	   the	  choices	  of	  drugs	  used.	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The	   bi-­‐directional	   inter-­‐relationship	   between	   CHF	   and	   diabetes	   also	  extends	   to	   insulin	   resistance	   (IR).	   IR	   precedes	   and	   also	   predicts	   the	  development	  of	  CHF,	  independent	  of	  established	  risk	  factors	  for	  CHF	  including	  diabetes	  itself.	  The	  degree	  of	  IR	  positively	  correlates	  with	  severity	  of	  CHF	  and	  is	  associated	   with	   adverse	   functional	   consequences	   (i.e.	   reduced	   endothelial	  function,	   exercise	   capacity	   and	   associated	  with	   abnormal	   serum	   biomarkers).	  	  The	  exact	  pathophysiology	  of	  IR	  and	  CHF	  is	  not	  fully	  understood.	  	  Activation	  of	  SNS,	   RAS,	   inflammation,	   altered	   adipocytokines	   levels,	   formation	   of	   advanced	  glycosylation	  products,	  changes	  in	  substrate	  utilization	  of	  the	  myocardium	  and	  ED	  are	  possible	  explanations	  of	  how	  IR	  affecting	  disease	  process	   in	  CHF.	  With	  our	   increased	   understanding	   of	   the	   pathophysiological	   role	   of	   IR	   in	   CHF,	  improving	  IR	  may	  represent	  a	  new	  target	  for	  treatment	  for	  patients	  with	  CHF.	  
So,	  how	  can	  we	  improve	  IR?	  Lifestyle	  changes	  such	  as	  diet	  and	  exercise	  are	   possible	   but	   very	   difficult	   to	   prescribe,	   and	   patients’	   adherence	   can	   be	   of	  great	   challenge.	   	   Therefore,	   pharmacological	   approach	   is	   needed	   for	   most	  patients	   with	   evidence	   of	   IR/DM	   and	   CHF.	   We	   are	   mindful	   that	   certain	  conventional	  HF	  medications	  only	  have	  modest	  beneficial	  effects	  on	  glycaemic	  control	   and	   the	   prevention	   of	   the	   development	   of	   diabetes.	   Therefore,	   more	  potent	  “insulin	  sensitizers”	  are	  needed	  to	  reverse	  IR	  in	  CHF.	  TZDs	  were	  initially	  thought	  to	  be	  a	  blockbuster	  drug	  when	  it	  was	  first	  marketed	  owing	  to	  its	  potent	  insulin	   sensitizing	   property	   and	   favourable	   impacts	   on	   cardiovascular	  parameters	   such	   as	   lipids,	   blood	   pressure,	   inflammatory	   biomarkers,	  endothelial	  function,	  and	  fibrinolytic	  status	  (332,333).	  However,	  its	  use	  in	  CHF	  was	   restricted	   because	   of	   its	   ability	   to	   increased	   fluid	   retention	   caused	   by	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increased	   re-­‐absorption	   in	   the	   distal	   nephron	   as	   well	   as	   increased	   vascular	  permeability	   in	   adipose	   tissue	   (334).	   	   Furthermore,	   there	   are	   additional	  concerns	  regarding	  the	  risk	  of	  myocardial	  infarction	  with	  TZDs	  especially	  with	  rosiglitazone,	  which	  has	  now	  been	  withdrawn	  from	  the	  market.	  	  
The	   incretin	   system	   has	   received	   a	   great	   deal	   of	   attention	   in	   the	  treatment	   of	   diabetes	   in	   recent	   years.	   A	   few	   randomized	   controlled	   trials	   are	  currently	  underway	  to	  define	  the	  utility	  of	   targeting	  the	   incretin	  system	  in	  HF	  patients	   with	   DM.	   Incretin-­‐based	   therapy	   may	   represent	   a	   novel	   therapeutic	  strategy	  in	  the	  treatment	  of	  HF	  patients	  with	  diabetes,	  as	  it	  has	  been	  shown	  to	  have	   cardioprotective	   effects	   independent	   of	   those	   attributable	   to	   tight	  glycaemic	   control.	   Our	   increased	   insights	   and	   understanding	   of	   the	   incretin	  system	  has	  opened	  up	  new	  horizons	  in	  the	  potential	  treatment	  options	  in	  CHF,	  and	  outcome	  trials	  are	  awaiting.	  	  
Metformin,	   another	   insulin	   sensitizing	   medications,	   has	   been	   on	   the	  market	   for	   almost	   50	   years.	   	   The	   use	   of	  metformin	   in	   patients	  with	   CHF	   has	  been	  discouraged	  previously	  because	  of	  previous	  experience	  with	  phenformin	  back	  in	  the	  1970’s.	  The	  precise	  mechanisms	  of	  action	  are	  not	  fully	  understood.	  However,	   with	   increased	   understandings	   and	   refreshed	   insights	   from	  accumulating	  experience	  of	  metformin	  use,	  metformin	  has	  proven	  to	  be	  safe	  in	  patients	  with	  CHF	  and	  DM.	  More	  importantly,	  there	  are	  now	  large	  observational	  data	   and	   retrospect	   studies	   to	   support	   the	   notion	   that	  metformin	   is	   not	   only	  safe,	  but	  also	  its	  use	  was	  associated	  with	  a	  better	  outcome	  in	  patients	  with	  CHF	  and	  DM.	  Although	   these	  data	  were	   encouraging,	   the	  main	   limitations	  of	   these	  observational	  studies	  were	  the	  potential	  for	  selection	  bias	  imposed	  by	  different	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therapies.	  What	  is	  needed	  is	  prospective	  placebo	  controlled	  studies	  to	  examine	  the	  impact	  of	  metformin	  in	  CHF	  and	  DM.	  	  
Therefore,	   in	   a	   randomized	   placebo	   controlled	   trial,	   we	   evaluatedthe	  impact	  of	  metformin	  on	   IR	  and	   its	  effects	  on	  exercise	  capacity	   in	  non-­‐diabetic	  patients	   with	   CHF.	   The	   primary	   endpoint	   of	   the	   trial	   was	   to	   determine	   if	  improvement	  of	  IR	  with	  metformin	  lead	  to	  improvement	  of	  peak	  VO2.	  However,	  many	   patients	  with	   CHF	   are	   unable	   to	   perform	  maximal	   exercise	   and	   oxygen	  requirements	  for	  activities	  of	  daily	  living	  rarely	  approach	  maximal	  levels	  (185).	  Therefore,	  we	  have	   included	   the	  sub-­‐maximal	  derived	  exercise	  variable	  of	   the	  slope	  of	  the	  ratio	  of	  minute	  ventilation	  to	  carbon	  dioxide	  production	  (VE/VCO2)	  as	  a	  secondary	  end-­‐point	  of	  this	  study.	  VE/VCO2	  slope	  is	  an	  index	  of	  ventilatory	  response	   to	   exercise.	   Unlike	   peak	   VO2,	   VE/VCO2	   is	   not	   influenced	   by	   the	  mechanical	   work	   done	   during	   exercise	   testing	   but	   reflects	   alterations	   in	   the	  peripheries	   caused	   by	   the	   disease	   in	   CHF,	   which	   can	   in	   turn	   lead	   to	   the	  progression	   and	   symptomatology	   of	   CHF	   (186).	   Furthermore,	   we	   have	   also	  explored	   possible	   mechanisms	   of	   improvement	   of	   exercise	   capacity	   by	  measuring	   left	   ventricular	   ejection	   fraction	   by	   echocardiography,	   endothelial	  function	  and	  related	  biomarkers.	  
Our	  study	  had	  two	  main	  findings.	  Firstly,	  we	  showed	  that	  in	  CHF	  patients	  with	  insulin	  resistance,	  metformin	  treatment	  significantly	  reduced	  FIRI	  and	  this	  treatment	   was	   associated	   with	   a	   weight	   loss	   of	   1.9	   kg.	   Secondly,	   although	  metformin	   had	   no	   effect	   on	   peak	   exercise	   parameters	   such	   as	   peak	   VO2,	  metformin	  treatment	  did	  result	  in	  a	  significant	  improvement	  in	  VE/VCO2	  slope,	  a	   pre-­‐specified	   endpoint	   of	   this	   proof	   of	   concept	   study.	   There	   are	   several	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possible	  explanations	  of	   improved	  VE/VCO2	  slope.	  Firstly,	   the	  improvement	  in	  functional	  capacity	  might	  be	  related	  to	  the	  weight	  loss	  of	  1.9	  kg	  associated	  with	  metformin	  therapy.	  However,	  in	  our	  regression	  model,	  we	  showed	  that	  weight	  reduction	   alone	   did	   not	   correlate	   with	   the	   reduction	   in	   VE/VCO2	   slope.	  Secondly,	   the	   insulin	   sensitizing	   properties	   of	   metformin	   might	   confer	   some	  beneficial	   effects	   on	   exercise	   capacity.	   Improving	   insulin	   sensitivity	   has	   been	  shown	   to	   improve	   exercise	   capacity.	   In	   this	   regard,	   we	   found	   that	   with	  metformin	  treatment,	  reduction	  of	  FIRI	  and	  serum	  leptin	  level	  was	  significantly	  correlated	  with	   the	   reduction	  of	  VE/VCO2	  slope.	  Doehner	   et	   al	   had	  previously	  demonstrated	   that	   hyperleptinaemia	   is	   an	   independent	   predictor	   of	   IR	   in	  patients	  with	  CHF,	  and	   it	  may	  play	  an	   important	  role	   in	  energy	  metabolism	  in	  these	   patients	   (63).	   Reduction	   of	   serum	   leptin	   has	   been	   previously	   reported	  following	  chronic	  metformin	  therapy	  (206)	  and	  might	  be	  due	  to	  a	  direct	  effect	  of	   metformin	   on	   leptin	   secretion	   (207).	   Recent	   studies	   have	   shown	   the	  significance	   of	   adipocytokines	   modulation	   in	   HF	   patients	   and	   high	   levels	   of	  adiponectin	  were	  associated	  with	  adverse	  outcomes	  in	  CHF	  (75,76).	  There	  was	  no	  significant	  change	  in	  adiponectin	  levels	  in	  our	  study	  (p=0.168).	  However,	  we	  did	   notice	   that	   patients	   in	   the	   metformin	   treated	   group	   have	   decreased	  adiponectin	  level,	  whereas	  adiponectin	  levels	  were	  higher	  in	  the	  placebo	  group.	  Therefore,	   the	   improvement	   of	   sub-­‐maximal	   exercise	   capacity	   in	   our	   cohort	  may	  in	  part	  be	  due	  to	  an	  improvement	  of	  IR	  and	  the	  reduction	  of	  serum	  leptin	  level.	  A	  third	  consideration	  was	  metformin’s	  ability	  to	  activate	  AMPK,	  which	  is	  expressed	   in	   various	   tissues	   including	   the	   skeletal	   muscle,	   myocardium	   and	  vascular	   endothelium	   (165).	   Therefore,	   activation	   of	   AMPK	   could	   impact	   on	  central	  as	  well	  as	  peripheral	  haemodynamic	  mechanisms	  which	  in	  turn	  leads	  to	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changes	   in	   VE/VCO2	   slope	   and	   hence,	   ventilatory	   class.	   Improvement	   of	  myocardial	  substrate	  utilization	  and	  glucose	  uptake	  through	  activation	  of	  AMPK	  may	   improve	   myocardial	   contraction	   and	   increase	   cardiac	   output	   (196).	   In	  animal	  models	   of	   heart	   failure,	  metformin	   has	   been	   shown	   to	   activate	   AMPK	  and	   improve	   left	   ventricular	   function,	   and	   attenuate	   oxidative	   stress-­‐induced	  cardiomyocyte	   apoptosis,	   resulting	   in	   improved	   survival	   (197).	   However,	   we	  did	  not	  observe	  any	  significant	  effect	  of	  metformin	  on	  echo-­‐derived	  LVEF	  or	  CO	  at	   rest	   and	   during	   peak	   exercise.	   With	   respect	   to	   peripherally	   mediated	  mechanisms,	  effects	  of	  metformin	  on	  exercising	  skeletal	  muscles	  could	  account	  for	   improvement	   in	   VE/VCO2	   slope.	   	   Alterations	   in	   skeletal	   muscle	   energy	  metabolism,	   IR	   and	   functional	   adiponectin	   resistance	  have	  been	   reported	  and	  linked	  to	  exercise	  intolerance	  in	  patients	  with	  CHF	  (208).	  A	  study	  of	  the	  effects	  of	  metformin	  on	  skeletal	  muscle	  enzyme	  activities	   in	  our	  subjects	  would	  be	  of	  interest.	   In	  our	  original	  proposal,	  we	  had	  planned	   to	  do	   this,	  but	   this	   invasive	  procedure	  was	  offered	  as	  an	  option	  and	  no	  patient	  consented	  to	  the	  procedure.	  We	   did	   not	   see	   any	   significant	   effect	   of	   metformin	   on	   endothelial	   function.	  Obviously	   any	   evidence	   that	   metformin	   improves	   exercise	   capacity	   through	  central	   cardiac	   or	   peripheral	   mechanisms	   in	   patients	   with	   CHF	  must	   remain	  speculative,	   and	   cannot	   be	   inferred	   directly	   from	   this	   study.	   Clearly,	   further	  studies	   are	   required	   to	   define	   the	   mechanisms	   underlying	   these	   effects	   of	  metformin	  in	  CHF.	  
AMPK	   pathway	   has	   been	   the	   focus	   of	   recent	   research,	   owing	   to	   his	  central	   role	   in	   modulating	   cardio-­‐metabolic	   processes.	   Recent	   mechanistic	  studies	   have	   shown	   that	   AMPK	   has	   an	   important	   role	   in	   the	   mechanism	   of	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action	  of	  metformin,	  thiazolidinediones	  and	  statins.	  Activation	  of	  AMPK	  may	  be	  responsible	  for	  the	  insulin	  sensitizing	  and	  beneficial	  cardio-­‐metabolic	  effects	  of	  these	  drugs.	  For	  example,	  in	  animal	  models	  of	  heart	  failure,	  metformin	  has	  been	  shown	   to	   activate	   AMPK,	   improve	   left	   ventricular	   function	   and	   to	   attenuate	  oxidative	   stress-­‐induced	   cardiomyocyte	   apoptosis,	   resulting	   in	   improved	  survival	   (197).	   Increased	   understanding	   of	   the	   beneficial	   effects	   of	   AMPK	  activation	  provides	  the	  rationale	  for	  targeting	  AMPK	  in	  the	  development	  of	  new	  therapeutic	  strategies	  to	  improve	  IR,	  cardio-­‐metabolic	  disease	  and	  heart	  failure.	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